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I 
 
Summary 
Genetic variation in the gene ZNF804A has been shown to be related to risk for 
psychopathology, especially schizophrenia and bipolar disorder. The main aim of this 
thesis was to characterise the behavioural effects of Zfp804a, the mouse orthologue 
of ZNF804A, in order to understand more about how this gene influences brain and 
psychological functioning, and hence provide clues as to its possible role in 
mediating risk for mental disorders. 
Prior to this work, two ENU-mutant mouse lines had been generated from a 
DNA library of ENU mutagenised mice with two non-synonymous mutations selected 
as viable candidates for further investigation. The C59X mutation encodes a 
premature stop codon in exon 2, thought to lead to a functional null of the gene, and 
the C417Y mutation is missense, substituting cysteine for tyrosine in exon 4. A first 
series of experiments examined the early development of the ENU-mutant lines and 
showed no gross developmental abnormalities, although the C59X mutants weighed 
significantly less than their WT littermate controls at weaning and during adulthood. 
A comprehensive series of behavioural tests then assayed aspects of emotion, 
motivation, hedonia, sensorimotor gating and response control. In general, the C59X 
mutants showed the greatest effects, displaying reduced anxiety, anhedonia, and 
sensorimotor gating deficits, together with evidence of enhanced response 
inhibition. The C417Y mutants only showed selective effects in terms of enhanced 
motivation. 
The data dissociate between the effects of the two ENU-induced mutations of 
Zfp804a. Furthermore, the findings with the C59X mutants would suggest, a priori, 
that genetic variance leading to alterations in ZNF804A expression may be an 
important mechanism contributing to risk for psychopathology.  
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Chapter I; General introduction 
Schizophrenia is a complex and severely debilitating disorder, with significant 
medical, societal and economic impacts (Tandon, Keshavan & Nasrallah, 2008). Due 
to its high incidence in the population, its pervasive nature and its relative resistance 
to treatment, the World Health Organisation (WHO) has rated schizophrenia as one 
of the top ten leading causes of disease related disability worldwide (2001), with an 
estimated societal cost in England of £6.7 billion in 2004/2005 (Mangalore & Knapp, 
2007), and an estimated direct economic burden of $62.7 billion in the USA in 2002 
(Wu, Birnbaum, Shi et al., 2005). The worldwide median prevalence rate of 
schizophrenia is estimated to be 15.2 in 100,000 people (Aleman, Kahn & Selten, 
2003; McGrath, Saha, Welham, et al., 2004; McGrath, Saha, Chant et al., 2008).  
Males are more likely to suffer with the disorder than females; the male to female 
rate ratio (median) is of the order of 1.4:1 (McGrath et al., 2004), with men often 
having both an earlier age of onset and a more serious and chronic form of the 
disorder (with poorer outcomes) than women (Jablensky, 2000). Urban living 
increases the risk of schizophrenia (Pedersen & Mortensen, 2001), as does migration 
(McGrath et al., 2004; Saha, Chant, Welham & McGrath, 2005). 
Schizophrenia not only impacts on the affected individual due to the wide 
array of disabling symptoms, but also at both a family and broader societal level, as a 
result of social isolation, poverty and homelessness. These problems are often 
exacerbated by the residual prejudice, discrimination and stigma attached to the 
disorder. Despite the high economic and social costs of schizophrenia, and the large 
amount of research conducted (~5000 publications/year, Tandon et al., 2008) the 
aetiology and pathophysiology of the disorder still remain largely unknown. At the 
broadest level, schizophrenia is thought to arise from a complex interaction between 
environmental factors and biological predispositions, most likely genetic in nature, 
that impact, in particular, on developmental factors that have multiple effects across 
diverse brain areas and circuits in the adult. 
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1.1 Early concepts and more recent thinking 
Schizophrenia, as a discrete diagnosis, has been an ever changing concept 
over the last 100 years. Before the turn of the 20th century, ‘psychosis’ was thought 
of as a unitary construct, with all forms viewed as variations of one major disease 
process. In 1919 the physician Emil Kraepelin (1856-1926) divided psychosis into two 
distinct forms; 1) affective psychosis (described in modern terms as bipolar disorder) 
and 2) dementia praecox (1919). Affective psychosis included short term episodic 
emotional problems which were eventually followed by full remission of symptoms, 
whereas dementia praecox was seen as a progressive decline in cognitive function, 
an organic disease of the brain, and regarded as incurable by Kraepelin (Andreasen, 
2011). The psychiatrist Eugen Bleuler disagreed with this diagnosis, reformulating 
dementia praecox as schizophrenia (‘split mind’), refuting the idea that it was a type 
of dementia involving mental decline, but instead suggesting that thought disorder 
was the key symptom alongside deficits in cognition and emotion (Andreasen, 2011). 
The ‘Kraepelinian dichotomy’ marked the start of the classification of mental 
disorders based on commonality of symptoms, paving the way to a more clinical 
approach to mental illness. The dichotomy to this day is a subject of debate, and 
even though the diagnostic boundary between bipolar disorder and schizophrenia 
has remained in the clinic, some argue that viewing them as distinct disorders may 
be hampering research and even clinical care (Craddock & Owen, 2005; Craddock & 
Owen, 2010). This is in part due to a number of patients presenting with both major 
mood and psychotic symptoms, but also, crucially, due to the recent emergence of 
evidence suggesting a shared genetic aetiology between schizophrenia and bipolar 
disorder (Craddock & Owen, 2005) and increased risks of both disorders that 
increases with family relatedness (Lichtenstein, Yip, Björk, et al., 2009). 
Single nucleotide polymorphisms (SNP) within certain schizophrenia 
candidate genes revealed in large sample genome-wide association studies (GWAS) 
also seem to suggest a genetic overlap between schizophrenia and bipolar disorder 
(Moskvina, Craddock, Holmans, et al., 2009). For example, the SNP in the gene 
encoding Zinc finger protein 804A (ZNF804A) which showed robust association with 
risk for schizophrenia, was found to have an increased association signal when 
bipolar disorder cases were added to the sample (O’Donovan, Craddock, Norton et 
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al., 2008). The emerging biological data from the latest generation of genetic studies 
indicates strongly that the nosology of psychiatric disorders, including schizophrenia 
and bipolar, should be viewed more on a dimensional basis than as a dichotomy, and 
that investigations into psychiatric disorders should be aware of the possibility of 
shared aetiology at the level of biological mechanism(s).  
 
1.2 Diagnosis of schizophrenia and clinical features 
In the UK, diagnoses of patients with schizophrenia and bipolar disorder are 
currently conducted using a combination of the American Psychiatric Association’s 
DSM 5th edition (DSM-V) and the International Classification of Diseases (ICD-10, by 
the WHO). These manuals lay out a number of criteria for a diagnosis of 
schizophrenia, which includes the presence of 2 or more of the following symptoms; 
delusions, hallucinations, disorganised speech, grossly disorganised or catatonic 
behaviour and negative symptoms such as blunted affect, alogia, reduced pleasure 
and motivation. In addition to these medical symptoms, the person must also show 
occupational/social dysfunction, with these disturbances persisting for at least 6 
months, including a minimum of 1 month of medical symptoms. A diagnosis of 
schizophrenia will be ruled out if the person presents with symptoms of bipolar 
disorder (i.e. persistent bouts of mania/depression), a pervasive developmental 
disorder (such as autism) or if the symptoms are directly the result of another 
medical condition or substance.   
Schizophrenia is often characterised by a loss of contact with reality, with 
abnormal perception of external stimuli including the occurrence of delusions and 
hallucinations. Symptoms of schizophrenia have been grouped into 3 categories; 
positive, negative and cognitive. Positive symptoms are those which represent an 
exaggeration of normal function; symptoms which a healthy individual would not 
experience, including hallucinations, delusions, disorganised or catatonic behaviour 
and disordered speech. Negative symptoms are characterised by attenuation or lack 
of function normally seen in healthy individuals, including blunted affect, avolition, 
poverty of speech and anhedonia (Arango & Carpenter, 2011). Cognitive symptoms 
include impaired working memory, poor attentional capabilities and overall reduced 
executive functioning (Arango & Carpenter, 2011).  
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1.2.1 Positive symptoms  
 Positive symptoms are those which represent an exaggeration or distortion of 
normal function. Delusions occur in 90% of schizophrenia patients, with the most 
common type being delusions of persecution (Cutting, 2003). Hallucinations can 
occur in any modality, with 50% of patients experiencing auditory hallucinations, 
15% visual and 5% tactile (Arango & Carpenter, 2011). Often auditory hallucinations 
appear in the form of voices talking to the patient or among themselves (Arango & 
Carpenter, 2011). Other examples of positive symptoms include disorganised 
thought, manifesting in speech disturbance, tangentiality (failing to get to the point 
of the conversation), thought blocking (loss in their train of thought) and 
perseveration (the repetition of an idea) (Arango & Carpenter, 2011). Anti-psychotic 
drugs are most effective in treating these positive symptoms. When modelling 
schizophrenia in animals, it is accepted that the positive symptoms are especially 
challenging, as many cannot be (convincingly) measured, such as hallucinations and 
delusions. However, sensorimotor effects such as pre-pulse inhibition (PPI) and 
latent inhibition (LI) have been successfully modelled in animals for many years 
(Desbonnet, Waddington & O’Tuathaigh, 2009). Sensorimotor functioning as indexed 
by changes in acoustic startle reactivity and the low level attentional sensorimotor 
gating phenomenon of prepulse inhibition (PPI) was employed in the current 
experimental work examining N-ethyl-N-nitrosourea (ENU)-induced mutant lines 
targeting the mouse orthologue of ZNF804A, Zfp804a (detailed in Chapter VI).  
 
1.2.2 Negative symptoms 
Negative symptoms, characterised by attenuation or lack of function 
normally seen in healthy individuals, including blunted affect, avolition, alogia and 
anhedonia, contribute in a major way to adverse functional outcome and quality of 
life in schizophrenia patients (Rabinowitz, Levine, Garibaldi et al., 2012).  They often 
present before positive symptoms, and can persist after the positive symptoms have 
subsided (Arango & Carpenter, 2011). Unlike the positive symptoms of 
schizophrenia, the treatment of negative symptoms is often unsuccessful 
(Kirkpatrick, Fenton, Carpenter & Marder, 2006). One possible reason for this may be 
that the negative symptoms are similar to personality traits, which may be viewed as 
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more stable and enduring, and less influenced by environmental factors (An der 
Heiden & Häfner, 2011). Obviously, several of the negative symptoms such as 
poverty of speech are impossible to model in animals, and indeed negative 
symptoms in general, though clearly important, have proved difficult to recapitulate 
in animal models (O’Tuathaigh, Kirby, Moran & Waddington, 2010). One of the main 
aims of this thesis was to examine emotional functioning, and anhedonia and 
motivation, using valid approaches in Zfp804a mutant mouse lines (Chapters IV and 
V). 
 
1.2.3 Cognitive deficits 
Cognitive impairments have long been recognised as a major part of the 
presentation of schizophrenia (Arango & Carpenter, 2011). However, despite the 
clear evidence linking cognitive deficits such as poor working memory, reduced 
attentional capabilities and diminished executive function to schizophrenia, 
impairments in cognition still do not form part of the DSM-IV criteria for a diagnosis 
of the disorder. Lower quality of life and poor functional outcome in patients have 
been associated with severity of cognitive impairment, perhaps due to the fact that, 
as with most negative symptoms, there are still no viable drug treatments for 
cognitive deficits (Green, Kern, Braff and Mintz, 2000). 
Cognitive impairments in schizophrenia encompass most functional domains 
and patients with schizophrenia generally perform worse than healthy controls in 
almost every cognitive task used (Heinrichs and Zakzanis, 1998). Cognitive deficits 
may be stable over time (Rund, 1998; Saykin, Shtasel, Gur et al., 1994), and even 
premorbid, with patients showing lower IQ in childhood and adolescence 
(Woodberry, Giuliano & Seidman, 2008). However, IQ changes may be transient, 
with reductions only at the onset of the illness and a gradual reinstatement of 
premorbid levels through the course of the disease (van Winkel, Myin-Germeys, 
Delespaul, et al., 2006). Unlike the positive and negative symptoms seen in 
schizophrenia, cognitive deficits can, arguably, be modelled more easily in animals, 
investigating domains such as attention, impulsivity, working memory and social 
cognition (Arguello & Gogos, 2010) with reference to standardised assessment scales 
such as the Measurement and Treatment Research to Improve Cognition in 
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Schizophrenia (MATRICS, Nuechterlein, Green, Kern, et al., 2008) or Cognitive 
Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS, 
Carter & Barch, 2007). These batteries incorporate a number of different tasks, 
which have mostly been translated for use with primates and rodents, assessing 
dissociable cognitive functions: e.g. Impulse Control, Speed of Processing, 
Attention/Vigilance, Working Memory, Verbal Learning and Memory, Visual Learning 
and Memory, Reasoning and Problem Solving, and Social Cognition (Nuechterlein et 
al., 2008). Abnormalities in response control are increasingly recognised as an 
important component of a number of psychiatric disorders (Newman, Widom, & 
Nathan, 1985; Heerey, Robinson, McMahon & Gold, 2007; Humby & Wilkinson, 
2011) and there is some evidence supporting the utility of monitoring impulsivity as 
a possible biomarker for schizophrenia (Barch, Braver, Carter et al., 2009). 
Consequently, we pursued this novel angle in the experimental work reported in 
Chapter VII, examining response control in Zfp804a mutant lines in a recently 
developed murine version of the stop-signal reaction time task (SSRTT, Humby, Eddy, 
Good et al., 2013). 
 
1.3 Neurobiological substrates of schizophrenia 
 The neurobiology of schizophrenia remains obscure. Unlike 
neurodegenerative disorders such as Alzheimer’s disease, there are no obvious 
neuropathological signs of schizophrenia (Harrison, Lewis & Kleinman, 2011). With 
no known reliable and robust biomarkers for the disorder, treatment options at best 
alleviate the symptoms with little disease modifying efficacy. Understanding the 
aetiology and pathogenesis of schizophrenia are key requirements for improved 
diagnosis and the development of safe and effective therapeutics.  
 
1.3.1 Neuropathology of schizophrenia 
Despite the controversial, but initially well supported, statement that there is 
no neuropathology of schizophrenia, some progress has been made in this area of 
research. The first major findings based on meta-analyses have been that 
schizophrenia patients have a reduced brain volume of around 4% (Wright, Rabe-
Hesketh, Woodruff & David, 2000) and a 3% reduction in brain weight (Harrison, 
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Freemantle & Geddes, 2003). Post-mortem studies of schizophrenia patients have 
shown enlarged lateral ventricles (Brown, Colter, Corsellis et al., 1986; Pakkenberg, 
1987), decreased temporal lobe volume (Bogerts, Meertz & Schönfeldt-Bausch, 
1985; Brown et al., 1986) and decreased thalamic volume (Pakkenberg, 1990; 1992). 
Other evidence has shown increased cell packing density in the dorso-lateral 
prefrontal cortex (DLPFC, Daviss & Lewis, 1995; Selemon, Rajkowska & Goldman-
Rakic, 1995; 1998).  A potential confound of any neuropathological finding is that 
antipsychotic drug treatments may contribute, and even cause some, if not all, of the 
neuropathology observed in the disease. However, studies investigating chronic 
treatment of non-human primates with antipsychotic drug agents, failed to produce 
some of the pathologies seen in schizophrenia such as increased cell packing density 
in the DLPFC, although the study did not examine the full range of schizophrenia 
neuropathology (Selemon, Lidow & Goldman-Rakic, 1999). 
The neuropathological causes of schizophrenia are thought to be either 
neurodegenerative or neurodevelopmental in nature (Harrison et al., 2011). If 
neurodegenerative, we would expect to find the hallmarks of these types of 
disorders, such as neurofibrillary tangles, gliosis or neuronal and synaptic loss 
gradually increasing over time. However, none of these signs are consistently 
observed in the schizophrenic brain. On the other hand, the only neuropathological 
support for a neurodevelopmental hypothesis of schizophrenia remains the lack of 
findings that actually negate a neurodevelopmental aetiology; some studies describe 
hippocampal neuron disarray, but without replication of these types of findings, the 
neurodevelopmental hypothesis of schizophrenia remains unconfirmed (Harrison et 
al., 2011), although indications of risk in early life also provide support for this 
hypothesis (See Section 1.4). 
 
1.3.2 Neurochemistry in schizophrenia 
The dopamine hypothesis of schizophrenia posits, essentially, that the 
disorder is caused by an excess of dopamine. This idea stems from the observation 
that all of the current antipsychotics are D2 dopamine receptor antagonists. Laruelle 
and colleagues (1996) provided further support for this hypothesis by demonstrating 
that acute psychosis could be induced in drug-free schizophrenia patients through 
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increased striatal dopamine release, bought on by an amphetamine challenge. There 
is also post-mortem evidence for increased density of striatal D2, D3 and D4 receptors 
(Abi-Dargham & Grace, 2011), however, many post-mortem and positron emission 
tomography (PET) studies are unable to rule out potential antipsychotic drug effects 
(Keshavan, Tandon, Boutros & Nasrallah, 2008). 
 The excess striatal dopamine associated with the positive symptoms of 
schizophrenia has been well replicated (Laruelle, Abi-Dargham, Gil et al., 1999;  
Harrison, 1999a), however, the neurobiological correlates of the cognitive and 
negative symptoms of schizophrenia are more complex (Keshavan et al., 2008), and 
have led to a reformulation of the dopamine hypothesis to account for these non-
psychotic symptoms. One explanation that has been put forward is that there is a 
deficit of dopamine in the cortex, which is thought to cause hypo-stimulation of D1 
receptors (Keshavan et al., 2008). This idea that cortical dopamine deficits cause the 
cognitive symptoms of schizophrenia has been further supported by a clinical study 
demonstrating that high DLPFC D1 receptor availability was associated with poorer 
performance in patients with schizophrenia on a working memory task (Abi-
Dargham, Mawlawi, Lombardo et al., 2002) as well as an animal model showing that 
induced dopamine depletion in the pre-frontal cortex produced cognitive 
impairments (Abi-Dargham & Grace, 2011). As a result of these findings, it is 
currently thought that the cognitive and negative symptoms of schizophrenia can be 
explained by an underactive mesocortical dopaminergic system and that the positive 
symptoms are due to an over-active mesolimbic dopamine system (Weinberger, 
1987). 
 Serotonin (5-hydroxytryptamine, 5-HT) is another neurotransmitter that has 
been linked to schizophrenia, originally due to observations of the similarity between 
serotonin and the hallucinogenic drug lysergic acid diethylamide (LSD), which caused 
users to experience psychotic-like episodes comparable to schizophrenia (Iqbal & 
van Praag, 1995). Consequently it was proposed that schizophrenia was due to a 5-
HT deficit, although this was later revised, as it was discovered that LSD could be 
both 5-HT antagonist and agonist, hence both a decrease in serotonin and an 
increase could produce psychotic like symptoms (Iqbal & van Praag, 1995). The 
strongest evidence for the role of serotonin in the pathogenesis of schizophrenia is 
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the fact that atypical antipsychotics such as risperidone and clozapine (Keshavan et 
al., 2008), show greater affinity for 5-HT-2A receptors in comparison to their affinity 
for D2 receptors, potentially working as serotonin antagonists rather than dopamine 
antagonists; relieving the negative symptoms, as well as the more treatment 
resistant forms of schizophrenia (Moghaddam & Krystal, 2004). Despite this, direct 
evidence for serotonergic dysfunction in schizophrenia pathogenesis is lacking, but a 
potential interaction between serotonin and dopamine remains promising (Keshavan 
et al., 2008). 
 The neurotransmitter glutamate has also been implicated in schizophrenia 
due to the initial observations of reduced glutamate in the cerebrospinal fluid of 
schizophrenia patients (Kim, Kornhuber, Schmid-Burgk et al., 1980). This theory was 
supported by the finding that the drug phencyclidine (PCP), an NMDA (N-methyl-D-
aspartate) antagonist, produces both the positive and negative symptoms of 
schizophrenia in healthy individuals and exacerbates the symptoms in patients with 
schizophrenia. Glutamate neurotransmission is the principal method for excitatory 
communication in the brain, leading to the theory that a deficit in glutamate 
transmission is responsible for at least part of the pathogenesis of schizophrenia 
(Krystal & Moghaddam, 2011). Support for this hypothesis comes from 
pharmacological studies using glutamate transmission agonists to alleviate negative 
symptoms of schizophrenia (Coyle, Darby, Flood et al., 1996), and from post-mortem 
analysis of the brains of schizophrenia patients showing reduced expression of 
glutamate receptors in brain regions such as the prefrontal cortex and the 
hippocampus (Keshavan et al., 2008).  
 It is not likely that one neurotransmitter can explain the complete 
pathogenesis of schizophrenia. What is needed is a better understanding of the 
interactions between neurotransmitters and how aberrant signals may contribute to 
some of the mechanisms underlying this disorder.  
 
1.3.3 Structural and functional neuroimaging in schizophrenia 
Modern imaging techniques make it possible to visualise the brain, 
confirming the brain abnormalities seen in patients with schizophrenia from earlier 
post-mortem studies. Magnetic resonance imaging (MRI) studies measuring regions 
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of interest (ROI) in the brains of patients with schizophrenia have discovered areas 
which are more reduced in volume than the brain as a whole (Lawrie, Johnstone & 
Weinberger, 2004). Findings include a 5-10% reduction in the volume of the PFC and 
temporal lobes (Lawrie & Abukmeil, 1998; Wright et al., 2000), a 10% reduction in 
the volume of the amygdala (Wright et al., 2000), and a 6% reduction in both the left 
and right hippocampi (Wright et al., 2000). Lateral and third ventricle sizes are 
thought to be increased by as much as 30% in cases with schizophrenia as compared 
to controls (Lawrie & Abukmeil, 1998; Wright et al., 2000). Variations in structures 
such as the basal ganglia are thought to be due to the effects of antipsychotic 
medication, as basal ganglia volume correlates with first episode antipsychotic dose 
and regresses on second generation treatment (Lawrie & Pantelis, 2011). The 
Edinburgh high risk study followed young unaffected relatives of schizophrenia 
patients in Scotland, with a known family history of schizophrenia (Johnstone, 
Cosway & Lawrie, 2002). Imaging results found that these high risk subjects, in 
comparison to controls, had a 4% reduction in their amygdala-hippocampal complex, 
perhaps suggesting that a reduction in medial temporal lobe structures could be a 
risk marker for schizophrenia (Lawrie et al., 2004). Whole brain gray matter volumes 
are also reduced by approximately 3-4% in schizophrenia patients, particularly in 
temporal lobe structures like the hippocampus, amygdala and the superior temporal 
gyri (Lawrie & Abukmeil, 1998). White matter tract abnormalities have also been 
found, with whole brain white matter reduced by approximately 2% (Wright et al., 
2000), with specific reductions found in the corpus callosum of patients with 
schizophrenia, as well as their relatives (Keshavan et al., 2008). 
Positron emission tomography (PET) scans use radioactive-labelled reagents 
to measure metabolism (as indexed by glucose levels), ratio of receptors (occupied 
at a ligand) and blood flow (Meyer-Lindenberg & Bullmore, 2011), with findings 
indicating elevated D2 and D3 receptor density in schizophrenia patients in the PFC, 
hippocampus and anterior cingulate cortex regions (Vyas, Patel, Nijran et al., 2010). 
PET imaging studies on patients who were currently experiencing auditory 
hallucinations revealed increased blood flow in the thalamus, right straitum, left 
hippocampus, parahippocampus, orbitofrontal, and cingulate areas (Shenton, 
Dickey, Frumin & McCarley, 2001). 
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Alongside the findings of structural neuroimaging, functional magnetic 
resonance imaging (fMRI) can be used to relate potential brain abnormalities to 
cognitive states and behavioural symptoms. Functional MRI uses blood oxygenation 
levels as an index of brain activity and has been used to assess the activation 
patterns of schizophrenia cases and controls at baseline and whilst performing 
various cognitive challenge paradigms. Using these methodologies, schizophrenia 
patients have shown hypoactivation, as compared to controls, of the DLPFC during a 
selective attention task (MacDonald & Carter, 2003 and a working memory task (the 
n-back test) (Minzenberg, Laird, Thelan et al., 2009). The DLPFC and ventro-lateral 
PFC were also hypoactivated during the encoding and retrieval of episodic 
memories, while the left pre-central and right medial frontal gyrus were 
hyperactivated (Achim & Lepage, 2005). Emotional regulation has also been 
investigated using imaging techniques. Research has shown hypoactivation of the 
amygdala when schizophrenia patients (as compared to controls) are presented with 
emotional stimuli versus neutral stimuli (Aleman & Kahn, 2005). The fMRI 
investigations into the neurocognitive functions of ZNF804A are discussed in detail in 
Section 1.6.3.  
In summary, there is good evidence for structural and functional brain 
changes in schizophrenia, including in relation to possession of risk alleles of the 
ZNF804A gene, as considered in more detail below, (see section 1.7.4), however, the 
effects are often subtle and the precise implications of the imaging findings remains 
an issue.  
 
1.4 Environmental risk factors 
Current thinking has it that the aetiology of schizophrenia involves a complex 
mix of risk factors, of which environmental influences are thought to play a 
substantial part. As mentioned earlier, migrancy has been shown to increase the risk 
of developing schizophrenia (Pedersen & Mortensen, 2001; McGrath et al., 2004). 
Although the reasons for this remain unclear, some have suggested that the 
incidence rates may be raised due to ethnic disadvantage (the relative deprivation of 
resources and rewards as a result of being a given race), as opposed to migrancy per 
se; a hypothesis supported by the increased vulnerability to schizophrenia among 
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the Afro-Caribbean population living in England (Wessely, Castle & Murray, 1991; 
Castle, Wessely, Der & Murray, 1991). Additionally, it is likely that severe disruptions 
to the social fabric of life also play a role, especially in first generation migrants (van 
Os, Kennis & Rutten, 2010). Individuals living in urban areas also have an increased 
incidence of schizophrenia, perhaps due to the stress of overcrowding and 
environmental pollutants (McGrath et al., 2008). 
Early life trauma, such as obstetric difficulties, including premature birth, 
foetal growth retardation, foetal hypoxia and prenatal complications are all thought 
to increase the risk of developing schizophrenia in adulthood (Clarke, Harley & 
Cannon, 2006). There has also been considerable interest in the impact of 
malnutrition on the developing foetus, with one ecological study examining the 
effect of the Dutch Hunger Winter (during World War II) on the development of 
individuals who were in utero during this famine, finding that those individuals had 
higher rates of schizophrenia and schizophrenia spectrum disorders than the general 
population (Susser & Lin, 1992). Serum taken from pregnant mothers has also 
suggested a possible link between low vitamin D levels during the 3rd trimester and 
increased incidence of schizophrenia (McGrath, Eyles, Mowry et al., 2003b). 
Prenatal infections are also thought to confer risk of schizophrenia, originally 
examined in the context of Winter-borne viruses, but the evidence is inconsistent 
(McGrath & Murray, 2011).  Some studies have found links between the incidence of 
schizophrenia and non-affective psychosis and maternal exposure to the herpes 
simplex virus type 2 (Buka, Tsuang, Torrey et al., 2001) and rubella (Brown, Cohen, 
Greenwald et al., 2000a), although again these findings have not been replicated. 
Adult exposure to infectious agents such as Toxoplasmosis gondii and its links to 
schizophrenia have been better replicated, with meta-analyses showing that cases 
with schizophrenia have an increased presence of antibodies to Toxoplasmosis 
gondii (Torrey, Bartko, Lun et al., 2007), although it is as yet unknown whether the 
presence of these antibodies came before the onset of the illness (and were 
causative) or contributed to the disease process already in place (McGrath & Murray, 
2011).   
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The precise neurodevelopmental routes to psychopathology in adulthood 
remain to be established but are likely to involve, at least in part, interactions with 
genetic background. 
 
1.5 The genetic architecture of schizophrenia  
1.5.1 Genetic epidemiology 
It has long been recognised that schizophrenia clusters among relatives of 
patients with schizophrenia to a greater extent than in the general population. The 
first published systematic study into the heritability of schizophrenia was conducted 
by Rudin in 1916, who found that schizophrenia was more common in the siblings of 
affected individuals than in the general population (Riley & Kendler, 2011). This was 
later extended by Kallman (1938) who found that the offspring of probands also 
displayed an increased risk of developing schizophrenia (Riley & Kendler, 2011). 
Much has been learnt about the heritability of schizophrenia from twin studies of 
monozygotic (MZ) and dizygotic (DZ) twins. The most recent meta-analysis of twin 
study data found a consistent genetic effect with higher concordance rates among 
MZ (41-65%) than DZ (0-28%) twins, and a heritability estimate of 80-85% (Cardno & 
Gottesman, 2000). 
 Adoption studies have attempted to further the investigation into 
schizophrenia heritability by examining offspring of probands adopted away from 
their biological parents, thereby attempting to more definitely separate environment 
effects from shared genes. The Finnish adoptive family study of schizophrenia looked 
at adopted-away offspring of mothers with schizophrenia versus adopted away 
offspring of control mothers. Of the children whose mothers had schizophrenia, 9.1% 
went on to develop a schizophrenia spectrum disorder and 4.9% went on to develop 
schizophrenia, compared to only 1.1% of the control offspring who went on to 
develop schizophrenia (Tienari, 1991), providing further strong evidence for a major 
genetic contribution to schizophrenia. The methods of uncovering the specific 
genetic variation at the sub-microscopic level conferring risk for schizophrenia fall 
into two main approaches; linkage and association, with a third approach involving 
the study of large chromosomal abnormalities assessed using cytogenetic methods.  
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1.5.2 Linkage studies 
‘Mendelian’ genetic illnesses are caused by mutations in a single gene (or 
limited number of genes) (e.g. Huntington’s disease). These types of illnesses are 
comparatively rare, and are in large part passed on faithfully down the generations 
(unless the mutation is lethal prior to reproduction); these illnesses can also arise 
spontaneously by de novo mutations. Linkage analysis maps functionality of genes to 
their location on chromosomes. As DNA segments lying near to each other on a 
chromosome tend to be inherited together, markers are often used as tools for 
tracking the inheritance pattern of a gene that has not yet been identified but whose 
approximate location is known. Through this genetic mapping, families where some 
have the disorder and some don’t can be used to identify loci associated with that 
disorder. Typically, linkage analysis allows rare variants of large effect to be 
discovered, and has proved a fruitful tool for schizophrenia research, with many 
putative candidate genes discovered this way, such as DISC-1 (St Clair, Blackwood, 
Muir et al., 1990), Neuregulin 1 (Stefansson, Sigurdsson, Steinthorsdottir et al., 
2002), and DTNBP1 (Straub, Jiang, MacLean et al., 2002). However, replication of 
these findings is difficult and as yet no specific risk alleles in these genes have been 
identified and replicated successfully. 
 
1.5.3 Association studies 
Association studies examine genetic variation between populations of 
individuals with a diagnosed disorder and non-affected controls without the 
disorder. If one allele is more frequent in people with the disease, the SNP is said to 
be "associated" with the disease. The associated SNPs are then thought to highlight a 
region of the genome which influences the risk of disease. The association of the SNP 
can be explained by one of two possibilities: either that the SNP is directly associated 
with the disease and has functional relevance, or that the SNP is indirectly associated 
with the disease through linkage disequilibrium. Recent advances in genotyping 
technology have meant that high throughput sequencing of whole genomes is 
possible, leading to the development of genome wide association studies (GWAS). 
Here, almost 1 million DNA variants can be assessed in a single experiment, 
providing genome wide coverage of possible genetic variants between cases and 
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controls. For many common diseases, GWAS have transformed our knowledge of 
genetic susceptibility by identifying putative causal alleles, often of relatively small 
effect. It should be emphasised that, despite many of the discovered variants from 
GWAS having little effect on overall risk burden, functional studies examining their 
mechanism(s) of action and the pathways they interact with can be highly 
illuminating in terms of pathogenesis and options for treatments (Willer & Mohlke, 
2012). 
Early GWAS for schizophrenia failed to implicate specific loci, probably due to 
small sample sizes (O’Donovan & Owen, 2011). One of the more recent genome wide 
association studies (discussed in detail in section 1.7.1) utilised a much larger sample 
and was successful in identifying loci associated with a diagnosis of schizophrenia, 
with the greatest association stemming from a SNP in the gene ZNF804A, an 
association that, crucially, has been replicated several times (O’Donovan et al., 
2008). Schizophrenia genetics was further enhanced by publications in 2009 of three 
more GWAS, each containing more than 2000 cases and almost 14000 controls. 
These studies, stemming from three different consortia, combined their datasets 
enabling meta-analysis, giving almost 13000 cases and 34000 controls (Stefansson, 
Ophoff, Steinberg, et al., 2009). Four loci emerged as genome wide significant, with 2 
mapping to chromosome 6, including the major histocompatibility complex (MHC) 
region (P = 1.4 x 10-12), one loci is adjacent to neurogranin (NRGN) (P = 2.4 x 10-9), 
and the other is located in an intron of transcription factor 4 (TCF 4) (P = 4.1 x 10-9). 
There are limitations with association studies, including the fact that low 
frequency variants are often not tagged, and even when they are detected they 
require much larger samples to gain equivalent effect sizes (O’Donovan & Owen, 
2011). There is also the fact that there are no biomarkers for schizophrenia, and as 
such the samples of patients included may be heterogeneous, and findings may 
therefore be ambiguous (O’Donovan & Owen, 2011). The hope is that some of these 
limitations, especially in terms of molecular resolution, can be overcome by ‘next 
generation’ sequencing methods. However, whilst there is much research activity in 
this area going on, at the time of writing there were no substantial published 
reports. 
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1.5.4 Structural abnormalities 
Structural genomic variation occurs in the form of duplications, deletions, 
sequence inversion and translocation. Copy number variants (CNVs) are structural 
variants that are at least 1000 bases in size and change the number of copies of a 
given portion of DNA sequence. Velo-cardio-facial syndrome (VCFS) involves 
deletions in chromosome 22q11, giving rise to an increased risk of schizophrenia (25-
30 times that of the general population). These findings have led to work examining 
this interval for susceptibility genes and a number of genes have been suggested, 
notably Catechol-O-methyltransferase (COMT, see Section 1.5.5.1) and proline 
dehydrogenase (PRODH). 
Most studies have found that at a genome wide level, cases have a greater 
load of low frequency CNVs than controls, but there are differences in terms of the 
effect sizes (Walsh, McClellan, McCarthy et al, 2008; International Schizophrenia 
Consortium, 2008; Kirov, Grozeva, Norton et al, 2009). In the International 
Schizophrenia Consortium study, cases had a 1.15-fold excess of low frequency 
CNVs, increasing to 1.6-fold for deletions >500kb (O’Donovan & Owen, 2011). Three 
deletions were discovered in two recent genome wide CNV studies, with both 
studies in agreement over two loci, one at 1q21.1 and one at 15q13.32 (International 
Schizophrenia Consortium, 2008; Kirov et al, 2009b). A third deletion was discovered 
by only one of the studies (International Schizophrenia Consortium, 2008), but this 
locus was later independently confirmed (Kirov et al., 2009). 
Although this data suggests that there is greater CNV burden in 
schizophrenia, some of the associations between certain CNVs are not exclusive to 
schizophrenia, with the 1q21.1 locus also conferring high risk for autism, mental 
retardation and epilepsy, and the 15q13.3 locus linked to idiopathic generalised 
epilepsy (O’Donovan & Owen, 2011). Currently CNVs are thought to occur in only 2% 
of schizophrenia cases (Kirov et al., 2009b); however this does not mean that they 
are not meaningful in terms of helping to uncover biological mechanisms involved in 
the pathogenesis of schizophrenia. Indeed, in conjunction with SNP analysis, they 
have great potential to unravel the complexity of the disease. 
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1.5.5 ‘Functional’ schizophrenia candidate genes 
The functional candidate gene approach originates from the idea that those 
genes that have a potential role in the pathogenesis of schizophrenia from a priori 
evidence (such as drug targets for anti-psychotics) may also be statistically 
associated with this disorder. These studies have struggled to find true positives; 
with no evidence emerging that is on par with the discovery of APOE in Alzheimer’s 
disease or HLA in Type I diabetes (O’Donovan & Owen, 2011). The power issues 
associated with much of the candidate gene literature means that although an 
association may fail to replicate, it does not necessarily rule out the possibility of a 
true association. With the technology for genotyping rare high penetrance SNPs ever 
increasing, there is hope for further discoveries in the future. 
 
1.5.5.1. Dopamine genes 
As discussed previously (Section 1.3.2), there is a convincing body of evidence 
that altered dopaminergic functioning contributes to the aetiology of schizophrenia, 
and as such, genes which have been shown to influence dopamine function have 
been posited as potential candidate genes. COMT is one such gene, and encodes an 
enzyme which catabolises dopamine, and is located in a region of chromosome 
22q11, which when deleted results in a multifaceted syndrome of which 
schizophrenia is a common feature (Williams, Owen & O’Donovan, 2007). The gene 
also contains a polymorphism resulting in a valine-to-methionine substitution 
(Val/Met locus), thought of as the main source of genetic variation in COMT activity. 
The association between COMT and schizophrenia has been reviewed by Williams 
and colleagues (2007), with results indicating both positive and negative findings at 
the Val/Met locus, perhaps due to the low power of some of the studies included in 
the meta-analysis. There are also some interesting interactions between COMT and 
environmental factors such as cannabis use (O’Donovan & Owen, 2011). 
DRD2 is a gene which encodes dopamine 2 receptors, and is a plausible 
candidate due to the therapeutic effect of antipsychotic drugs with a high affinity for 
dopamine 2 receptors (O’Donovan & Owen, 2011). One study has found an 
association between a serine to cysteine polymorphism in DRD2 in a Japanese 
population diagnosed with schizophrenia but not suffering from negative symptoms 
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(Arinami, Gao, Hamuguchi & Toru, 1997), with a meta-analysis confirming the 
association of this polymorphism with schizophrenia (Glatt & Jönsson, 2006). 
Another variant, rs6277, has also received statistical support for its association with 
schizophrenia (Lawford, Young, Swagell et al., 2005; Monakhov, Golimbet, Abramova 
et al., 2008), suggesting that DRD2 may warrant further investigation.  
1.5.5.2 Serotonin genes 
Many atypical antipsychotics influence the 5-HT system, and therefore genes 
implicated in this system have been suggested as likely candidate genes (Section 
1.3.2). The first studies to provide evidence for a potential serotonin gene found that 
the variant rs6313 within the gene HTR2A (which encodes the 5-HT2A receptor) was 
associated with schizophrenia (Inayama, Yoneda, Sakai et al., 1996; Williams, 
Spurlock, McGuffin et al., 1996); however this association has not been replicated 
since. The 5-HT transporter gene (SERT) has been vigorously studied (due to its role 
in the treatment of psychosis) but no variants within this gene were significantly 
associated with risk for developing schizophrenia (O’Donovan & Owen, 2011). One 
other gene, TPH1, is one of 2 enzymes encoding tryptophan hydroxylase; the rate 
limiting enzyme in the synthesis of serotonin. One particular SNP in this gene has 
been associated with schizophrenia in a meta-analysis of 1200 case and 1700 
controls (SZGene; Allen, Bagade, McQueen et al., 2008), but as the numbers are 
fairly small, replication may in fact show this to be a false positive. 
 
1.5.6 Positional candidate genes 
 Positional candidate genes are those genes that have been linked to 
schizophrenia based on evidence of their involvement from linkage studies or 
chromosomal location/abnormalities. DISC1 has been put forward as a potential 
candidate gene for schizophrenia due to a translocation (chromosome 1:11, 
q42.1:q14.3) co-segregating with mental illness in a Scottish family (St Clair et al., 
1990), with further research identifying the translocation breakpoint to two genes; 
Disrupted in Schizophrenia 1 (DISC1) and Disrupted in Schizophrenia 2 (DISC2). The 
translocation disrupts the coding sequence of DISC1, hypothesised to result in a 
truncated protein, with reduced DISC1 expression in the family members 
(O’Donovan & Owen, 2011). The translocation appears to be unique to this family, 
19 
 
but other research has attempted to link DISC1 to schizophrenia and other mood 
disorders such as bipolar, but with little success. DISC1 does, however, appear to be 
linked to brain development, including processes such as neural migration and 
proliferation, neurogenesis and synaptic plasticity (O’Donovan & Owen, 2011). There 
is also data suggesting that variants in this gene are associated with performance on 
various neurocognitive tests, and with functional neuroimaging (Callicott, Straub, 
Pezawas et al., 2005; Di Giorgio, Blasi, Sambataro et al., 2008) 
RGS4 is another positional candidate gene for schizophrenia, mapping to a 
potential linkage region on 1q21-q22. RGS genes are thought to suppress the effects 
of neurotransmitter-receptor interaction at G protein coupled receptors, including 
the dopamine receptors (O’Donovan & Owen, 2011). Chowdari and colleagues have 
also shown RGS4 to be down-regulated in the brains of schizophrenia patients 
(Chowdari, Mirnics, Semwal et al., 2002), although association studies have failed to 
provide support for a specific haplotype which survives correction for multiple 
testing. 
 
1.6 ZNF804A 
1.6.1 Discovery of ZNF804A as a potential schizophrenia candidate gene 
O’Donovan and colleagues conducted a large-scale GWAS for schizophrenia, 
incorporating 479 cases and 2937 controls from the UK, genotyped using a mapping 
array chip containing roughly 500,000 SNPs (O’Donovan et al., 2008). Loci with a 
moderately strong association to schizophrenia (p<1 x 10-5) were followed up in a 
more international sample of 6666 cases and 9897 controls (Table 1.1). The 
strongest association in the replication sample came from the risk allele at 
rs1344706, found on chromosome 2 in the region of the zinc finger protein 804A 
(ZNF804A, p<9.25 x 10-5). This same SNP in ZNF804A surpassed the benchmark for a 
strong association with schizophrenia when bipolar cases were added to the affected 
sample (p<9.96 x 10-9), suggesting that SNPs in the area of ZNF804A may influence 
risk for a broader psychosis phenotype (O’Donovan et al., 2008). 
The genetic association between the ZNF804A risk allele and schizophrenia 
has since been thoroughly replicated; firstly in an Irish Case-Control study with a 
reported p-value of 0.0113 (Riley, Thiselton, Maher et al., 2009), followed by another 
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replication study showing a p-value of 0.0029, which strengthened to 0.00065 when 
bipolar cases were included (Steinberg, Mors, Børglum et al., 2011). The association 
has also been replicated in a Han Chinese sample with a p-value of 0.00083 (Zhang, 
Lu, Qiu, et al., 2012), although another study on a different Asian population failed to 
find an association between rs1344706 and schizophrenia, with a p-value of 0.26 (Li, 
Shi, Shi et al., 2012). Furthermore, recently, the investigators who originally 
uncovered the association between ZNF804A and schizophrenia conducted a large 
scale meta-analysis (Williams, Norton, Dwyer et al., 2011), which provided yet more 
compelling evidence that the risk SNP at rs1344706 in ZNF804A is associated with 
schizophrenia in both schizophrenia cases alone (p= 2.5 x 10-11) and schizophrenia 
and bipolar cases combined (p= 4.1 x 10-13). It appears that ZNF804A may be one of 
the most robustly replicated genes in schizophrenia to date. 
 
Table 1.1: Loci selected for follow up in the O’Donovan et al. GWAS (2008). 
 
 
Table showing the 12 loci with moderately strong association to schizophrenia selected for follow 
up in the O’Donovan et al. GWAS (2008). 
 
ZNF804A maps to chromosome 2q32.1 and contains 4 exons which code for a 
protein consisting of 1210 amino acids. Little is known about the encoded protein, 
although its sequence highlights a zinc finger domain at the N-terminus end 
suggesting that it may regulate gene expression through its role in binding DNA 
(Donahoe, Morris & Corvin, 2010). Steinberg et al. (2011) not only sought to 
replicate the association between the risk SNP in ZNF804A and schizophrenia, but 
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also set out to examine ZNF804A for any gain or loss in copy number. Using 4235 
psychosis patients, 1173 patients with other psychiatric disorders and 39481 
controls, they identified two psychosis patients with CNVs affecting part of ZNF804A 
and none in controls. These CNVs included a deletion in a schizophrenia patient and 
duplication in an individual with bipolar disorder. They also uncovered a deletion in 
ZNF804A in an individual with anxiety disorder. These cases contrast with no CNVs at 
the ZNF804A locus in around 40000 controls. Despite this, Steinberg notes that it is 
hard to draw any conclusions about CNVs in ZNF804A and schizophrenia as there is 
overlap with other psychiatric disorders such as anxiety. 
 The risk SNP in ZNF804A, rs1344706 is an intronic SNP found 47kb from the 3’ 
end of exon 2 20kb from the 5’ end, in intron 2 (Okada, Hashimoto, Yamamori et al., 
2012), located in  roughly 30bp of conserved mammalian sequence (Riley et al., 
2009). Given the intronic location of the SNP, any functional effects are thought to 
be due to splicing or transcriptional factors (Hill & Bray, 2012). It is not known 
whether the SNP is directly related to schizophrenia in a causative way or if the SNP 
is indirectly related and merely in linkage disequilibrium with another more 
informative variant. Williams et al. (2011) conducted extensive mapping of the locus 
and high density linkage disequilibrium mapping to better localise the association 
signal, covering 96% of all the known SNPs in ZNF804A. Despite this thorough 
investigation, rs1344706 remained the strongest associated polymorphism in the 
gene.  
 
1.6.2 ZNF804A variants and risk for disease 
Although there has been extensive research into the statistical association 
between schizophrenia and ZNF804A, little is currently known about the biological 
function of ZNF804A, and how the SNP rs1344706 actually confers risk for 
schizophrenia.  ZNF804A is expressed widely throughout the adult and developing 
brain, including the cortex and hippocampus (Johnson, Kawasawa, Mason, et al., 
2009; Kang, Kawasawa, Cheng, et al., 2011). Riley et al. (2010) carried out post 
mortem qPCR expression analyses of brain tissue taken from rs1344706 carriers and 
non-carriers in schizophrenia cases versus controls, showing that controls carrying 
the risk allele had significantly higher levels of ZNF804A expression in the DLPFC than 
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controls carrying the non risk allele (p=0.033). Patients with schizophrenia showed 
increased ZNF804A expression in the DLPFC relative to controls; however this failed 
to reach significance. Williams et al. (2011) also investigated ZNF804A expression, 
using carriers and non carriers of the risk allele (T), and finding that the risk allele 
was associated with higher expression of ZNF804A. As there was no difference in the 
degree of differential expression in rs1344706 homozygotes compared to 
heterozygotes, the authors point out that the risk allele was not the expression 
quantitative trait loci (eQTL) directly responsible for the higher expression (Williams 
et al., 2011). This may suggest that the SNP affects expression by altering its 
regulatory sequence, and as such is acting in cis; affecting expression of the gene 
copy that is transcribed from the parental chromosome on which it lies. Both these 
studies support, ostensibly, the idea of a link between the risk allele, increased 
expression of ZNF804A in adult brain and risk for schizophrenia. 
Another allelic expression study looked at the binding of the risk allele to 
nuclear proteins derived from human neural cell lines, using a synthetic 
oligonucleotide containing the rs1344706 locus (Hill & Bray, 2011). Here they found 
that the rs1344706 risk allele (T) resulted in reduced nuclear protein binding; binding 
46% less than the non-risk allele (G), suggesting a direct effect of the SNP on 
ZNF804A expression through altered DNA-protein interactions, and support the idea 
that the SNP might be a cis-acting transcriptional regulator of the gene (Okada et al., 
2012).  A very recent expression study examining foetal brain tissue (Hill & Bray, 
2012) has shown that the risk allele is associated with a relative decrease in 
expression of ZNF804A during the second trimester of development. These data are 
important as they emphasise how stage of development needs to be taken into 
account in formulating ideas about how variants in ZNF804A might impact on 
disease risk and also suggest that models where gene expression is reduced 
constitutively may be of use in discerning pathogenic mechanisms.  
Acute knockdown of ZNF804A has marked effects on expression of genes 
involved in cell adhesion, with the most significant differences observed for STMN3, 
a gene that has been implicated in axonal and dendritic branching adhesion and 
neurite outgrowth. The fact that ZNF804A knockdown affected genes belonging to 
the cell adhesion category, could mean that ZNF804A may have a role in processes 
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such as synapse formation and neural migration, which are thought to be abnormal 
in schizophrenia (Hill, Jeffries, Dobson, Price, & Bray, 2012). Moreover, the mouse 
orthologue of ZNF804A, Zfp804a, is a target of the gene Hoxc8. Chung and 
colleagues (2008) found that Hoxc8 bound to an intronic region in the 3rd intron of 
Zfp804a, and that Hoxc8 upregulated Zfp804a mRNA levels. The two genes were also 
co-expressed in E11.5 mouse embryos. The combined expression of various Hox 
genes are thought to make up the ‘Hox code’; the genetic program posited to be 
responsible for the fate of cells, such as morphogenesis, growth and differentiation 
during embryonic development. This link with Hoxc8 could further indicate a role for 
ZNF804A in early neurodevelopment.  
In summary, the relatively limited studies carried out so far suggest a direct 
effect of the risk SNP on ZNF804A expression through altered DNA-protein 
interactions, and support the idea that the SNP might be a cis-acting transcriptional 
regulator of the gene (Riley ey al., 2009; Williams et al., 2011; Hill & Bray, 2011, 
2012). ZNF804A knockdown studies show that ZNF804A may have a role in cell 
adhesion processes such as synapse formation and neural migration, which are 
thought to be abnormal in schizophrenia (Hill et al., 2012). Despite the recent 
developments in understanding the biological function of ZNF804A, there are still 
many unanswered questions on exactly how the risk allele in ZNF804A contributes 
towards the development of schizophrenia, and indeed what the exact biological 
functions of ZNF804A are remain something of a mystery. Finally, it is important to 
emphasise that there may be as yet unidentified variants at the locus which may also 
influence susceptibility to schizophrenia. 
 
1.6.3 Neurocognitive functions of ZNF804A 
Work looking into the neurocognitive phenotype of the risk allele at 
rs1344706 began with an fMRI study looking at the connectivity between certain 
brain regions (Esslinger, Walter, Kirsch et al., 2009). Using 115 healthy German 
participants, they found that carriers of the risk allele had disturbed functional 
coupling between certain brain regions whilst performing the n-back task, a well 
validated working memory cognitive probe. Specifically, risk allele carriers showed 
reduced connectivity both within the DLPFC and to the contralateral DLPFC whereas 
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connectivity between the DLPFC and the hippocampus was increased in a dose 
dependent manner for homozygous risk allele carriers. The risk allele was also 
associated with increased connectivity from the amygdala to the hippocampus, the 
medial prefrontal cortex and to the orbitofrontal cortex. Regional brain activation 
was not related to genotype, nor was overall performance in the task, perhaps 
indicating that the risk allele may be predominantly influencing the neurobiological 
phenotype (Esslinger et al., 2009). Due to widespread research of reduced brain 
function in schizophrenia, and the fact that ZNF804A has been associated with 
schizophrenia, the authors speculated that the reduced connectivity within the 
DLPFC may contribute to disturbed executive function (an endophenotype of 
schizophrenia), but that the increased connectivity between the DLPFC and 
hippocampus could disrupt interactions between the prefrontal and limbic cortices, 
perhaps pointing towards a more bipolar like phenotype. 
Another study offers an alternative theory concerning the role of ZNF804A in 
cognition. Here an independent sample of German and Irish schizophrenia cases and 
healthy controls were tested on cognitive functions that are impaired in 
schizophrenia, for example IQ, working memory, episodic memory and attention 
(Walters, Corvin, Owen et al., 2010). Irish schizophrenia patients homozygous for the 
rs1344706 risk allele performed relatively better on measures of episodic memory 
and working memory than patients homozygous for the non-risk allele, with these 
results replicated in a German sample. The allelic association between ZNF804A and 
schizophrenia further increased when patients with IQs lower than 90 were excluded 
from the analysis. These findings suggest that the ZNF804A risk allele has a 
protective effect on cognition in schizophrenia cases but not controls, and that it 
may contribute to risk for a sub-type of schizophrenia not affected by cognitive 
impairments.  
A further study has looked at theory of mind measures and rs1344706 
genotype by investigating brain activation in a theory of mind task using healthy 
volunteers (Walter, Schnell, Erk et al., 2011). Risk allele carriers exhibited a 
significant risk allele dose effect on brain activity in the theory of mind network, 
including the dorsomedial prefrontal cortex and the left temporo-parietal cortex. 
The same effect was found in the left inferior parietal cortex and left inferior frontal 
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cortex, the human analogue of the mirror neuron system. The study also found 
altered connectivity between the fronto and temporo-parietal regions in rs1344706 
risk allele carriers. This study supports the idea that ZNF804A has an impact on the 
neural activity associated with social cognition, and that the risk variant could be 
used to test intermediate phenotypes of schizophrenia with a view to developing 
biological interventions to alleviate social dysfunction in this disorder. There were, 
however, no risk allele dose effects on performance in the task, with a possible 
explanation being that behavioural effects of genes are more distal biologically than 
brain activation effects (Walter et al., 2011).  
Esslinger and colleagues sought to investigate interactions between cognitive 
state and ZNF804A genotype on connectivity (Esslinger, Kirsch, Haddad et al., 2011). 
Continuing on from their earlier study, they set out to examine whether the deficits 
in connectivity within the DLPFC for risk allele carriers were specific to the working 
memory task or broadly present and therefore structural. Imaging healthy control 
subjects during a working memory task, an emotion recognition task and at rest, 
they found that during all three conditions there was a linear decrease in 
connectivity within the DLPFC with increasing number of risk alleles. This decrease in 
interhemispheric prefrontal connectivity in subjects with the risk allele was cognitive 
state independent, indicating a potential structural abnormality within the working 
memory network of risk allele carriers, affecting functional connectivity irrespective 
of task. The second main finding was that risk allele carriers showed increased 
connectivity between the DLPFC and the hippocampus during the working memory 
task only, indicating that this finding was cognitive state dependent (Esslinger et al., 
2011). 
Another study looking at functional brain connectivity and cognition found 
that ZNF804A risk allele homozygotes as well as heterozygotes had increased 
connectivity between the anterior cingulated cortex (ACC) and the right DLPFC 
compared to non-risk allele homozygotes during a response inhibition task (Thurin, 
Rasetti, Sambataro et al., 2012). During the interference and monitoring aspect of 
the task, risk allele homozygotes and heterozygotes showed decreased right DLPFC 
and ACC activation compared to non risk allele carriers. These results suggest that 
ZNF804A could be modulating mechanisms which underlie cognitive control and 
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functional connectivity (Thurin et al., 2012). Another study has looked into how the 
ZNF804A risk allele may modulate neural activity during a working memory task. 
Alterations in neural activity in ZNF804A risk allele carriers were seen during a 
working memory task which incorporated an emotional facial processing element 
(Linden, Lancaster, Wolf et al., 2013). Specifically the rs1344706 risk allele carriers 
demonstrated a reduced activation of the right DLPFC (rDLPFC) during the working 
memory task for faces. This hypoactivation of the rDLPFC is a common finding in 
schizophrenia patients, and perhaps suggests that the ZNF804A risk allele may 
influence neural activity during working memory. A subsequent study aimed to 
replicate the findings of Esslinger and colleagues (2009) and looked into the link 
between the ZNF804A risk allele and functional connectivity during a working 
memory task. They failed to replicate the decrease in connectivity within the DLPFC, 
but did find the increased functional coupling between the right DLPFC and 
hippocampus (Paulus, Krach, Bendenbender et al., 2013). 
 These results, taken together, do seem to support the role of the ZNF804A 
risk allele in cognition, such as working memory and emotional processing. The 
majority of the results indicate fronto-hippocampal disconnectivity and 
hypoactivation of the DLPFC as intermediate phenotypes potentially linking the risk 
allele to schizophrenia, by way of mirroring the aberrant connectivity seen in 
schizophrenia patients when performing working memory tasks. However, in terms 
of the association between cognitive performance and the risk allele, one study 
implies that rs1344706 has a protective effect on cognition in schizophrenia cases 
but not controls, as patients with schizophrenia who were homozygous for the risk 
allele performed relatively better on the cognitive tasks than those patients not 
carrying the risk allele. The other studies, using healthy participants, did not indicate 
a relationship between the risk allele and cognitive performance leading to the 
suggestion that the effects of the risk allele may be influencing the neurobiological 
phenotype as opposed to the cognitive phenotype per se. 
 
1.6.4 Brain structure and ZNF804A 
A structural MRI study examined the effect of the ZNF804A risk allele on 
white and gray matter volumes as well as regional brain volumes in healthy 
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volunteers (Lencz, Szeszko, DeRosse et al., 2010). It was found that individuals 
homozygous for the risk allele had larger total white matter volumes than those with 
at least 1 non-risk allele. Furthermore, Donohoe and colleagues found that 
schizophrenia patients homozygous for the risk allele had larger gray matter brain 
volumes, particularly in the superior temporal gyrus, insula and hippocampus 
(Donohoe, Rose, Frodl et al., 2011), suggesting that ZNF804A is contributing to risk 
for a schizophrenia subtype characterised by relatively intact brain volume (Donohoe 
et al., 2011). Wassink and colleagues sought to further investigate these structural 
findings using a larger sample of 335 schizophrenia cases and 198 controls (Wassink, 
Epping, Rudd et al., 2012). They found that in the schizophrenia group, risk allele 
carriers had larger volumes and more severe psychotic symptoms, than non-risk 
allele homozygotes. Whereas in the healthy control group, risk allele homozygotes 
showed increased total white matter volume compare with non risk allele carriers, 
concordant with previously reported research (Lencz et al., 2010). It appears that the 
risk allele is associated with distinct structural phenotypes in both schizophrenia 
patients and healthy volunteers. 
125 Chinese patients with schizophrenia were examined for the effect of 
ZNF804A risk allele genotype on brain white matter integrity (Kuswanto, Woon, 
Zheng et al., 2012). Patients homozygous for the risk allele had lower white matter 
integrity in bilateral parietal lobes and left cingulated gyrus compared with non-risk 
allele carriers. Secondly, compared to healthy controls homozygous for the risk 
allele, homozygous schizophrenia patients had decreased white matter integrity in 
these same areas as well as the right medial temporal lobe, perhaps suggesting that 
the ZNF804A risk variant may influence white matter integrity involving cortico-
limbic brain regions in schizophrenia (Kuswanto et al., 2012). 
 
1.7 Animal models for schizophrenia 
 Animal models are a useful means of investigating the biological, and to an 
extent psychological, mechanisms that may confer risk and can also help in 
determining the ‘biological plausibility’ of a potential candidate gene for complex 
psychiatric disorders (Powell & Miyakawa, 2006). Model studies are driven by the 
genetic similarity between certain animal and human genomes, and the high level of 
28 
 
conservation between certain species. In particular, animal models have strengths in 
offering a controlled experimental environment and allowing the use of methods 
which may be viewed as unethical/impossible with humans, such as those requiring 
direct access to the brain. Currently, mice are one of the most popular species used 
in the laboratory, mostly due to their genetic tractability, short breeding cycle and 
worldwide availability. There are also catalogues of mutant mice already generated 
and available for testing (e.g. MRC Mammalian Genetics Unit, Harwell, 
http://www.har.mrc.ac.uk/services). 
 Mouse models which recapitulate all aspects of schizophrenia are currently 
non-existent, as many of the symptoms such as disorganised speech, hallucinations 
and delusions remain unobservable in the murine species. There is also the issue of 
translatability; how similar are the symptoms and underlying pathological processes 
seen in schizophrenia similar to the phenotypes tested in mice? Researchers might 
argue that the deficits in cognition cannot be fully replicated in species which are 
less cognitively developed. The heterogeneity of schizophrenia also poses a problem 
for animal models, as patients can experience differing combinations of symptoms, 
with the course and outcome of the disorder extremely variable (Marcotte, Pearson 
& Srivastava, 2001). 
 In view of the formidable complexity of mental disorders, a more systematic 
approach to mouse models for schizophrenia has been suggested; examining 
phenotypic indicators which could point to more discrete aspects of the condition 
(Arguello & Gogos, 2006). The mutant models of Zfp804a used extensively in this 
thesis aim to do just that, looking at how alterations in function in the mutants could 
be related to components of the complex mix of symptoms seen in schizophrenia 
and/or bipolar disorder. For example, the Zfp804a mutants were tested on prepulse 
inhibition and assays measuring hedonic responses in an attempt to model core 
attentional and affective symptoms, respectively.  
 
1.7.1 Non genetic animal models of schizophrenia 
 These types of animal models have mainly focused on the dopamine system, 
due to many antipsychotic drug treatments having D2 receptor antagonist activity, 
and the observation that dopamine agonists can induce psychotic-like symptoms 
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(Lipska & Gogos, 2011). The psychosis-inducing effects of amphetamine (a 
dopamine-releasing agent) are well reported, leading to investigations of chronic 
administration of amphetamine to rodents, with hyperactivity a common finding 
(Jones, Watson & Fone, 2011).  
As mentioned previously, glutamate has also been implicated in 
schizophrenia due to the finding that both the drugs phencyclidine (PCP) and 
ketamine (NMDA antagonists) produce both positive and negative symptoms of 
schizophrenia in healthy individuals and exacerbate the symptoms in patients with 
schizophrenia. Acute PCP administration in rodents has been shown to cause 
hyperactivity (Kalinichev, Robbins, Hartfield et al., 2007), social withdrawal (Sams-
Dodd, 1995), and impairment of both PPI (Mansbach and Geyer, 1989) and cognition 
(Egerton, Reid & McKerchar et al., 2005). 
Other models for schizophrenia have focused on the posited 
neurodevelopmental aspect of schizophrenia including perinatal stress, examined 
with techniques such as isolation rearing. This environmental manipulation was 
found to induce hyperactivity of the mesolimbic dopamine systems in rats, with 
these rats exhibiting reduced PPI (Geyer, Wilkinson, Humby et al., 1993). Rat 
maternal malnutrition induced enhanced amphetamine locomotion and reduced PPI 
(Palmer, Printz, Butler et al., 2004). Other models have looked at neonatal damage of 
certain brain regions in rats.  The hippocampus has been one of the targeted regions, 
a brain area implicated in the neurobiology of schizophrenia (Lipska & Gogos, 2011). 
Neonatal excitotoxic lesions of the ventral hippocampus in rats has produced 
promising phenotypes in adolescence and adulthood, including reduced sociability 
(Sams-Dodd, Lipska & Weinberger, 1997), enhanced sensitivity to PCP agents, 
deficits in PPI and latent inhibition and working memory problems (Lipska & Gogos, 
2011). Crucially, anti-psychotic drugs have helped to normalise some of the 
phenotypes seen in the lesioned animals (Sams-Dodd et al., 1997).  
MAM (methylazoxymethanol acetate), an anti-mitotic agent which 
methylates DNA, has been given to pregnant dams to investigate its effect on brain 
development in the affected rodent foetuses. MAM treatment at gestational day 17 
was found to produce enhanced sensitivity to PCP and ketamine on locomotor 
activity, and altered electroencephalogram responses to NMDA receptor agonists 
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(Phillips, Cotel, McCarthy et al., 2011), as well as disrupted sleep, (Phillips,  Bartsch,  
McCarthy et al., 2012), PPI and LI (Moore, Jentsch, Ghadjarnia et al., 2006). 
 
1.7.2 Genetic animal models for schizophrenia 
Many genes identified from linkage and association studies have a largely unknown 
biological function. Schizophrenia is highly heritable, and polygenic, comprising of a 
complex genetic architecture with a large number of common alleles of small effect, 
likely to have escaped the rigours of natural selection, and a number of much rarer 
but highly penetrant variants (e.g. CNVs), which due to their highly damaging effects 
are of a much more recent origin, often de novo (Xu, Roos, Levy et al., 2008). Genetic 
mouse models offer a way in to examining the effects of manipulating a ‘risk gene 
candidate’ in an intact in vivo system. Genetic animal models can be divided into 2 
basic categories: those investigated in a candidate-led manner from putative 
disease-associated mechanisms (e.g. dopamine related genes) and those discovered 
from ‘hypothesis free’ investigations of clinical samples e.g. GWAS, and linkage 
analysis. 
 
1.7.2.1 Genes modelled from putative disease-associated mechanisms 
Many of these models have again focused on the dopamine system. As 
mentioned previously, striatal overexpression of D2 receptors (D2R) has been linked 
to the pathogenesis of schizophrenia, and this has been modelled in mice 
overexpressing D2R in this brain region, with findings indicating increased activation 
of D1 receptors in the PFC and impaired working memory (Kellendonk, Simpson, 
Polan et al., 2006), as well as reduced incentive motivation (Drew, Simpson, 
Kellendonk et al., 2007) in these mice. COMT, encoding an enzyme which catabolises 
dopamine, has been put forward as a potential schizophrenia candidate gene. It 
contains a polymorphism resulting in a valine-to-methionine substitution (Val/Met 
locus), and it is this variant which has been overexpressed in mice. These COMT Val-
tg mice have shown working memory deficits, and object recognition deficits, which 
have been rescued with amphetamine treatment (Papaleo, Crawley, Song et al., 
2008). COMT knockout mice, interestingly, show improved working memory 
(Papaleo et al., 2008). Models looking into the glutamate hypothesis of 
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schizophrenia have included transgenic mice with 90% reduction in NMDA receptor 
1 expression (NR1), showing hyperactivity, and reduced social and sexual behaviour, 
with hyperactivity reduced with the administration of antipsychotics (Mohn, 
Gainetdinov, Caron, et al., 1999). 
 
1.7.2.2 Genetic models from clinical association 
Neuregulin 1, discovered originally from linkage analysis in Icelandic families 
(Stefansson et al., 2002) is a leading candidate gene for schizophrenia. The NRG1 
protein gives rise to many different proteins and isoforms, and as a pleiotropic 
growth factor, homozygous knockout of NRG1 is lethal in mice leading to NRG1 
heterozygotes and hypermorphs/conditional knockouts being utilised instead. NRG1 
heterozygotes for a mutation at the transmembrane domain showed hyperactivity, 
PPI deficits and altered sociability (O’Tuathaigh, O’Connor, O’Sullivan et al., 2008). A 
mouse model of a separate NRG1 isoform also found PPI deficits, and also working 
memory impairments and enlarged ventricles characteristic of certain schizophrenia 
neuropathologies (Chen, Johnson, Lieberman et al., 2008).  
DISC-1 was discovered from a translocation which co-segregated with mental 
illness in a Scottish family (St Clair et al., 1990). One mouse model took a ‘knock-in’ 
approach generating mutant mice carrying the translocation seen in humans (Koike, 
Arguello, Kvajo et al., 2006). These mice were found to have working memory 
deficits on a number of tasks, as well as altered neuronal distribution in the 
hippocampus. Hikida and colleagues (2007) used a dominant negative form of DISC1 
in mutant mice, finding enlarged lateral ventricles and behavioural phenotypes 
including disturbed PPI and hyperactivity. Another study used a conditional model to 
induce expression of the C-terminal section of DISC1, to test the hypothesis that the 
mutation uncovered in the original Scottish family was developmental in nature (Li, 
Zhou, Jentsch et al., 2007). They found that early postnatal (but not adult) induction 
resulted in impaired synaptic transmission, reduced sociability, depressive-like 
behaviour and altered spatial memory. Other mutations in exon 2 of DISC-1 (not 
linked to the translocation), were studied by Clapcote and colleagues (2007), 
through ENU mutagenesis. The Q31L mutation showed depressive like behaviour in 
the forced swim test, with the L100P mutant mice showing reduced PPI and LI, 
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behaviours which were reversed with antipsychotic drugs. Structural abnormalities, 
such as in the 22q11 locus deletion covering multiple genes, can also be modelled in 
mice, using chromosomal engineering approaches (Lipska & Gogos, 2011), with these 
mutants displaying deficits in PPI, fear memory and the acquisition of working 
memory (Stark, Xu, Bagchi et al., 2008). 
Genetic animal models recapitulating (to an extent) aspects of schizophrenia 
are proving to be a useful tool for understanding the neurobiological pathways 
involved in schizophrenia. As the molecular techniques become more advanced, so 
too will the genetic models. We are also at an important juncture in this area of 
research, insofar as with the increasing detail and veracity of the genetic data from 
hypothesis free studies in very large clinical samples, we can now model the action 
of candidate risk genes that have a high probability of actually being involved in 
pathogenic processes in some way, such as the robust findings with ZNF804A.  
 
1.8 Aims of the thesis 
The overall aim of the experimental work in this thesis was to further 
characterise the functions of Zfp804a, the mouse orthologue of ZNF804A, with the 
goal of understanding more about how variance in this gene may increase the risk of 
developing schizophrenia/bipolar disorder. Prior to the current work, two ENU 
mouse lines had been generated from a DNA library of ENU mutagenised mice (DNA 
Archive, MRC Mary Lyon Centre, Harwell) by a previous member of the laboratory. In 
brief, this DNA library was screened for single base pair point mutations in the 
Zfp804a gene (Al-Janabi, 2012, See Chapter II, Section 2.1), with two non-
synonymous mutations selected as viable candidates for further investigation and 
founder mice generated through in vitro fertilisation. The first line selected for re-
derivation was a nonsense mutation within exon 2 (C59X), encoding a premature 
stop codon, thought to lead to a functional null of the gene. The second mutation, 
within exon 4 (C417Y), was missense and predicted significant effects on the 3D 
structure of Zfp804a due to the substitution of the relatively small, nonpolar cysteine 
residue with a larger, polar tyrosine residue. Much of the work that follows exploited 
the availability of these two ENU Zfp804a mutant mouse lines.  
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Specifically the aims of this thesis were to: 
1) Utilise the previous work of Al-Janabi (2012) in producing the two ENU 
mutant lines - but to make use of mice with a more pure (>98%) non-ENU 
strain genetic background. 
2) Make a detailed assessment of the developmental profile and basic 
sensorimotor capabilities of the Zfp804a mutant mice (Chapter III). 
3) Examine the effects of Zfp804a mutagenesis on anxiety-related behaviours 
(Chapter IV). 
4) Examine the effects of Zfp804a mutagenesis on motivational and hedonic 
responding (Chapter V). 
5) Determine sensorimotor gating changes in the Zfp804a mutant lines using 
acoustic startle and pre-pulse inhibition of acoustic startle (Chapter VI). 
6) Assess whether Zfp804a mutagenesis influences response control and 
impulsivity (Chapter VII). 
7) Compare and contrast between effects observed following Zfp804a 
mutagenesis in exon 2 (nonsense) and exon 4 (missense) with respect to wild-
type littermate controls. 
 
It is important to note, at the outset, that this work was not an attempt to explicitly 
model the human ZNF804A risk variant rs1344706 nor to model schizophrenia in a 
mouse, but to alter the function of Zfp804a to gain understanding of how genetic 
variation in this gene may contribute to risk for schizophrenia. 
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Chapter II; General materials and methods 
This chapter describes the procedures that were performed throughout the course 
of this thesis, and the behavioural apparatus that were employed. All procedures 
that involved the usage of live animals were carried out in accordance with the 
requirements of the U.K. Animals (Scientific Procedures) Act (1986) and in line with 
the Home Office Project Licence granted to Dr William Davies (PPL 30/2601). Work 
was carried out under the Home Office Personal License granted to Jessica Eddy (PIL: 
30/8796). 
 
2.1 Production of the Zfp804a mutant mouse lines 
There are a number of methods for the creation of genetically modified mice, 
including models with spontaneous or engineered targeted mutations at the loci of 
interest using knock-in or knock-out strategies, or N-ethyl-N-nitrosourea (ENU) 
mutagenesis. The approach used here was that of ENU mutagenesis, whereby a DNA 
library of ENU mutagenised mice (DNA Archive, MRC Mary Lyon Centre, Harwell) was 
screened for single base pair point mutations in the Zfp804a gene. The melting 
profiles of 5856 samples using Hi-Resolution Melting was determined, resulting in 
the discovery of ten non-synonymous mutations, which were then sequenced to 
confirm the presence of a mutation in Zfp804a (Al-Janabi, 2012). Two mutations 
were selected as candidates for further investigation (see below). Frozen sperm from 
the Harwell archive corresponding to the DNA sequences screened was used to re-
derive founder mice by in vitro fertilisation (IVF); DNA was collected from the 
progeny of the mutagenised mice (F1) where mutations had affected the germ line. 
All of the founder re-derivation was performed by the MRC Centre at Harwell. 
The two non-synonymous Zfp804a mutations selected for re-derivation, 
designated C59X and C417Y (Fig. 2.1), were chosen as they were considered (on the 
very limited functional and bioinformatic data available) likely to lead to functional 
effects (Al-Janabi, 2012). The C59X nonsense mutation is within exon 2, and encodes 
a premature stop codon in the gene sequence, predicting a severely truncated 
protein product, if transcribed/translated, at aa59 of the aa1200 protein. The C417Y 
mutation is missense, affecting aa417 within exon 4, predicting significant effects on 
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the 3D structure of Zfp804a due to the substitution of the relatively small, nonpolar 
cysteine residue with a larger, polar tyrosine residue. Therefore, it was expected that 
the C59X mutation should lead to a functional null of the gene, whereas the C417Y 
mutation would lead to altered function of Zfp804a. 
 
Figure 2.1: Summary of the two Zfp804a mutations in the Zfp804a protein selected 
to carry forward for further analysis. 
 
The C59X mutation is located in exon 2 and encodes a premature stop codon, truncating the 1200aa 
protein prematurely at 59aa (aa6 of 28 comprising zinc finger domain, ZnF). The C417Y mutation is 
located in exon 4 (aa417) and substitutes a nonpolar cysteine residue with a larger polar tyrosine 
residue. 
 
A disadvantage of ENU mutagenesis is that it causes many random mutations, 
in addition to the target mutation of interest, at unknown locations across the 
genome; estimated to be approximately 31 in founder mice (see Keays, Clark & Flint, 
2006). G2 heterozygous Zfp804a founder mice (bred on a BALB/c x C3H/HeJ 
background, re-derived at Harwell), from both lines (C59X and C417Y), were crossed 
with wild type C57BL/6JOlaHsd mice, to produce offspring (G3) which were 75% 
genetically similar to C57BL/6JOlaHsd mice (and would therefore carry ~8 other ENU-
induced mutations). Male and female progeny of each line which were positive for 
the C59X and C417Y mutations were then backcrossed again to C57BL/6JOlaHsd 
mice (C57BL/6J). Heterozygous progeny from the 6th backcross, with a 
predominantly C57BL/6JOlaHsd genetic background (average of 98.5% at G7) and 
where only the Zfp804a mutations should be consistently expressed in each mouse, 
were inter-crossed with other heterozygous mice of the same line to generate 
Zfp804a heterozygous ENU-mutants, homozygous ENU-mutants and C59X and C417Y 
wild-type (WT) littermate control mice for testing. Two cohorts of mice from both 
mutant lines were generated for the studies described in this thesis; G7i and G7ii (Fig. 
2.2). 
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Figure 2.2: Flow diagram to show the breeding programme for the generation of 
the G7i and G7ii Zfp804a cohorts. 
 
G1 male mice (0% C57BL/6JOlaHsd mice) were crossed to C57BL/6JOlaHsd females. These progeny 
(G2) were sent from Harwell and estimated at 50% similarity to C57BL/6J, carrying ~15 other 
mutations from the ENU mutagenesis. The Zfp804a heterozygous ENU-mutant mice (for both C59X 
and C417Y mutant lines) were then backcrossed to the C57BL/6JOlaHsd mice 5 more times, until the 
G7 generation were 98.5% similarity to C57BL/6J and carrying less than one other potential ENU 
mutation. G7 heterozygous ENU-mutant mice (for either the C59X or C417Y mutation) were then inter-
crossed with other G7 heterozygous ENU-mutant mice from the same line to generate G7i 
heterozygous ENU-mutants, homozygous ENU-mutants WT littermate control mice for the Zfp804a 
behavioural cohorts. The G7i heterozygous ENU-mutant mice were then inter-crossed with other G7i 
heterozygous ENU-mutants from the same line, generating a second experimental group of 
homozygous ENU-mutants, heterozygous ENU-mutants and WT littermate controls, known as the G7ii 
cohort. Hom= homozygous, Het= heterozygous, WT= wild-type littermate control. 
 
2.2 Subjects and animal husbandry 
Mice from each experimental cohort were group housed (2-5 mice per cage) 
in environmentally enriched cages (i.e. with cardboard tubes, shred-mats, tissue 
paper) in a temperature and humidity controlled animal holding room (21 ± 2°C and 
50 ± 10%, respectively) with a 12-hour light-dark cycle (lights on at 07:00 hours/lights 
off at 19:00 hours). Only subjects of the same line were housed together; most of 
the home cages included at least one mouse of each genotype (i.e. homozygous 
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ENU-mutant, heterozygous ENU-mutant and WT littermate control mice); birth litters 
were kept together whenever possible. Standard rodent laboratory chow and water 
were available at libitum unless otherwise stated. Home cages were cleaned and 
changed once a week, at approximately the same time of the day and on the same 
day of the week, in order to cause minimal disruption to the behavioural testing. 
Initially, both males and females of all genotypes and lines were monitored for 
weight gain and developmental profiling (Chapter III), but after this, testing was 
limited to just the male homozygous ENU-mutants and their male WT littermate 
controls. Throughout this thesis mice which were homozygous for the Zfp804a 
mutations are referred to as C59X or C417Y homozygous ENU-mutants, those that 
were heterozygous were C59X or C417Y heterozygous ENU-mutants and wild-types 
(WTs) were referred to as WT littermate controls. Experimental animals were 
regularly monitored and weighed from birth for signs of ill health. Any mice showing 
signs of illness were immediately assessed by a Veterinarian and, if necessary, 
withdrawn from the experiment.  
 
2.3 Behavioural methods  
2.3.1 Handling  
One experimental cohort of mice (G7ii) were weighed daily from birth and 
subjects from both cohorts were handled regularly post-weaning before beginning 
an experiment. This was for approximately 1 minute each, twice a week. 
 
2.3.2 Measurement of body weight 
Body weights of all mice were recorded on a regular basis as an index of 
growth and development and a measure of general health. Weights were registered 
daily (pre-weaning; cohort G7ii) and fortnightly (post-weaning; all subjects) at the 
same time of day (at around 10:00). Subjects were also weighed before any 
behavioural experiments began, and after each behavioural experiment had finished. 
 
2.3.3 Behavioural testing environment 
Behavioural testing was carried out in sealed and air-conditioned testing 
rooms. Testing rooms were lit by fluorescent lights. Temperature and humidity levels 
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were not strictly controlled, but were generally maintained at around 21 ± 2°C and 
50 ± 10% respectively. Rooms were thoroughly cleaned once a week. 
 
2.3.4 Protocol for the water restriction schedule 
Prior to testing in behavioural paradigms where condensed milk was used as 
a reinforcer, subjects were placed on a schedule of reduced home cage water access 
(in order to enhance motivation for the reinforcer). This schedule lasted 6 days, 
encompassing 4 days of 4hr access/day and 2 days of 2 hr access/day. Mice were 
weighed daily during this schedule, as were their drinking bottles to ensure they 
were drinking during the period of water access. Importantly, subjects losing >10% of 
their ad libitum body weight or showing clinical symptoms of dehydration or ill-
health were immediately given ad libitum water access until normal ad libitum body 
weight was re-established. Subjects were allowed ad libitum access to standard 
laboratory chow, throughout the duration of the water deprivation schedule. After 
these 6 days, mice were maintained on a 2hr access/day schedule for the duration of 
the experiment. 
 
2.3.5 Reinforcer preference test/reactivity to a novel food substance 
Subjects undergoing appetitively motivated behavioural tasks (i.e. the 
progressive ratio task and the stop-signal serial reaction time task, SSRTT), were 
habituated to the liquid reinforcer before testing (10% condensed milk solution, 
Nestle Ltd, U.K.). Briefly, the reinforcer preference test (see Humby, Wilkinson & 
Dawson, 2005) was carried out in 10 small holding cages (285 x 130 x 120mm) with a 
single subject per cage, during a single 10-minute session per day, across a six-day 
period. During the first session, subjects were allowed to habituate to the test 
apparatus, while general water consumption was measured by placing two 
containers (max vol.= 3ml each)  containing an excess of tap water of registered 
weight, to the rear of each cage. Following each test session, the containers were re-
weighed in order to determine the total water consumption.  
Over the next four sessions, one of the containers was filled with the 
condensed milk reinforcer, and the second container was filled with tap water. The 
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locations of the two containers within the cage were pseudo-randomly switched 
between days. As before, the containers were weighed prior to, and immediately 
after, testing in order to determine the consumption of each liquid as well as the 
preference for condensed milk. Reinforcer preference was defined as the amount of 
condensed milk (CM) consumed in the final session of testing, as a percentage of the 
total amount of liquid (i.e. the CM and water collectively) consumed during that 
session. The final day of testing involved filling both containers with condensed milk, 
for a ‘milk vs. milk’ condition. This was to ensure that all of the subjects had sampled 
the condensed milk reinforcer before testing in the behavioural paradigms. The data 
on total volume of liquid consumed was normalized for body weight differences 
using Kleiber’s 0.75 mass exponent (Schmidt-Nielsen, 1990). Any subjects failing to 
reach 70% preference for the condensed milk on the final day of preference, and 
failing to consume condensed milk on the milk vs. milk day, were excluded from any 
experiments using condensed milk as a reinforcer. 
 
2.3.6 Behavioural phenotyping: general experimental control measures 
 Behavioural testing was always conducted in the light phase of the light-dark 
cycle of the animal holding room (i.e. between 07:00 hours and 19:00 hours), and 
water access was provided immediately subsequent to any behavioural assessment. 
Moreover, in order to maintain a constant time period between the time of testing 
and water access (which might affect motivation for the liquid reinforcer), and also 
to minimize any behavioural variation due to when the subjects were tested, 
individual subjects were tested at the same time each day. In addition, possible 
‘order of experimental run’ effects were negated by running the experimental and 
control subjects in a pseudorandom order. To minimize possible confounds related 
to cage/litters, the experimental subjects were drawn from as large a number of 
cages/litters as available.  
 
2.4 Behavioural apparatus 
The current section describes the experimental apparatus employed in this 
thesis. The different procedures used are described in more detail in the subsequent 
experimental chapters.  
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2.4.1: SHIRPA (the SmithKline Beecham, Harwell, Imperial College, Royal London 
Hospital, phenotype assessment) equipment 
A horizontal wire cage lid (28.5cm x 12cm) was used for the visual placing and negative 
geotaxis tests. The grip strength test and the wire manoeuvre test used a 16cm long 
(0.5cm diameter) fixed metal bar suspended 35cm above a soft surface.  
See Chapter III for experimental details. 
 
2.4.2: Locomotor activity chambers  
Testing of locomotor activity (LMA) was carried out in 
an apparatus consisting of twelve clear Perspex 
chambers (each 21 x 36 x 20cm, width x length x 
height), with two embedded infra-red beams crossing 
each cage, 30mm from each end and 1cm from the 
floor. Beam breaks were recorded as an index of 
activity, using a computer running custom written BBC 
Basic V6 programmes with additional interfacing by 
ARACHNID (Cambridge Cognition Ltd, Cambridge, 
U.K.). Data stored were the total number of beam-
breaks from each 2 hour session, as well as the 
number of beam-breaks made over each 30 minute 
quartile.  
See Chapter III for experimental details. 
 
 
2.4.3: EthoVision observer system 
All of the anxiety assays used the EthoVision Observer video tracking software (version 
3.0.15, Noldus Information Technology, Netherlands) to track and analyse the behaviour, 
movement and activity of the mice. EthoVision tracks a subject’s movement within 
previously defined zones within the arena (these zones differ between the different 
anxiety paradigms), performing calculations over a series of frames (12 frames/sec) and 
deriving a set of quantitative descriptors about the movement and location of subjects 
determined by the location of the greater body-proportion of subjects.  Tracking of the 
subject was calibrated using non-experimental mice of the same body size and coat colour 
as the experimental subjects.  
See Chapter IV for more details of the virtual zones set up in each anxiety assay. 
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2.4.4: Elevated plus maze 
The elevated plus-maze (EPM) was constructed of 
dulled black Perspex covered in white tape (to 
enable visualisation of dark coated mice) and 
consisted of two exposed open arms (17.5 x 7.8mm, 
length x width) and two enclosed arms (19 x 8 x 
15cm, length x width x height) with an open roof. 
The maze was positioned 94cm above the floor and 
illuminated evenly with a 60w bulb. Mice were 
tracked on the EPM using EthoVision 
(manufactured), an example of a trace can be seen 
below. 
See Chapter IV for experimental details. 
 
 
 
2.4.5: Open field  
The open field (OF) consisted of a square-shaped 
arena (75 x 75 cm, length x width), constructed of 
white plastic and illuminated evenly with a 60w bulb. 
For tracking purposes, using EthoVision, the OF was 
divided into 3 virtual zones of concentric squares; an 
inner zone, a middle and an outer zone. For analysis 
purposes the two inner zones were combined to 
become one central zone versus the outer zone. 
1. The Inner Zone (20*20cm) 
2. The Middle Zone (40*40cm) 
3. The Outer Zone (15cm periphery) 
The image to the right shows the EthoVision tracking 
of a subject in the OF. 
See Chapter IV for experimental details.  
 
 
3 
1 
2 
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2.4.6: Elevated zero-maze  
The elevated zero-maze (EZM) consisted of an 
elevated circular platform (5cm width) with a 
diameter of 65cm. Two of the quadrants are open and 
the other two quadrants are enclosed by 27cm high 
walls. The maze was constructed from Plexiglas, 
positioned 940mm from the floor and illuminated by a 
60w bulb. The image below shows the EthoVision 
tracking of a subject on the EZM. 
See Chapter IV for experimental details. 
 
 
 
 
2.4.7: Lick cluster analysis 
Testing took place in 16 home cages (32 x 15 x 
12cm) modified to incorporate lickometer 
equipment (Med Associates Inc., St Albans, VT, 
USA), including metal grid floors and wire mesh 
lids. The lickometer accurately detected each 
lick to the nearest 0.01s. Data was recorded 
with custom written software using Med-PC-IV, 
running on a PC (Med Associates Inc., St. Albans, 
VT, USA). Sucrose solutions were presented 
through stainless steel drinking spouts attached 
to 50 ml cylinders. Drinking bottles were 
weighed before and after testing to assess 
consumption.  
See Chapter V for experimental details. 
 
 
 
 
5cm 
65cm 
27cm 
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2.4.8: Startle chambers  
The startle chamber apparatus consisted of  
ventilated and sound attenuating SR-LAB startle 
chambers (San Diego Instruments, CA, USA) 
containing a non-restrictive Plexiglas cylinder 
(3.5cm in diameter) mounted on a Perspex 
plinth. Directly beneath the centre of the tube 
was a piezoelectric sensor that detected flexion 
in the plinth: the measure of startle reactivity.  
Above the animal enclosure (12cm) a loud 
speaker was mounted, via which all white-noise 
stimuli were presented. The motor responses of 
the subject were recorded via the piezoelectric 
accelerometer and values were transduced and 
digitised by a transducer linked to the computer 
running SR-LAB software. For each day of 
testing, the test chambers were calibrated, 
using mice of equivalent bodyweight to the test 
subject to equalise the measure of startle 
response from each chamber.  Similarly, the 
peak amplitude of the stimuli presented in each 
chamber was made equivalent.  
See Chapter VI for experimental details.  
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2.4.9: Apparatus for the progressive ratio and stop-signal reaction time task (SSRTT) 
Testing was carried out in ‘9-hole’ operant chambers (Cambridge Cognition Ltd, U.K.) based on 
a design first used in rats (Carli, Robbins, Evenden et al., 1983) and tailored for use in mice 
(Humby, Laird, Davies et al., 1999). The chambers were made of aluminium, with a clear 
Perspex roof, and a curved rear wall (at a distance of 130mm) into which nine 10mm diameter 
holes were set. Set into each aperture was a 2.5W bulb and for the progressive ratio task, 
aperture 5 (from the left side) was used, and for the stop-signal reaction time task (SSRTT) 
apertures 3 and 5 were used. Responses made by subjects into each aperture were measured 
by a vertically orientated infra-red beam. Opposite the aperture array was a food magazine 
(accessed through a clear Perspex door), into which condensed milk reward was delivered to a 
small food well in the floor via 0.8mm silicone tubing (Watson & Marlowe, U.K). This food 
delivery process was controlled by a peristaltic pump, with standard food delivery of 22l 
(equivalent to driving the pump for 1 second). A micro-switch recorded when the door to the 
food magazine was opened, and two infra-red beams (located 5mm off the floor, emanating 
from the side wall) detected general movement in the chambers. A loudspeaker was also 
located in the side wall, as well as two infra-red LEDS (providing background illumination for the 
CCTV systems) and two 2.5W house lights. The chamber was located in a sound attenuating 
outer box complete with a fan to keep a constant low background noise and provide 
ventilation. Infra-red sensitive cameras mounted in the roof of the outer boxes meant that 
CCTV could be used to observe the mice (Watac WM6, Tracksys Ltd, U.K.), located 100mm 
above the chambers. Control of the chambers was managed by an Acorn RISC-PC computer 
running custom-written BBC BASIC V6 programmes with further interfacing by ARACHNID 
(CeNeS Ltd, U.K.). 
See Chapter V and VIII for experimental details. 
 
1 response array (9 apertures, 10mm diameter, spanned by vertical infra-red beams and each containing a 
small light), 2 food magazine (containing tray light and food well) accessed via a hinged panel, 3 silicone 
tubing, 4 peristaltic pump, 5 reinforcer bottle (10% condensed milk solution), 6 house light and 7 loudspeakers. 
140mm 130mm 
1 
2 3 
7 
5 
4 
7 
6 
 
6 
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2.5 General data presentation and statistical methods 
Behavioural data are presented as mean values (M) with the standard error 
of the mean (SEM), unless stated otherwise. Data for each line (C59X and C417Y) 
were analysed separately, and separate ANOVAs were performed with between 
subjects factor of GENOTYPE (homozygous ENU-mutant vs. heterozygous ENU-
mutant vs. WT littermate control) and occasionally GENDER (male vs. female) as well 
as within subject factors as appropriate. All significance tests were performed at 
alpha level of 0.05 and where significant interactions were identified in the main 
ANOVA, post-hoc tests using appropriate pair-wise comparisons were performed. 
Bonferroni corrections for multiple comparisons were applied where appropriate 
and Greenhouse-Geisser degrees of freedom (df) corrections were applied as 
required to repeated-measures factors. Specific statistical designs and analyses are 
described in the relevant experimental chapter.  
 
2.6 Molecular methods  
2.6.1 Standard genotyping and sequencing protocol 
To identify the genotype of each mouse, DNA was extracted from tail biopsies 
(2mm), amplified by Polymerase chain reaction (PCR) and then sequenced to 
determine the presence/absence of either the C59X or C417Y mutation. 
 
2.6.1.1 Tail lysis 
A tail biopsy was collected from each mouse following weaning, at 
approximately four to six weeks of age. The collected tissue samples were placed in 
1.5ml micro-centrifuge tubes and digested in 400μl of lysis buffer (0.2% SDS, 50mM 
Tris (tris(hydroxymethyl)aminomethane);pH=8.0, 10mM EDTA 
(ethylenediaminetetraacetic acid), 100mM NaCl (sodium chloride) with 2μl of 
Proteinase K (Qiagen, Crawley, U.K.) with a final concentration of 0.2mg/ml, at 55-
60°C overnight. 
 
2.6.1.2 DNA extraction 
 Digested tissue samples were spun in a centrifuge (13,000rpm, 14 min) to 
sediment debris, and the supernatant subsequently transferred into new micro-
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centrifuge tubes. Next, an equal volume of cold isopropanol (i.e. 400μl) was added to 
the obtained supernatant and the samples left on ice for 20 minutes to facilitate 
DNA precipitation. Samples were then re-centrifuged (13,000rpm, 12 min) and the 
supernatant discarded. The tubes were then left to air dry for 1 hour to allow the 
isopropanol to evaporate. A volume of 50l of TE buffer, (10mM of Tris and 1mM of 
EDTA, bought to pH=8 with hydrogen chloride to down-regulate the activity of 
nucleases), was added to stabilize and protect the dissolving DNA from degradation. 
Samples were then spun at 4C overnight to allow any DNA adhering to the sides of 
the tubes to be resuspended into the TE buffer.  
 
2.6.1.3 DNA quantification 
DNA was quantified using a spectrophotometer (NanoDrop 2000, Thermo 
Scientific). The absorbance (A) of UV light at wavelengths () of 260nm and 280nm 
was calculated. Assuming that an A (260nm) of 1 is equivalent to 50g of DNA, a 
ratio of A (260nm) to A (280nm) of above 1.8 indicated a suitable amount of clean 
DNA without contamination by RNA and protein. The spectrophotometer calculated 
a concentration (in ng/l) for the sample based on the UV absorbance. 
 
2.6.1.4 Polymerase chain reaction (PCR) for genotyping 
DNA was tested at a working dilution of 5ng/l. PCRs were performed in 96-
well skirted plates. Reaction mixtures were produced as per the protocol described 
in Table 2.1, using primer sets detailed in Table 2.2. The reactions were run in a 
Peltier Thermal Cycler (MJ Research, U.K.). 
 
2.6.1.5 PCR purification 
 This purification stage removed unincorporated dNTPs, primers, primer 
dimers, salts and other contaminants from the samples. The PCR product was mixed 
with 21.6l/sample Agencourt AMPure reagent (Beckman Coulter, USA), which 
contains metallic beads which adhere to the amplimers. Successive washing of the 
samples in 85% ethanol removed any products that were not adhered to the 
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magnetic beads and purified the samples. PCR amplimers were then eluted in 100l 
of pure water into a new plate. 
 
Table 2.1: PCR reaction protocol. 
Zfp804a C59X line Zfp804a C417Y line Program-cycle 
6.18µl of nuclease-free H2O 6.18µl of nuclease-free H2O 1. 94°C for 15min 
0.96 µl of dNTPs (5mM, 
Invitrogen, U.K.) 
0.96 µl of dNTPs (5mM, 
Invitrogen, U.K.) 
2. 95°C for 20sec 
1.2µl of 10x Taq buffer 
(Qiagen, U.K.) 
1.2µl of 10x Taq buffer (Qiagen, 
U.K.) 
3. 55°C for 30sec 
0.56µl of Zfp804a C59X 
Forward +Reverse primer 
(5uM) 
0.56µl of Zfp804a C417Y Forward 
+ Reverse primer (5uM) 
4. 72°C for 45sec 
0.1 µl of Taq Polymerase 
buffer (Qiagen, U.K.) 
0.1 µl of Taq Polymerase buffer 
(Qiagen, U.K.) 
5. Go to steps  2-4; 
44 times 
3µl of genomic DNA (5ng/µl) 3µl of genomic DNA (5ng/µl) 6. 72°C for 3min 
12 µl 12 µl 7. 4°C for 5min 
 
Table 2.2: Primer sets used for genotyping of the Zfp804a gene. 
Primers Primer sequence 
Base 
pairs 
amplified 
Genotype detection 
Zfp804a 
C59X 
Forward 
5’aatatcatagaaaagaatcccact-3’                                   430 
C59X homozygous and 
heterozygous ENU-mutants and 
their WT littermate controls 
Zfp804a 
C59X 
Reverse 
5’cttctgttcagagaaaaggtca-3’ 430 
C59X homozygous and 
heterozygous ENU-mutants and 
their WT littermate controls 
Zfp804a 
C417Y 
Forward 
5’tcatgttttcaaacttgttttg-3’ 397 
C417Y homozygous and 
heterozygous ENU-mutants and 
their WT littermate controls 
Zfp804a 
C417Y 
Reverse 
5’ttgattcatcatcacagaattac-3’ 397 
C417Y homozygous and 
heterozygous ENU-mutants and 
their WT littermate controls  
 
2.6.1.6 Sequencing PCR 
 The purified and cleaned PCR product was added in a 6l volume to a 4l 
reagent mix consisting of 0.2l of Big Dye termination mix, 0.8l of water, 2l of Big 
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Dye sequencing buffer and 1l of Primer (either the Forward or Reverse 
oligonucleotide primer used in the original PCR reaction (3uM, see Table 2.2). The 
reactions were then run on the Thermal Cycler as detailed in Table 2.3. 
 
Table 2.3: PCR conditions for the 
sequencing reactions. 
1. 94 °C for 4 minutes 
2. 94°C for 45 seconds 
3. 61°C for 45 seconds 
4. 72°C for 45 seconds 
5. Repeat steps 2-4 , 35 times 
6. 72°C for 5 minutes 
 
2.6.1.7 Post-sequencing PCR clean-up 
Post-sequencing clean-up employed an Agencourt CleanSEQ chemistry 
protocol (Beckman Coulter, USA) that was semi-automated. The process removed 
unincorporated dye terminators and other sequencing contaminants. Sequencing 
reaction product (10l) was added to 10l CleanSEQ reagent and 41.59l of 85% 
ethanol and aspirated to mix. The sequencing product bound to magnetic beads 
contained in the CleanSEQ reagent. The non-bound sequencing reaction 
contaminants were washed off and removed in successive 85% ethanol wash steps. 
The cleaned sequencing product was then eluted in pure water (75l) and was ready 
for analysis using a capillary sequencer. 
 
2.6.1.8 Sequencing and analysis 
All sequencing was performed using the fluorescent Sanger sequencing 
method via Big Dye termination chemistry and analysed using a 3130xl Genetic 
Analyzer (Applied Biosystems, USA). The fluorescent sequencing reaction involved large 
amounts of template DNA and then the random incorporation of four fluorescently 
labelled ddNTPs (di-deoxy-dinucleotide-triphosphates: ddATP, ddCTP, ddGTP and 
ddTTP) that terminate after extending one base during primer extension. This 
produced a series of DNA fragments where the chain growth was terminated at each 
successive position. When electrophoresed in the 4-capillary sequencer and 
detected by a laser, each base of the sequence was fractioned by size and fluoresced 
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according to the base at that size. Sequencing required 12l of PCR product for the 
genomic region to be sequenced.  
The raw data generated by the 3130xl Genetic Analyzer was automatically 
analysed by Sequence Analysis Software (Applied Biosystems). The software reads 
the amount of fluorescence at each nucleotide as the corresponding base. 
Sequencher software (Gene Codes, USA) was then used, which aligned multiple 
sequencing traces and allowed comparison to a reference sequence. The software 
then highlighted where differences occurred between the traces, allowing the user 
to visually inspect these and judge whether a polymorphism existed (for each 
possible trace outcome for both lines, see Appendix 1.1). 
 
2.6.2 Sex/genotype determination protocol for Zfp804a pup survival rates 
In order to examine the survival rates, sex ratios and patterns of inheritance 
of the Zfp804a mutant lines it was necessary to determine the gender and genotype 
of the pups which did not survive to weaning. 
 
2.6.2.1 Genotyping protocol for Zfp804a pup corpses  
Pup corpses were genotyped and sequenced as described in the protocol set 
out in Section 2.6.1. DNA extraction and lysis were performed as described in 
Sections 2.6.1.1 and 2.6.1.2, except that the tissue used was whole head instead of 
tails.  
 
2.6.2.2 Sex determination protocol for Zfp804a pup corpses  
To determine the gender of the Zfp804a pup corpses a multiplex PCR was 
performed using a Y-linked gene family (Ssty) and an autosomal control gene Om1a 
(myogenin). PCR primer sets used can be seen in Table 2.4. The PCR reaction (25l) 
contained 17.75l of sterile water, 2.5l 10x Taq buffer (Qiagen, UK), 1l of dNTPs 
(5mM, Invitrogen, UK), 1l of Ssty Forward primer (10uM), 1l of Ssty Reverse 
primer (10uM), 0.25l of Om1a Forward primer (500ng/l), 0.25l of Om1a Reverse 
primer (500ng/l), 0.25l of Taq polymerase (Qiagen, UK), and 1l of DNA. The PCR 
conditions can be seen in Table 2.5. 
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Table 2.4: Primer sets used for sex determination of the Zfp804a mouse pups. 
Primers Primer sequence Base pairs Gender detection 
Ssty (Forward) 5’-ctggagctctacagtgatga-3’ 343 Male 
Ssty (Reverse) 5’-cagttaccaatcaacacatcac-3’ 343 Male 
Om1a 
(Forward) 
5’-ttacgtccatcgtggacagcat-3’ 245 Male and Female 
Om1a 
(Reverse) 
5’-tgggctgggtgttagtcttat-3’ 245 Male and Female 
  
Table 2.5: PCR conditions for sex 
determination of the Zfp804a 
mouse pups. 
1. 94 °C for 4 minutes 
2. 94°C for 45 seconds 
3. 61°C for 45 seconds 
4. 72°C for 45 seconds 
5. Repeat steps 2-4 , 35 times 
6. 72°C for 5 minutes 
  
Once the reaction had finished 8μl of 6x DNA loading buffer was added to each 
reaction and a total of 30μl of the reaction/loading buffer mixture was loaded on a 
1.2% agarose gel. Finally, 5μl of DNA ladder (Hyperladder IV, Bioline, U.K.) was 
loaded at both sides next to the reaction samples, and the gel subsequently run at 
120 V for 20-25 minutes, allowing the DNA to separate. Once the gel had been run, 
the amplicons were examined. A single band at 245bp indicated the presence of the 
X linked gene Om1a, and confirmed the correct amplification of the DNA template. A 
further band at 343bp indicated the amplification of the Y-chromosome gene (Ssty), 
and hence the male gender of the sample. 
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Chapter III: Developmental and initial behavioural phenotyping of 
Zfp804a mutant mice 
 
3.1 Introduction 
This chapter is concerned with the developmental characterisation and initial 
behavioural phenotyping of the selected Zfp804a mutant lines. These were 
important investigations for a number of reasons. Firstly, the developmental profile 
of the ENU-mutants was of general interest, but also of specific interest given the 
well established hypotheses regarding the neurodevelopmental bases of mental 
disorders, including schizophrenia and bipolar disorder (Marenco & Weinberger, 
2000; Owen, O’Donovan, Thapar & Craddock, 2011). Secondly, it was necessary to 
determine if there were any pre-existing differences in basic sensory and/or motor 
performance in the Zfp804a ENU-mutants lines which could have confounded the 
findings from the subsequent in-depth testing reported later in the thesis.  
 As previously described (Chapter II, Section 2.1) the Harwell DNA library of 
ENU-mutagenised mice was screened for mutations in Zfp804a, on mouse 
chromosome 2, by comparing the DNA melting profiles of the samples using Hi-
Resolution Melting (Al-Janabi, 2012). Ten non-synonymous mutations in Zfp804a 
were discovered, with two selected to carry forward for re-derivation through in 
vitro fertilisation; the C59X mutation and the C417Y mutations were selected based 
upon the hypothesis that they should lead to functional effects (Fig. 3.1). The C417Y 
missense mutation located in exon 4 (genomic position 82097223) substitutes 
cysteine for tyrosine at aa417 (base change TGT>TAT). This mutation is thought to 
have damaging effects on the 3D structure of Zfp804a due to the substitution of the 
relatively small, nonpolar cysteine residue with a larger, polar tyrosine residue. 
PolyPhen (http://genetics.bwh.harvard.edu/pph/), a program which predicts the 
functional effects of human non-synonymous SNPs, but can also be used to predict 
the effects of non-synonymous SNPs in mice, found the C417Y mutation to be 
probably damaging. The C59X mutation located in exon 2 (genomic position 
82076020) encodes a premature stop codon in the zinc finger domain at aa59 of the 
aa1200 Zfp804a protein (base change TGT>TAA). The expectation was that the 
mutant mRNA transcript would not be fully translated due to nonsense mediated 
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decay (NMD), which selectively degrades mRNAs harbouring premature stop codons 
(for a review of NMD see Chang, Imam and Wilkinson, 2007). If the aberrant mRNA 
transcript was to escape NMD and be translated it would produce a truncated 
protein with possible deleterious gain of function or dominant-negative activity 
(Chang et al., 2007). 
 
Figure 3.1: Loci of the selected mutations in the Zfp804a protein. 
 
Ten non-synonymous Zfp804a mutations were discovered in different samples screened from the 
Harwell mouse ENU DNA library. Two of these were selected for further investigation based on 
putative function. The C59X mutation, located in exon 2, encodes a premature stop codon, 
truncating the 1200aa protein prematurely at 59aa (aa6 of 28 comprising zinc finger domain, ZnF). 
The C417Y mutation, located in exon 4 (aa417), substitutes a nonpolar cysteine residue with a larger 
polar tyrosine residue. It is hypothesised that the C417Y mutation may affect the 3D structure of the 
protein. Founder mice which carried each of the mutations were re-derived and used to create lines 
of mice for behavioural and neurobiological investigation. Summary edited from SMART (Simple 
Modular Architecture Research Tool). 
 
 To generate mice for the experiments, founder mice for each of the lines (G1, 
bred on a BALB/c x C3H/HeJ background), heterozygous for the target mutations, 
were backcrossed onto a wild-type background (C57BL/6JOlaHsd) and positive 
progeny subsequently crossed to the same background, for a number of generations. 
An important consideration when using mouse lines derived from ENU mutagenesis 
is the presence of additional residual mutations in the genome, which may be 
inherited along with the mutation of interest, and could potentially confound any 
observed findings. Previous work by others in the lab assessed early growth and 
development of the G4i generation of C59X and C417Y homozygous ENU-mutant 
mice (and their WT littermate controls) and found no gross physical or 
developmental abnormalities (Al-Janabi, 2012), as well as no differences in the birth 
ratios between genotypes or sex. Initial investigations did, however, reveal that both 
male and female C59X homozygous ENU-mutant mice stayed longer on the RotaRod 
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and were lighter in adulthood than their heterozygous and WT littermates. With this 
earlier work carried out with the G4i generation there were no differences between 
genotypes in the C417Y line. Mice of the G4i generation were hypothesised to be 
only ca. 96% similar to the C57BL/6J strain, and would be expected to be carrying an 
average of 3-4 other ENU-induced in addition to the Zfp804a ENU mutations of 
interest (Keays et al., 2006). Thus, in the initial investigations (Al-Janabi, 2012) using 
Zfp804a mutant mice from the G4i generation, other ENU-induced mutations may 
have been present which could have, in theory, influenced phenotype. To minimize 
this potential problem, the current studies utilised mice from the the G7 generation 
(See Chapter II, Fig. 2.2) which should be >98.4% similarity to C57BL/6J and carrying 
on average less than 0.49 other residual mutations (as calculated from Keays et al., 
2006). In addition to a general dilution of additional mutations, mice from different 
litters were inter-crossed at each stage of breeding as a way of disrupting the 
consistent transmission of other mutations in each mouse. 
 In the present work, heterozygous mice of 7th generation (G7) were then 
inter-crossed such that litters (G7i and G7ii) would contain male and female, 
homozygous and heterozygous ENU-mutants and wild-type littermates according to 
Mendelian inheritance ratios. Using this approach, littermates would have identical 
rearing conditions and subsequent differences in behaviour could be attributed 
more confidently to the genomic differences present. Although no major 
developmental or behavioural effects of the mutations were observed at G4i (Al-
Janabi, 2012) further developmental characterisation and behavioural screening 
were warranted with G7i and G7ii mice, as the extra 3 generations of breeding could 
have unmasked significant effects of the C59X and C417Y mutations. Here, 
investigations included an assessment of the weight gain, growth rate and 
emergence of somatic developmental indices in both of the Zfp804a ENU mutant 
lines, as well as the litter sizes and distribution of the different genotypes across 
gender. The total number of pups born and pre-weaning deaths was measured to 
assess the survivability of the mutant mice, and Mendelian inheritance patterns. In 
terms of the initial behavioural phenotyping, different tests were carried out to 
assess any deficits in sensory-motor functioning. Hence locomotor activity, 
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habituation to a novel environment, the SHIRPA screen and the reactivity to a novel 
food substance to test for neophobia were assessed. 
The general strategy employed throughout the thesis of comparing the 
effects of the two ENU mutations relative to wild type littermate controls, was 
interesting insofar as it allowed investigation of the phenotypic consequences of 
different variants within the same gene. This strategy was also useful in helping to 
dissociate the specific effects of the ENU mutations from any effects on phenotype 
due to co-segregating genes from the original ENU-treated mouse strain which can 
be transmitted through generations of breeding in association with the gene-
mutation of interest as a result of recombination, leading to linkage disequilibrium 
(Gerlai, 1996; Preuss, Riemenschneider, Wiedmann & Stoll, 2012). Common effects 
across both the C59X and C417Y ENU mutant mice, relative to wild type littermate 
controls, could theoretically be due to these ‘hitchhiking’ flanking genes. However, 
phenotypic dissociations between the two different lines are highly likely to be due 
to specific effects of ENU-induced changes in Zfp804a function. 
 
3.2 Materials and Methods 
Full methodological descriptions can be found in the relevant sub-sections of 
the General Methods Chapter (Chapter II). 
 
3.2.1 Subjects and animal husbandry 
A subset of mice from the total litter cohort, consisting of mice from the 
Zfp804a G7ii C59X and C417Y lines were weighed and examined on several measures 
of somatic/neurological development during the first 30 days of postnatal life (See 
Table 3.1). Litters were derived from heterozygous*heterozygous pairings for each 
ENU-mutant line. At weaning, a tissue biopsy was made and DNA extracted for PCR 
analysis of genotype. As part of the developmental analysis, tissue from any dead 
pups found was also analysed for Zfp804a genotype and gender (See Chapter II, 
Section 2.6.2).  
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Table 3.1: Sample size and genotype of each cohort-subset of the Zfp804a 
mice assayed on measurements of somatic/neurological development. 
Mutation 
line 
Gender Genotype 
Weight and 
Growth Curves 
Somatic Indices of 
development 
C59X line 
♀ 
WT 19 19 
Heterozygous 29 29 
Homozygous 13 13 
♂ 
WT 10 10 
Heterozygous 35 35 
Homozygous 8 8 
C417Y Line 
♀ 
WT 8 8 
Heterozygous 35 39 
Homozygous 9 9 
♂ 
WT 9 11 
Heterozygous 12 13 
Homozygous 16 16 
 
Initial behavioural testing was carried out on male mice from the C59X and 
C417Y lines of the G7i generation. Details of specific mouse numbers per genotype 
can be seen in Table 3.2. For the SHIRPA screen, mice were on average 6 months old 
at testing, and for the reactivity to a novel food substance mice were on average 7 
months old. For the locomotor activity assay mice were tested in separate batches 
and had a mean age of 3 months at testing. All mice were housed in littermate 
groups of two to five animals per cage, under temperature- and humidity controlled 
conditions, with a 12-hour light: 12-hour dark cycle (lights on at 07:30). All subjects 
had ad libitum access to standard laboratory chow and water, unless otherwise 
stated. Mice were weighed on a regular basis. Any mice dropping 10% of their body 
weight or more were removed from the experiment. All experimental procedures 
were conducted under licenses issued by the Home Office (U.K.) in compliance with 
the Animals (Scientific Procedures) Act 1986. 
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Table 3.2: Sample size and genotype of each cohort-subset of mice assayed on 
the initial behavioural tasks 
Behavioural 
Task 
C59X line C417Y line 
WT  Homozygous W T Homozygous 
SHIRPA 14 16 16 19 
Locomotor 
activity 
14 17 15 19 
Reactivity to 
novel food-
substance 
14 15 14 16 
 
3.2.2 Neonatal health/viability of the lines 
3.2.2.1 Assessment of birth weight and somatic/neurological indices of 
development  
Pregnant dams were monitored twice daily so that accurate times of birth 
and birth litter sizes could be determined; fathers were removed from the cage 
when the litters were born. Body weights of the newborn pups, from the 2nd cohort 
of Zfp804a mice (termed as G7ii), were registered on the day of birth, and 
subsequently monitored every day for the first 30 days of postnatal life. Somatic 
indices of development were systematically examined by visual inspection on a daily 
basis until mice were weaned, and consisted of the following parameters; the first 
day of ear opening (the unfolding of the ear pinna in both ears), incisor eruption 
(eruption of the upper incisors), fur growth (the first visible appearance of coat 
colour) and bilateral eye opening (the first visible break in eye lids and membranes 
covering the eyes). 
 
3.2.2.2 Assessment of pre-weaning deaths/infanticide 
For each cohort of mice, the date of birth and number of pups born was 
recorded.  Litters were subsequently checked daily and the number of pups alive was 
noted, in addition to the number of pups found dead, mutilated or missing. Whole 
bodies (if intact) and heads (if found mutilated) were kept for DNA genotyping (see 
Chapter II, Section 2.6.1). A simple PCR assay was also carried out to determine the 
gender of the dead pups (see Chapter II, Section 2.6.2). 
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3.2.3 Initial behavioural phenotypic screen 
3.2.3.1 SHIRPA phenotype assessment 
SHIRPA (the SmithKline Beecham, Harwell, Imperial College, Royal London 
Hospital, phenotype assessment), is a set of standardised screens designed to test 
rodent sensory-motor function (as described in Rogers, Fisher, Brown, Peters, Hunter 
& Martin, 1997, developed from Irwin, 1968). The range of tests include assessments 
of locomotor activity, startle responding, pain assessment and anxiety-related 
behaviours, but for the purpose of these studies 4 behaviours from the primary 
observational screen were used to assess aspects of sensory and motor function 
(Irwin, 1968; Rogers et al., 1997); ‘Grip Strength’, ‘Visual Placing’, ‘Wire Manoeuvre’ 
and ‘Negative Geotaxis’.  Apparatus for these procedures are described in Chapter II, 
Section 2.4.1).   
The visual placing test assessed muscle and lower motor neuron function, as 
well as sensory and spinocerebellar function.  Subjects were lifted by the base of the 
tail to a height of 15cm and lowered onto a flat surface. The experimenter then rated 
at what point the subject extended their forelimbs (scoring criteria for all tests can 
be found in Appendix 2.1). The grip strength test assessed spinocerebellar function 
and involved allowing the mouse to grip a horizontal bar. Applying a gentle 
backwards pull, the subject’s resistance was then rated. The wire manoeuvre test 
assessed muscle strength and lower motor neuron function. For this, subjects were 
allowed to grasp a horizontal bar with their forelimbs. They were then held in 
extension and rotated around partially downward and released. Subjects were rated 
for their ability to grasp the bar with their forelimbs, but also their hindlimbs too.  In 
the test of negative geotaxis, which assays an unlearned orientation response in 
opposition of cues of a gravitational vector (Fraenkel & Gunn, 1961), and which is 
thought to measure vestibular and proprioceptive function, the mice were placed on 
a wire cage lid, which was then raised to vertical orientation with the mouse facing 
the floor.  The mice were rated for their ability to turn and climb the grid, in a 30-sec 
period.  
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3.2.3.2 Locomotor Activity 
 Locomotor activity (LMA) was tested in a battery of twelve clear Perspex 
chambers, each 210 x 360 x 200mm and equipped with two infra-red sensors 
projecting across each cage at 30mm from each end and 10mm from the cage floor 
(see Chapter II, Section 2.4.2). All animals were run in the dark between the hours 
09:00 and 17:00 on three consecutive days in order to assess their habituation to a 
novel environment, with each animal run in the same chamber at a similar time on 
each day. The total number of beam-breaks made within each 2hr session was 
recorded, as well as the total number of beam breaks in each 30 minute time bin 
(quartile), using a computer running custom written BBC BASIC V6 programmes with 
additional interfacing by ARACHNID. Cages were thoroughly cleaned with 2% acetic 
acid between subjects.   
 
3.2.3.3 Assessment of reactivity to a novel food substance 
The reactivity to a novel foodstuff was assessed in the Zfp804a mice following a 
period of 24-hour water restriction as described previously (see Chapter II, Section 2.3.4). 
The test of food neophobia (a choice between water and the 10% condensed milk solution) 
was carried out within the reinforcer preference testing, which was implemented prior to 
behavioural paradigms which required habituation to a reward (the progressive ratio and 
stop-signal reaction time tasks, see Chapters IV and VII). Briefly, on each of the 6 test days, 
the mice were individually placed into a small chamber containing 2 small containers, for 10 
minutes. The volume consumed from each container was calculated by weighing the 
containers before and after each test.  On the first day of each experiment both containers 
contained tap water, but between the 2nd and 5th days of testing one of the containers 
contained the 10% condensed milk solution. On the 6th day of testing, both containers 
contained the 10% condensed milk solution to ensure that all mice had sampled the reward. 
The total volume consumed from both containers and the preference for 10% condensed 
milk solution (days 2 to 5) was calculated for each subject. Consumption data were 
normalised for potential body weight differences using Kleiber’s 0.75 mass exponent 
(Schmidt-Nielsen, 1990). Further details of this procedure are described in Chapter II, Section 
2.3.5. 
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3.2.4 Statistical analysis  
Data were analysed using SPSS (Version 18.0) and presented as mean values 
(M) with the standard error of the mean (SEM), unless stated otherwise. All data 
were analysed by either ANOVA or t-tests with data for each strain (C59X and C417Y) 
and gender analysed separately, with separate ANOVAs performed with between-
subjects factor of GENOTYPE (homozygous ENU-mutant vs. WT) and within-subject 
factors as appropriate. All significance tests were performed at alpha level of 0.05 
and where significant interactions were identified in the main ANOVA, post-hoc tests 
using appropriate pair-wise comparisons were performed. Greenhouse-Geisser 
degrees of freedom (df) corrections were applied as required to repeated-measures 
factors. T-tests were performed where appropriate. For the SHIRPA phenotype 
assessment, the non parametric chi-squared statistic was calculated. Outliers which 
were 2 standard deviations or more from the mean were removed from the analysis. 
 
3.3 Results 
3.3.1 Establishing the lines 
As described previously (Al-Janabi, 2012 and Chapter II, Section 2.1), 
heterozygous ENU-mutant founder mice for the C59X and C417Y lines were crossed 
with C57BL/6J mice and positive progeny subsequently backcrossed to C57BL/6J 
mice for a further 4 generations.  There were no obvious signs of breeding related 
problems in either line of mice during this time and reasonable numbers of positive 
mice of both genders were produced in each generation for each line.  Heterozygous 
mice of the 7th generation were inter-crossed so that litters of each line were 
produced that contained male and female homozygous, heterozygous and WT 
littermate pups. Consequently, all litters were born to and raised by heterozygous 
mothers. 
 
3.3.2 Physiological results 
3.3.2.1 Neonatal health/viability of the C59X and C417Y mice 
Subjects from the G7i and G7ii cohorts of C59X and C417Y mice were 
continuously monitored throughout the duration of their lives for general health and 
wellbeing. The genotype of subjects was ascertained when the mice were 3-4 weeks 
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old, by the methods described in Chapter II, Section 2.6.1. In the G7i cohort from 25 
C59X and 23 C417Y litters, 188 and 185 mice were born, respectively (Table 3.3) and 
in the G7ii cohort from 39 C59X and 39 C417Y litters, 207 and 198 mice were born, 
respectively. Mean birth litter sizes were on average, between 5 and 8 for both lines, 
consistent with reported birth litter sizes for inbred C57BL/6J mice (Jackson 
Laboratories, 2009; Harlan Laboratories, UK). All pups appeared normal at birth, with 
no indications of observable health problems in either the C59X or C417Y lines.  
However, there were a perceived high number of deaths in the earliest days of 
postnatal life in both lines of Zfp804a mice, with approximately 19% of all mice of 
the G7i cohort and 35% of the G7ii cohort not surviving to weaning (combined pup 
mortality of 27% for both C59X and C417Y mice). It is unclear why there was a 
difference in survival between the two cohorts of mice, mothers were of the same 
breeding generation and litters were treated in the same way. Comparison with 
C57BL/6J mice suggests that these levels of post-natal mortality are, in fact, 
comparable with the pure inbred strain. One paper looking at murine infanticide 
found that 28.9% of C57BL/6J whole litters were found dead (Weber, Olsson & 
Algers, 2007), similar to the 25% and 27% rates found for both the C59X and C417Y 
lines, respectively, suggesting that Zfp804a maternal influences were not an issue in 
pup survivability. Where possible, the bodies of dead pups were collected. It was 
unclear as to why pups were dying, but a significant number had been mutilated (ca. 
40%), presumably by the mothers. Comparable data for pure inbred C57BL/6J line is 
not available, so whether this reflects increased maternal aggression by C59X and 
C417Y heterozygous ENU-mutant mothers is not clear. 
There was a noticeable imbalance between the number of male and female 
C59X mice weaned (male:female ratios for G7i and G7ii cohorts were 0.64 and 0.77, 
combined 0.70), suggesting possible pre-natal effects on male foetal development in 
this line or an increase in post-natal deaths of male mice (Table 3.3). Analysis of 
tissue from dead C59X pups appeared to confirm the former hypothesis, and showed 
that less male pups died during the post-natal period, suggesting that the decrease 
in male offspring is most likely to be a pre-natal effect. There were no gender 
differences in survivability of C417Y mice (male:female ratios for G7i and G7ii cohorts 
at weaning were 1.1 and 0.86, combined 0.98) however, the proportion of 
61 
 
male:female mice found dead pre-weaning was 0.57 for G7i, 0.29 for G7ii, and 0.58 
combined, hinted that potentially fewer male mice were born for the C417Y line as 
well, also suggesting a pre-natal effect.  
 
Table 3.3: Birth numbers and survivability of Zfp804a mutant mouse lines 
Mutation line C59X C417Y 
Cohort G7i G7ii Total G7i G7ii Total 
Total number 
born 
188 207 395 185 198 383 
Litters 25 39 64 23 39 62 
Average litter 
size at birth 
7.5 5.3 6.4 8 5.5 6.8 
Total Infant 
mortalities 
34 
(18.1%) 
71 
(34.3%) 
105 
(26.6%) 
35 
(18.9%) 
72 
(36.4%) 
107 
(27.9%) 
Whole litters 
found dead 
3 (12%) 13 (33%) 16 (25%) 3 (13%) 14 (36%) 17 (27%) 
Male:female 
mortalities 
0.5 0.26 0.35 0.57 0.29 0.48 
Number 
Mutilated 
14 33 47 13 25 38 
Number 
Unmutilated 
20 38 58 22 47 69 
Mutilated: 
unmutliated 
0.70 0.87 0.81 0.59 0.53 0.55 
Total surviving 
to weaning 
154 
(81.9%) 
136 
(65.7%) 
290 
(73.4%) 
150 
(81.1%) 
126 
(63.6%) 
276 
(72.1%) 
Average litter 
size at weaning 
6.2 3.5 4.5 6.5 3.2 4.5 
Males  
weaned 
60 59 119 78 58 136 
Females 
weaned 
94 77 171 72 68 140 
Male:female 
weaned 
0.64 0.77 0.70 1.1 0.85 0.98 
 
Genotype distribution amongst the dead pups was analysed based on 
expected Mendelian ratios of 25% WT, 50% heterozygous and 25% homozygous with 
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heterozygous*heterozygous pairings. Analysis of dead C417Y pups (N=80) showed 
close to the expected Mendelian ratio for the different genotypes, with 24% 
homozygous ENU-mutants, 17% WTs and 59% of the dead pups revealed to be 
heterozygous ENU-mutants. Thus, survivability to weaning or maternal aggression to 
pups did not appear to be significantly moderated by the genotype of the pup, 
although there was a small tendency for more C417Y WT mice to survive to weaning.   
Genotype analysis of dead C59X pups was not as clear cut, it appeared that more WT 
pups were killed (ca. 43%) than homozygous (ca. 28.5%) or heterozygous (ca. 28.5%) 
pups, although this was based on a significantly smaller sample (N=7). Therefore, it 
would appear that male C59X and C417Y mice, of any genotype, seemed less likely to 
be born but, once born, C417Y WTs were more likely to prosper to adulthood, 
whereas C59X homozygous and heterozygous ENU-mutant mice were more likely to 
survive to weaning than their C59X WT littermate controls.  
 
Table 3.4: Genotype analysis of weaned C59X mice 
Cohort 
Gender ♀ ♂ 
Genotype +/+ mut/+ mut/mut +/+ mut/+ mut/mut 
G7i 
Number 
Weaned 
24 38 29 14 28 16 
Genotype (%) 26.37 41.76 31.87 24.14 48.28 27.59 
Expected n 22.75 45.50 22.75 14.50 29.00 14.50 
Concordance 1.05 0.84 1.27 0.97 0.97 1.10 
G7ii 
Number 
Weaned 
23 45 18 12 43 11 
Genotype (%) 26.74 52.33 20.93 18.18 65.15 16.67 
Expected n 21.50 43.00 21.50 16.50 33.00 16.50 
Concordance 1.07 1.05 0.84 0.73 1.3 0.67 
Total 
Number 
Weaned 
47 83 47 26 71 27 
Genotype (%) 26.55 46.89 26.55 20.97 57.26 21.77 
Expected n 44.25 88.50 44.25 31.00 62.00 31.00 
Concordance 1.06 0.94 1.06 0.84 1.15 0.87 
Expected n is based on the 1:2:1 Medelian ratio and concordance is the ratio between actual n and 
expected n, with a concordance value of 1.0 being perfect Mendelian inheritance. 
  
 At 3-4 weeks old, the pups were separated from their mothers, split into 
groups by gender (but littermates were kept together), and a tissue biopsy taken. 
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Analysis for each line showed that the distribution of the different genotypes (Tables 
3.4 and 3.5) were close to Mendelian ratios of 1:2:1 (based on 
heterozygous*heterozygous pairings), suggesting similar survivability and viability of 
all C59X and C417Y mice. 
 
Table 3.5: Genotype analysis of weaned C417Y mice 
Cohort 
Gender ♀ ♂ 
Genotype +/+ mut/+ mut/mut +/+ mut/+ mut/mut 
G7i 
Number 
Weaned 
17 33 20 14 44 19 
Genotype (%) 24.29 47.14 28.57 18.18 57.14 24.68 
Expected n 17.50 35.00 17.50 19.25 38.50 19.25 
Concordance 0.97 0.94 1.14 0.73 1.14 0.99 
G7ii 
Number 
Weaned 
9 49 12 17 22 21 
Genotype (%) 12.86 70.00 17.14 28.33 36.67 35.00 
Expected n 17.50 35.00 17.50 15.00 30.00 15.00 
Concordance 0.5 1.4 0.68 1.13 0.73 1.4 
Total 
Number 
Weaned 
26 82 32 31 66 40 
Genotype (%) 18.57 58.57 22.86 22.63 48.18 29.20 
Expected n 35.00 70.00 35.00 34.25 68.50 34.25 
Concordance 0.74 1.17 0.91 0.91 0.96 1.17 
Expected n is based on the 1:2:1 Medelian ratio and concordance is the ratio between actual n and 
expected n, with a concordance value of 1.0 being perfect Mendelian inheritance. 
  
 Somatic indices of development were monitored from birth and showed the 
expected order of occurrence with ear pinna opening (ca. postnatal day 3) preceding 
fur growth (ca. postnatal day 6) and incisor opening (ca. postnatal day 11). The final 
physical indication recorded was eye opening, which occurred between postnatal 
days 12 and 13 (Fig. 3.2). There were no significant differences between WT, 
heterozygous and homozygous ENU-mutants of either gender for either C59X or 
C417Y mice (See Appendix 2.3 for p-values). 
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Figure 3.2: Development of a number of somatic indices for both Zfp804a mutant 
lines and genders, cohort G7ii. 
   
     
  
C59X (top) and C417Y (bottom) mice were checked daily from birth and the age at which certain 
developmental characteristics first appeared recorded. For both lines of Zfp804a mutant mice, there 
was no genotype or gender-related differences for any of these measures. Data shows the mean 
values ±SEM. For subject N see Table 3.1. 
 
3.3.2.2 Postnatal growth  
Postnatal growth was assessed by weighing a subset of C59X and C417Y mice 
from the G7ii cohort daily during the first 30 days of postnatal life. As expected, male 
mice in both lines were heavier than female mice, and all mice showed significant 
weight gain up to weaning. All mice showed growth curves with an initial dramatic 
increase in the rate of growth between days 1 and 6, and a secondary surge in 
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growth from approximately day 18 (see Appendix 2.4). For ease of analysis, separate 
analyses were used for the C59X and C417Y lines of mice and males were analysed 
separately from females. There were no differences in the birth weight of C59X 
female homozygous and heterozygous ENU-mutants or WT littermate control 
females (Fig 3.3A, main effect of GENOTYPE, F2,50=1.9, p=0.16) or between male mice 
of each genotype (Fig. 3.3B, main effect of GENOTYPE, F2,49= 0.2, p=0.87). However, 
when the mice were 30 days old it was noticeable that both female and male C59X 
homozygous ENU-mutant mice were lighter than their WT and heterozygous ENU-
mutant littermates (main effect of GENOTYPE, F2,60= 8.9, p=0.0, F2,52= 11.1, p=0.00, 
respectively). This weight difference was maintained when the mice were adults 
(over 2 months old, main effect of GENOTYPE, F2,42= 9.9, p=0.0, and F2,45= 8.0, 
p=0.001), although for the females this effect was driven by the difference between 
homozygous and heterozygous ENU-mutants. Examination of the profiles of the 
weight changes in C59X mice showed that the growth characteristics of female and 
male homozygous ENU-mutant mice diverged from WT and heterozygous ENU-
mutant mice at different times. Thus, through the first 10 days of life there were no 
differences in weight gain between the different genotypes of both female and male 
C59X mice (Fig. 3.3C and Fig. 3.3D, main effect of GENOTYPE, F2,47=1.7, p=0.20, F2,45= 
0.01, p=0.99, respectively). However, male C59X homozygous ENU-mutant mice then 
weighed significantly less than their WT and heterozygous ENU-mutant littermates 
between postnatal days 11-20 and 21-30 (main effect of GENOTYPE, F2,35=11.7, 
p=0.00, F2,50=9.4, p=0.00, respectively). In contrast, the C59X females homozygous 
ENU-mutants weighed significantly less than their heterozygous littermates but had 
equivalent weights to their WT littermates between postnatal days 11-20 (main 
effect of GENOTYPE, F2,40=3.4, p=0.04), but as with the males, the female C59X 
homozygous ENU-mutants weighed significantly less than their heterozygous ENU-
mutant and WT littermates between postnatal days 21-30 (main effect of 
GENOTYPE, F2,57=6.9, p=0.002). 
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Figure 3.3: Growth, as indexed by body weight in C59X mice 
   
   
  
C59X female (A and C) and male (B and D) WT, heterozygous and homozygous ENU-mutant mice 
were weighed daily from birth until they were separated from their mothers at approximately 30 
days old. There was no weight difference between the different groups of subjects at birth, for both 
female (A) and male (B) mice, but by day 30 C59X homozygous ENU-mutants of both genders were 
significantly lighter than their WT and heterozygous ENU-mutant littermates. This difference in 
weight was maintained in adulthood. There was a dissociation between female and male mice as to 
when the pattern of reduced weight originated, with male homozygous ENU-mutant mice (D) 
showing a divergence from their WT and heterozygous ENU-mutant littermates earlier than female 
mice (C); from day 11, thought to be around the time that mice are weaned onto solid food. Data 
shows the mean values ±SEM. For subject N see Table 3.1. 
 
It is noticeable from Fig. 3.3D that the age at which the weights of the male C59X 
homozygous ENU-mutants start to diverge corresponds closely with the time when 
mice wean from their mothers, generally associated with the age at which the eyes 
are fully open (Silver, 1995), in this case between postnatal days 12 and 13 (Fig. 3.2A 
and 3.2B). Therefore it could be concluded that the decreased weight of male C59X 
homozygous ENU-mutant mice resulted from their transfer to solid food from 
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maternal milk, but the growth deficit maintained for the remainder of their lives. 
This was probably not the situation for the C59X female homozygous ENU-mutants 
(Fig. 3.3C), where the reduced growth appeared to occur later in the postnatal 
period, but still prior to separation from their mother. These differential patterns of 
growth are also apparent when investigating the percentage weight change/day 
through the early postnatal period (see Appendix 2.4), where between postnatal 
days  5-10 the C59X homozygous ENU-mutant males showed significantly reduced 
percentage growth than their WT littermate controls (main effect of GENOTYPE, 
F2,50=3.5, p=0.04). 
There were no differences between C417Y female WT, heterozygous and 
homozygous ENU-mutant mice at birth (Fig. 3.4A, main effect of GENOTYPE, 
F2,51=0.2, p=0.82), at 30 days old (main effect of GENOTYPE, F2,51=0.6, p=0.57) and in 
adulthood (main effect of GENOTYPE, F2,40=0.3, p=0.72). There were also no 
significant differences between C417Y male homozygous, heterozygous and WT mice 
at birth (Fig. 3.4B, main effect of GENOTYPE, F2,36=0.4, p=0.70), however, at postnatal 
day 30, C417Y male homozygous ENU-mutant mice weighed significantly less than 
their heterozygous littermates (main effect of GENOTYPE, F2,36=4.9, p=0.014), with 
this effect still apparent in adulthood (main effect of GENOTYPE, F2,33=5.9, p=0.008), 
although they had equivalent weights to their WT littermate controls. There were no 
differences in the weight gain between postnatal days 1-10 for both female and male 
C417Y mice (Fig. 3.4C and Fig. 3.4D, main effect of GENOTYPE, F2,49=1.3, p=0.28, 
F2,34= 1.2, p=0.32, respectively). Between postnatal days 11-20 C417Y female 
homozygous ENU-mutants weighed significantly more than their female WT 
littermate controls (main effect of GENOTYPE, F2,49=4.2, p=0.021, pairwise 
comparison, p=0.019), however this increase was only transient as growth was 
equivalent between postnatal days 21-30 (main effect of GENOTYPE, F2,49=1.1, 
p=0.33). C417Y males of all genotype showed equivalent weight changes through 
postnatal days 11-20 and 21-30 (main effect of GENOTYPE, F2,34=1.3, p=0.29, 
F2,34=0.3, p=0.75, respectively). Therefore, growth characteristics and final 
bodyweights of C417Y females (all genotypes) and C417Y males (all genotypes) were 
essentially equivalent, further confirmed when the % weight change/day is also 
considered (see Appendix 2.4).  
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Figure 3.4: Growth, as indexed by body weight in C417Y mice 
   
    
  
C417Y female (A and C) and male (B and D) WT, heterozygous and homozygous mice were weighed 
daily from birth until they were separated from their mothers at approximately 30 days old. There 
were no weight differences between the different groups of subjects at birth, or at any other time 
of life, for both female (A) and male (B) mice, although heterozygous male mice were heavier than 
their WT and homozygous ENU-mutant littermates in adulthood (over 2 months old). There were 
equivalent rates of growth for both female (C) and male (D) C417Y mice. Data shows the mean 
values ±SEM. For subject N see Table 3.1. 
 
Note that from this point on in the thesis only C59X and C417Y male homozygous 
ENU-mutants and their male WT littermate controls are discussed, although female 
data from both lines was collected. 
 
3.3.3 Zfp804a C59X behavioural screen results 
3.3.3.1 SHIRPA performance 
For the visual placing test (a measure of subject’s sensory and spinocerebellar 
function) there was no relationship between the genotypes of the C59X line and 
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performance (Fig. 3.5A, x2=3.45, df =1, p=0.75). There were also no genotype 
differences in the grip strength test, a different measure of spinocerebellar function 
(Fig 3.5B, x2=1.88, df =1, p=0.30) where all mice demonstrated good levels of 
grasping.  
 
Figure 3.5: Analysis of sensory, spinocerebellar function, muscle strength and 
negative geotaxis in C59X male mice. 
  
       
  
 
Four tests from the SHIRPA battery were used to assess simple sensory-motor abilities in C59X 
mice. Although there appeared to be a genotype-related difference in the test of visual placing (A) 
this was not significantly different, and on average all mice performed the test adequately. All mice 
showed good grip strength (B) and reasonable performance in the wire manoeuvre test (C). C59X 
homozygous ENU-mutant mice, however, showed significantly better abilities in the test of 
negative geotaxis (D) than their WT littermate controls. Data shows the mean values. For subject N 
see Table 3.2. 
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In the wire manoeuvre test, which indexes muscle strength and lower motor 
neuron function, there was no difference in the patterns of behaviour shown by the 
different groups of mice (Fig 3.5C, x2=1.67, df =1, p=0.30), however, C59X 
homozygous ENU-mutant mice showed better performance in the test of negative 
geotaxis, with more mice better able to turn and climb the wire grid than their WT 
littermate controls (Fig 3.5D, x2=6.9, df =1, p=0.01). Results from the SHIRPA screen 
suggest that mice of the C59X line have equivalent spinocerebellar and lower motor 
neuron function, as well as equivalent muscle strength. However, it appears that the 
C59X homozygous ENU-mutant mice have better vestibular and proprioceptive 
function than their WT littermate controls. 
 
3.3.3.2 Locomotor activity performance 
 Locomotor activity (LMA) performance, measured as infra-red beam breaks, 
was assessed over three days, with separate 2-hour sessions/day. Although C59X 
homozygous ENU-mutant mice appeared to show reduced activity compared to their 
WT littermate controls, this difference was non-significant (Fig. 3.6, main effect of 
GENOTYPE, F1,28=2.7, p=0.11).  
 
Figure 3.6: Locomotor activity in C59X male mice. 
       
   
 
Locomotor activity was assessed over three consecutive days, indexed by infra-red beam breaks. All mice 
demonstrated habituation within each 2hr session, and there were no significant differences in activity 
between C59X homozygous ENU-mutant mice and their WT littermate controls. Data shows the mean values 
±SEM. For subject N see Table 3.2. 
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LMA reduced within sessions as all mice habituating to the novel environment (main 
effect of QUARTILE, F1.5,41.3= 77.8, p=0.00), although overall activity was equivalent in 
each session (main effect of DAY, F1.6,45.4= 2.9, p=0.08). There were no significant 
interactions between genotype and these other measures (DAY*GENOTYPE, F1.6,45.4= 
0.3, p=0.73, QUARTILE*GENOTYPE, F1.5,41.3= 0.5, p=0.55) suggesting that, not only 
was overall activity equivalent, but that the C59X homozygous ENU-mutant mice and 
their WT littermate controls habituated to a novel environment in the same way. 
 
3.3.3.3 Assessment of reactivity to novel foodstuff 
 Neophobia and habituation to a novel foodstuff (10% condensed milk 
solution, also used as the reward in appetitive conditioning paradigms, see Chapter 
II, Section 2.3.5) was assessed over 6 sessions. As there was a significant difference in 
bodyweight between C59X homozygous ENU-mutant mice and their WT littermate 
controls, Kleiber’s 0.75 mass exponent method was used to normalise consumption 
to bodyweight (Schmidt-Nielsen, 1990). In the first session, where only water was 
available, the mice drank equally from each container (t28= 1.0, p=0.33) suggesting 
that they did not show a side bias in which container they sampled solution from. 
Following the introduction of the novel foodstuff in the 2nd session, all mice 
increased their consumption (Fig. 3.7A, main effect of DAY, F5,135= 36.4, p=0.00, 
DAY*GENOTYPE, F5,135= 0.8, p=0.55), however there was no difference in overall 
consumption between C59X homozygous ENU-mutant mice and their WT littermates 
(main effect of GENOTYPE, F1,27= 3.6, p=0.07). Initially, all of the C59X mice showed a 
neophobic response to the novel foodstuff (Fig. 3.7B), demonstrating a preference of 
less than 50%, although they overcame this and reached >85% preference for the 
novel foodstuff by the 4th choice session (main effect of DAY, F3,81= 64.98, p=0.00, 
DAY*GENOTYPE, F3,81= 1.7, p=0.17). This neophobic response to the reinforcer was 
most pronounced for the C59X homozygous ENU-mutant mice, having a significantly 
reduced condensed milk preference on the 1st choice day in comparison to their WT 
littermate controls (t27= -2.2, p=0.04). When condensed milk preference was looked 
at over all 4 choice days, there were no genotype differences (main effect of 
GENOTYPE, F1,27= 1.2, p=0.29), nor was there an effect of genotype on condensed 
milk preference for the final choice day (t27= 0.3, p=0.81) indicating that both the 
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C59X homozygous ENU-mutants and their WT littermate controls had an equivalent 
preference for the condensed milk reinforcer over water. 
 
Figure 3.7: Food neophobia and habituation in C59X male mice. 
     
 
 
 
Neophobic responses to a novel foodstuff were assessed in 6 daily sessions. Following habituation 
to the test environment, where only water was present in the two drinking vessels, all of the mice 
readily consumed the available solutions (A). The novel foodstuff (10% condensed milk solution) 
was introduced on the 2
nd
 day of testing, and it was noticeable that all C59X mice showed a 
neophobic (<50% preference) response on the first day (B), although this effect was significantly 
greater in the homozygous ENU-mutant mice.  All mice then overcame this initial reluctance and 
showed significant preference for the condensed milk solution over water. Data shows the mean 
values ±SEM, normalised to bodyweight
0.75
. For subject N see Table 3.2. 
 
3.3.4 Zfp804a C417Y behavioural screen results 
3.3.4.1 SHIRPA performance 
 Evaluation of C417Y mice on the sensory-motor function tests from the 
SHIRPA primary observational screen demonstrated no significant differences 
between C417Y homozygous ENU-mutants and their WT littermate controls in terms 
of spinocerebellar and lower motor neuron function, muscle strength and vestibular 
and proprioceptive function. There were no genotype-related differences in the 
visual placing (Fig. 3.8A, x2=0.21, df =1, p=0.75), grip strength (Fig. 3.8B, x2=0.05, df 
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=1, p=0.75) wire manoeuvre (Fig. 3.8C, x2=0.05, df =1, p=0.75) or negative geotaxis 
(Fig. 3.8D, x2=0.87, df =1, p=0.30) tasks. 
 
Figure 3.8: Analysis of sensory, spinocerebellar function, muscle strength and 
negative geotaxis in C417Y male mice. 
       
 
 
Four tests from the SHIRPA battery were used to assess simple sensory-motor abilities in C417Y 
mice. All the mice demonstrated good levels of behaviour in the test of visual placing (A), showed 
good grip strength (B), reasonable performance in the wire manoeuvre test (C) and good abilities in 
the test of negative geotaxis (D).  Data shows the mean values. For subject N see Table 3.2. 
 
3.3.4.2 Locomotor activity performance 
There were no differences between C417Y mice in the assessment of LMA 
over the three 2hr sessions (Fig. 3.9, main effect of GENOTYPE, F1,32= 2.8, p=0.1), 
although there was a tendency for C417Y homozygous ENU-mutant mice to be 
hyperactive in relation to their WT littermates. Within each session all of the mice 
showed habituation within sessions (main effect of QUARTILE, F1.6,51.1= 90.4, p=0.00, 
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QUARTILE*GENOTYPE, F1.6,51.1= 1.1, p=0.35) and habituation between each of the 3 
sessions (main effect of DAY, F2,64= 43.8, p=0.00, DAY*GENOTYPE, F2,64= 0.1, p=0.91), 
but these alterations in locomotor activity did not differ between C417Y homozygous 
ENU-mutants and their WT littermate controls. 
 
Figure 3.9: Locomotor activity in C417Y male mice. 
 
Locomotor activity was assessed over three consecutive days, indexed by infra-red beam breaks. All mice 
demonstrated habituation within each 2hr session, and there were no significant differences in activity 
between C417Y homozygous ENU-mutants and their WT littermate controls. Data shows the mean values 
±SEM. For subject N see Table 3.2. 
 
3.3.4.3 Assessment of reactivity to novel foodstuff 
There were no differences between C417Y homozygous ENU-mutants and 
WT littermate controls in terms of their total consumption, normalised for 
bodyweight as previously described, (Fig. 3.10A, main effect of GENOTYPE, F1,28= 1.7, 
p=0.2) and the volume of the solutions consumed increased on each of the 6 days of 
this test (main effect of DAY, F5,140= 7.9, p=0.00, DAY*GENOTYPE, F5,140= 0.07, 
p=0.65). Importantly, as with the C59X subjects, all C417Y subjects displayed an 
equivalent consumption between the two containers during the first day of testing 
(t29= 0.2, p=0.87), illustrating that the spatial position of the containers was not a 
factor in subjects consumption. When the novel foodstuff was introduced from the 
2nd session, all C417Y mice (Fig. 3.10B, main effect of GENOTYPE, F1,28= 0.97, p=0.33) 
showed an increased preference for the novel foodstuff (main effect of DAY, F2.3,64.1= 
42.9, p=0.00, DAY*GENOTYPE, F2.3,64.1= 0.8, p=0.5). C417Y homozygous ENU-mutant 
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mice and their WT littermate controls also showed equivalent neophobic responses 
(<50% preference) on the introduction of the novel foodstuff (t28= -0.03, p=0.98) and 
had an equivalent preference for the condensed milk on the final choice session (t28= 
-0.8, p=0.42). 
 
Figure 3.10: Food neophobia and habituation in C417Y male mice. 
  
     
 
 
 
Neophobic responses to a novel foodstuff were assessed in 6 daily sessions. Following habituation to 
the test environment, where only water was present in the two drinking vessels, all of the mice 
readily consumed the available solutions (A) and demonstrated increasing preference for the novel 
foodstuff (10% condensed milk solution), following an initial neophobia (B), with no genotype 
differences in these measures. Data shows the mean values ±SEM, normalised to bodyweight
0.75
. For 
subject N see Table 3.2. 
 
 
3.4 Discussion 
3.4.1 General viability of the models 
 There were no obvious signs of breeding related problems in either mutant 
line with all pups appearing normal at birth, with no indications of observable health 
problems in either the C59X or C417Y lines. The mean litter sizes at birth for both the 
C59X and C417Y lines were consistent with reported data for the inbred C57BL/6J 
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strain (Jackson Laboratories, USA; Harlan Laboratories, UK), suggesting that the there 
were no major fertility problems with either of the Zfp804a mutant lines. However, 
there were a significant number of pups found dead in both lines (27%), with a high 
percentage of these found mutilated (40%); presumably by the mother. This may 
reflect an increased level of maternal aggression in the heterozygous mutant 
mothers, although comparison with the pure inbred C57BL/6J strain suggests that 
this post-natal mortality rate was in fact at normal levels (Weber et al., 2007), and 
therefore pup survivability was not unduly influenced by Zfp804a maternal 
aggression. 
 The distribution of gender and genotypes within the surviving Zfp804a mice 
uncovered an imbalance of C59X male mice weaned, with equivalent male to female 
ratios for the C417Y line. There were no significant differences in the Mendelian 
distribution of genotypes (1:2:1, for heterozygous* heterozygous pairings) for mice 
not surviving to weaning. There were, however, fewer males killed pre-weaning for 
both mutant lines, suggesting that fewer male mice were born in total for both the 
C59X and C417Y lines.  As there is no available data from the pure inbred C57BL/6J 
line to compare these findings with, it is difficult to conclude whether the C59X and 
C417Y mutations are influencing pre-natal male survivability or if the fewer males 
born to both lines were simply a natural occurrence for this ENU-mutant mouse 
strain. At weaning, Mendelian distribution of genotypes was also seen, further 
suggesting non-genotype related reasons for post-natal mortality.  
  There were no birth weight differences between any of the different 
genotypes of C59X and C417Y mice for either gender, with all mice showing the 
expected pattern of weight changes with increasing age, as well as a plateau 
between post-natal days 12 and 19 when they wean from the mothers and begin 
eating solid food (Silver, 1995). At 4 weeks old, when the mice were separated from 
their mothers, both C59X male and female homozygous ENU-mutant mice were 
significantly lighter than their WT littermate controls, a difference which was 
maintained into adulthood in the male C59X homozygotes. Interestingly, this 
difference in weight originated at different times, where C59X male homozygous 
ENU-mutant mice showed reduced growth from the time when they weaned from 
their mothers (ca. 12 days old) whereas C59X female homozygous ENU-mutant mice 
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showed significant weight difference from their WT littermates approximately 7 days 
later.  It is thought that complete weaning from their mother’s milk occurs when the 
pups eyes are fully open (ca. 13 days old, Silver, 1995), suggesting that the reduced 
bodyweight of the C59X male homozygous ENU-mutants may be related to poor 
weaning in these mice. This could be due to increased neophobia to the solid food, 
increased anxiety to explore the cage or perseveration of maternal contact. The 
weight difference seen in the C59X female homozygous ENU-mutants occurs later 
than this, and is not likely to be related to weaning as eye opening occurred at an 
equivalent time for all C59X female genotypes, as well as at an equivalent time to the 
C59X males. There were no differences in the growth characteristics or weight of 
C417Y male and female homozygous ENU-mutant mice relative to their WT and 
heterozygous littermates. Furthermore, somatic indices of development, such as ear 
and eye opening, emerged at equivalent time points between both C59X and C417Y 
mutants and their WT counterparts. As the early life development of the females in 
both the C59X and C417Y ENU-mutant lines was not affected by genotype, it was 
decided that for the behavioural aspects of the thesis, only the males of both lines 
would be tested. 
 Early life trauma, such as birth complications, foetal infection and growth 
retardation were discussed in the General Introduction (see Section 1.4) as factors 
thought to increase risk for schizophrenia. The C59X and C417Y mutations did not 
lead to lower birth weights, but the C59X male homozygous ENU-mutants did weigh 
significantly less than their WT counterparts at weaning and in adulthood, replicating 
the reduced adult weight found with the C59X homozygous ENU-mutants in the 
Zfp804a G4i cohort (Al-Janabi, 2012). The C59X homozygous ENU-mutant mice from 
the G4i cohort also showed reduced brain weight, albeit not significantly reduced 
from their WT littermate controls. It is difficult to relate these findings with other 
mouse models for schizophrenia as these types of analysis have not been presented 
previously, to our knowledge, but reduced adult body and brain weights have been 
reported in pups that, for example, were exposed to a low protein diet in utero 
(Barnes, Neely, Kwong et al., 1968; Marichich, Molina, & Orsingher, 1979).  
 Schizophrenia and bipolar disorder are thought to arise from a complex 
interaction between genetic predisposition and early life adversity (van Os, Rutten & 
78 
 
Poulton, 2008). These adverse early life events can occur prenatally, for example 
with maternal malnutrition (Susser & Lin, 1992), and/or postnatally with infection 
and obstetric difficulties (e.g. McGrath & Murray, 2011). Abnormal early life 
characteristics have been shown in both of the C59X and C417Y homozygous ENU-
mutants, with the reduced bodyweight seen in the C59X homozygous ENU-mutants 
(relative to their WT littermate controls) potentially due to delayed weaning to solid 
food and fewer males born to both mutant lines, perhaps due to an unknown gender 
related pre-natal effect caused by the mutations. It would therefore be interesting to 
examine a number of litters prenatally to ascertain the number, genotype and 
gender of pups in utero to determine if more male pups are present prenatally and if 
Mendelian ratios are intact before birth. 
 
3.4.2 Behavioural phenotypic screen 
 A preliminary SHIRPA screen (Rogers et al., 1997) was conducted assessing 
the visual placing, grip strength, wire manoeuvre and negative geotaxis capabilities 
of the Zfp804a mutants. WT mice of both lines showed good visual acuity, strength 
and co-ordination and were able to correctly orient themselves on a vertical grid, 
respectively. C417Y homozygous ENU-mutant mice did not differ from their WT 
littermates in any of these tests. C59X homozygous ENU-mutants displayed 
equivalent performance levels to their WT counterparts on all of the SHIRPA tests 
except for the negative geotaxis assay, displaying an enhanced ability to turn and 
orient themselves on a vertical grid, as compared to their WT littermate controls. 
This, however, may not be due to enhanced vestibular/proprioceptive abilities in the 
C59X homozygous ENU-mutants but rather point to poorer WT capabilities, where 
35% of the C59X WT controls showed poor negative geotaxis performance as 
compared to 0% poor performance in the C417Y WTs. Previous testing of the G4i 
Zfp804a mutants uncovered a genotype effect on another sensorimotor task; the 
RotaRod performance test, which assessed balance, co-ordination, grip and fatigue. 
Here, C59X male homozygous ENU-mutants were able to stay on the RotaRod longer 
than their WT and heterozygous counterparts, indicating greater sensorimotor 
abilities on this task (Al-Janabi, 2012).  
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 Locomotor activity and reactivity to novel foodstuff were also tested in the 
Zfp804a ENU-mutants. Neither the C59X nor the C417Y mutation induced locomotor 
activity differences in the locomotor activity task (LMA), with all mice habituating to 
the novel environment at an equivalent rate; reducing their locomotor activity as the 
sessions progressed. There was a tendency for the C59X homozygous ENU-mutants 
to display reduced levels of activity as compared to their WT littermate controls, 
although this was not found to be significant.  This pattern of effects is comparable 
to the previous study (Al-Janabi, 2012), with the G4i cohort of mice, where C59X 
homozygous ENU-mutant mice displayed significant reductions in locomotor activity 
in all sessions with C417Y homozygous ENU-mutant mice not differing from their WT 
counterparts. The difference in effect size between the two studies may be 
accounted for by other ENU-derived gene mutations present in the G4i cohort of 
mice, in addition to the Zfp804a target mutation (on average 3.88 mutations, See 
Chapter II, Fig. 2.2), whereas in the G7i/ii cohorts  other non-target gene mutations 
had been effectively eliminated. Alternatively, and much more likely, it may be due 
to slight variations in methodological details. 
 The reactivity to novel foodstuff did not uncover any neophobia or 
consumption differences between the C417Y homozygous ENU-mutants and their 
WT littermates, suggesting no overall differences in thirst, hunger, satiation, anxiety 
or motivation to freely drink. C59X homozygous ENU-mutants displayed significant 
neophobia to the novel foodstuff, consuming significantly less than their WT 
counterparts. This could be related to heightened reactivity in the C59X homozygous 
ENU-mutants, although this initial reaction disappeared after further presentations 
of the foodstuff with both C59X homozygous ENU-mutants and their WT controls 
habituating to the solution and displaying equivalent consumption levels. Overall, 
these findings indicated there were no major sensorimotor deficits in the Zfp804a 
mutants prior to going on to perform the more complex behavioural assays detailed 
later in the thesis. 
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3.4.3. Summary of key results from Chapter III 
 Fewer male mice were born to both Zfp804a mutant lines. 
 A Mendelian genotype inheritance pattern was observed for weaned Zfp804a 
mice from both lines. 
 C59X male homozygous ENU-mutants weighed significantly less than their 
WT littermate controls between PND 11-20, at weaning and in adulthood.  
 C59X female homozygous ENU-mutants weighed significantly less than their 
WT littermate controls between PND 21-30.  
 C59X homozygous ENU-mutants demonstrated significantly better 
performances on the negative geotaxis assay of the SHIRPA screen than their 
WT littermate controls. 
 No locomotor differences between homozygous ENU-mutant mice and their 
WT counterparts in either Zfp804a mutant line. 
 C59X homozygous ENU-mutant mice displayed neophobia to a novel 
foodstuff compared to their WT littermate controls. 
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Chapter IV: Investigating anxiety-related behaviour in Zfp804a mutant 
mice; elevated plus-maze, open field and elevated zero-maze 
 
4.1 Introduction 
Chapter III showed that the Zfp804a mutant lines were not compromised by any 
gross developmental or physiological effects which would undermine further testing. 
This chapter describes a detailed assessment of emotional functioning in the mutant 
lines, focusing on anxiety-related behaviours assessed using three separate tests of 
anxiety.  
As mentioned previously, in a GWAS published in 2008, ZNF804A was the top 
hit for an association with schizophrenia, with this association strengthened when 
bipolar disorder cases were added to the affected sample (O’ Donovan et al., 2008), 
providing further support for the view that there may be an overlap between 
schizophrenia and bipolar disorder in terms of their genetic risk architecture (Owen, 
Craddock and Jablensky, 2007). Moreover, this can be seen in a GWAS undertaken by 
Steinberg and colleagues (2011), where they found a copy number variant, in the 
form of a deletion of ZNF804A, in both a schizophrenia patient and an anxiety 
disorder patient. It is also recognised that there can be overlap between 
schizophrenia and bipolar disorder symptomatology, leading to the idea that the two 
disorders may be better viewed as lying within a spectrum and not the polarised 
‘‘Kraepelinian dichotomy‘‘ previously thought (See Chapter I, Section 1.1). Emotional 
problems occur in both bipolar disorder and schizophrenia, indeed schizophrenia is 
in many cases co-morbid with anxiety disorders. A literature review of studies 
published between 1966 and 2004 found that individuals with schizophrenia 
spectrum disorders had a lifetime prevalence rate for any anxiety disorder ranging 
from 30% to 85% with most studies showing rates higher than in the general 
population (Pokos & Castle, 2006). In more than half of the patients, the anxiety 
disorder preceded the onset of psychosis, potentially resulting in a misdiagnosis. 
Another literature review illustrates the variability in prevalence rates of anxiety 
disorders, but adds further weight to the observation that anxiety co-morbidities are 
prevalent in schizophrenia and that treatment for anxiety could help alleviate the 
symptoms in those patients (Braga, Petrides & Figueira, 2004). 
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Other studies have shown co-morbidity of schizophrenia with panic attacks 
(Argyle, 1990), obsessive-compulsive disorder (Fenton & McGlashan, 1986; Eisen, 
Beer, Pato et al., 1997), social anxiety (Pilkonis, Feldman, Himmelhoch & Cornes, 
1980; Penn, Hope, Spaulding et al., 1994), posttraumatic stress disorder (Meyer, 
Taiminen, Vuori, Aijala & Helenius, 1999) and agoraphobia (Braga, Mendlowicz, 
Marrocos & Figueira, 2005), with a further study illustrating the prevalence of 
obsessive-compulsive disorder (OCD, 30%) and panic disorder (15%) in bipolar 
disorder (Cosoff & Hafner, 1998). Despite the co-morbidity between schizophrenia 
and anxiety disorders, there are very few mouse models which have included a 
detailed assessment of anxiety phenotypes, with the limited number of studies that 
have done work in this area giving rise to mixed results. For example, heterozygous 
neuregulin 1 mice (NRG1+/-) showed equivalent levels of anxiety to wild-type controls 
on the elevated plus-maze (EPM) but demonstrated less anxiety in tests of 
neophobia or social interaction (Karl, Duffy, Scimone et al., 2007; O’Tuathaigh et al., 
2008). DISC1 knockout mice were no different to wild-types on the elevated plus 
maze (Clapcote et al., 2007), nor were DISC1 dominant negative mice different to 
their WT counterparts in the open field test of anxiety (Hikida et al., 2007). These 
previous data indicate that anxiety is likely to be an interesting phenotype to 
examine in the Zfp804a mutant lines and that the analysis should utilise a range of 
methods which tax different facets of anxiety-related behaviour. 
The neurobiological underpinnings of anxiety are only partly established, 
although research has implicated the limbic system, with particular emphasis on the 
hippocampus and amygdala (Engin & Dallas, 2007; Davis, 1992; Etkin, Prater, 
Schatzberg et al.,2009) with ventral hippocampal lesions leading to reduced anxiety 
in the light/dark exploration test (Bannerman, Grubb, Deacon et al., 2003). A number 
of neurotransmitter systems have also been implicated in anxiety behaviour, 
including GABA-ergic and serotonergic mechanisms. Indeed, benzodiazepines work 
by enhancing the effect of GABA, and serotonin reuptake inhibitors are thought to 
alleviate anxiety-related symptoms, suggesting that reduced serotonin levels may 
modulate the symptoms of anxiety (Baldwin & Rudge, 1995; Ballenger, 1999). 
Furthermore, certain GABA-ergic and serotonergic receptor subtypes have been 
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found to be greatly expressed in the hippocampus (Mehta and Ticku, 1999; Hoyer, 
Clarke, Fozard et al., 1994). 
The assays used in this chapter were the EPM, the open field (OF) and the 
elevated zero-maze (EZM); all well validated tasks in the study of rodent anxiety (for 
reviews see Lister 1990; Sousa, Almeida & Wotjak, 2006; Ramos, 2008; Sartori, 
Landgraf & Singewald, 2011). All 3 anxiety assays tap into unconditioned approach-
avoidance conflict situations based on two conflicting innate rodent tendencies: 
exploring a novel environment and avoiding elevated/open spaces with potential 
danger, including predator risk. Whilst the relevance of these animal tests of anxiety 
to human psychology and behaviour is a topic of debate (Sartori et al., 2011), they do 
appear to give rise to significant overlap in terms of sensitivity to anxiety provoking 
(anxiogenic) and anxiety relieving (anxiolytic) effects of drugs such as beta-carbolines 
(File & Baldwin, 1987; Rägo et al., 1988) and benzodiazepines (Treit, Engin & 
McEown, 2010; Prut & Belzung, 2003; Shepherd, Grewal, Fletcher et al., 1994).  
The EPM (Pellow, Chopin, File & Briley, 1985) is the most widely used 
exploratory paradigm of anxiety in rodents, partly because it is rapid to perform but 
also because it has been well validated with both anxiolytic and anxiogenic agents 
(Lister 1987a). The EPM assays aversion to elevated and open spaces, and consists of 
four arms where two opposing arms are enclosed by high walls and the other two 
arms are open. Anxiety is determined by measuring the frequency of entries and 
time spent by subjects in the open arms of the maze relative to the enclosed arms, in 
addition to a range of other behaviours sensitive to anxiety-provoking stimuli such as 
head-dips and stretch-attend postures (Rodgers et al., 1997). The OF (Walsh and 
Cummins, 1976) is an enclosed square arena (80cm in diameter) assaying the 
aversion of mice to open illuminated spaces. Rodents will spend a large proportion 
of time around the periphery, with the tendency to remain close to the walls 
(thigmotaxis) used as an index of anxiety. The EZM (Shepherd et al., 1994) is a 
modification of the EPM, and consists of two open and two enclosed elevated arms 
which form a zero/circle, thus lacking the ambiguous central area of the EPM. Like 
the EPM, the EZM measures the aversion of mice to elevated open spaces. 
Due to the multifaceted nature of anxiety, it can no longer be assumed that 
all rodent anxiety tests are measuring the same component of emotionality (Ramos, 
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2008; Sousa et al, 2006). One study using factor analysis found that emotionality-
related behaviours from the OF and EPM loaded on distinct factors, thus reflecting 
different psychological/behavioural dimensions (Trullus & Skolnick, 1993). Similarly, 
it has been shown that variables from the EPM and OF do not produce a common 
anxiety-related factor in rats (Ramos, Mellerin, Morme`de & Chaouloff, 1998). 
Despite this, some argue that these anxiety paradigms should not be viewed as 
measuring separate anxiety related behaviours but as measuring partially 
overlapping constructs (Ramos, 2008). Whatever view one takes it is important to 
utilise multiple assays in order to obtain a comprehensive assessment of any changes 
in emotional functioning in the Zfp804a mutant lines 
 
4.2 Materials and Methods 
4.2.1 Subjects and animal husbandry 
In total, 64 adult male mice were used in these experiments. For the elevated 
plus-maze (EPM) mice were tested at a mean age of 3 months, for the open field 
(OF) mice were on average 4 months old and for the elevated zero-maze (EZM) mice 
had a mean age of 8 months. The EPM was the first anxiety paradigm to be used, 
followed by the OF (1 month later) and then the EZM (4 months after the OF). A 
limited number of mice were dropped from the study between the EPM and the 
EZM, due to illness/death with further mice added in between the OF and EZM when 
additional genotyping results were obtained. Details of specific mouse numbers per 
genotype for each anxiety assay can be seen in Table 4.1. 
 
Table 4.1: The sample size and genotype of each cohort-subset of mice assayed in 
the tests of anxiety 
Behavioural 
Task 
C59X line C417Y line 
WT  Homozygous W T Homozygous 
Elevated plus-
maze 
14 15 15 20 
Open field 12 14 15 20 
Elevated zero-
maze 
14 15 14 15 
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The mice were housed in littermates groups of two to five animals per cage, 
under temperature- and humidity-controlled conditions, with a 12-hour light: 12-
hour dark cycle (lights on at 07:30). All subjects had ad libitum access to standard 
laboratory chow and water and were weighed on regular basis and any subjects 
losing greater than 10% of their body weight were removed from the experiment.  
All experimental procedures were conducted under licenses issued by the Home 
Office (U.K.) in compliance with the Animals (Scientific Procedures) Act 1986.  
 
4.2.2 General behavioural methods 
The experimental procedures for each of the behavioural assays were well 
established in the laboratory in previous work (Mikaelsson et al., 2013). Each of the 
anxiety paradigms involved testing mice individually; therefore, the apparatus was 
cleaned thoroughly with 1% acetic acid between each mouse, to remove any odours 
left by the previous occupant. All testing took place between the hours of 09:00 and 
18:00, with equal distribution of testing for subjects of different genotypes 
throughout the day. Prior to testing, mice were habituated to the dimly lit test room 
for at least 20 minutes. EthoVision Observer software (Version 3.0.15, Noldus 
Information Technology, Netherlands) was used to collect data for the EPM, OF and 
EZM. The software tracks the movement of a subject (via an overhead digital 
camera) within previously defined zones within the arena (these zones differed 
between the different anxiety paradigms; see Chapter II, Section 2.4.3). A number of 
measures were automatically calculated for each zone, including duration and 
entries into each zone, time spent moving, rearing frequency, mean velocity and 
distance travelled. Data were analysed as total values for each session and in 1 
minute intervals to assess performance within a session. Each session was also 
recorded using DVD HD recorders (Sony Corp, U.K.) for further analysis if required. 
 
4.2.3 The elevated plus-maze (EPM) paradigm  
 In order to assess the innate aversion of both mutant lines of Zfp804a mice to 
open space and height, subjects were placed at the centre of the EPM apparatus (as 
previously described in Chapter II, Section 2.4.4) facing one of the exposed open 
arms and allowed to explore the maze over a single session of 5 minutes. The maze 
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was illuminated by a single 60 Watt lamp positioned above the arena (facing 
upwards). For the data analysis, the EPM was divided into 5 virtual zones; 2 open 
arm zones, 2 closed arm zones and a middle zone from which all the arms originated. 
The 2 open arm zones were combined to form one open zone value, as were the 2 
closed arm zones. In addition to parameters previously mentioned in Section 4.2.2 
above, other measures, sensitive to emotional state, were recorded manually. These 
being the number of stretch attend postures (SAPs defined as stretching forward in 
an open zone) and number of head dips over the open arm (looking over the edge of 
an open arm). Data were expressed for the total session and the main parameters 
used as indices of anxiety-related behaviour were the number of entries onto the 
open arms, the total duration of time spent exploring the open arms, and the latency 
of first entry onto the open arms. Other potential indicators of anxiety states 
included; the number of rears, the number of SAPs and the number of head dips on 
the open arms. Entries made and time spent in the closed arms was also recorded. 
The parameters used as measurements of general locomotor activity were; the total 
distance moved, the total duration of movement and the mean velocity of 
movement. 
 
4.2.4 The open field (OF) paradigm  
Mice of the Zfp804a mutant lines were tested in the OF, a white square 
shaped Perspex arena enclosed by high walls (Chapter II, Section 2.4.5). The maze 
was illuminated by a single 60 Watt lamp, located directly above the central region 
(facing upwards). Subjects were placed, facing a wall, at the edge of the arena. The 
OF arena was divided into virtual zones consisting of 2 concentric squares, a central 
zone (400*400mm) and an outer zone (the 200mm wide periphery). Data were 
expressed for the total session and the main parameters used as indices of anxiety-
related behaviour were the total duration of time spent exploring the central region, 
the frequency of entries into the central region, the latency to first entry into the 
central zone and the number of rears. The parameters used as measurements of 
general locomotor activity were; the total distance moved, the total duration of 
movement and the mean velocity of movement. 
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4.2.5 The elevated zero-maze (EZM) paradigm 
Behaviour was assessed in the elevated zero-maze as previously described in 
Chapter II, Section 2.4.6). The EZM has the advantage over the EPM in containing no 
central region which can interfere with measurements of exploration of the open 
and closed arms; the idea being that the EZM will provide data with less noise and 
therefore be a more sensitive assay (Shepherd et al., 1994). Each subject was placed 
in one of the closed zones and allowed to explore the maze over a single session of 5 
minutes. The inside of the maze was 65 cm in diameter. The circular pathway was 
divided into four quadrants, two of which had walls (27 cm high) around the edge 
(closed quadrants); while the other two did not have walls (open quadrants). The 2 
closed quadrants were combined to form a single closed zone value, as were the 2 
open quadrants to form a single open zone value. As with the EPM, SAPs and head 
dips were recorded manually. Data were expressed for the total session and the 
main parameters used as indices of anxiety-related behaviour were the total 
duration of time spent exploring the open arms, the number of entries onto the 
open arms and the latency of first entry onto the open arms. Other potential 
indicators of anxiety states included; the numbers of rears, stretch attend postures 
(SAPs) and head dips on the open arms. The parameters used as measurements of 
locomotor activity were; the total duration of movement, the mean velocity of 
movement, as well as the distance moved. 
 
4.2.6 Statistical analysis 
The experimental data was analysed using SPSS (Version 18.0). Behavioural 
data are presented as mean values (M) with the standard error of the mean (SEM), 
unless stated otherwise. Data for each strain were analysed separately, and separate 
ANOVAs were performed with between-subjects factor of GENOTYPE (homozygous 
ENU-mutant vs. WT littermate control) and within subject factors as appropriate. All 
significance tests were performed at alpha level of 0.05 and where significant 
interactions were identified in the main ANOVA, post-hoc tests using appropriate 
pair-wise comparisons were performed. Greenhouse-Geisser degrees of freedom 
(df) corrections were applied as required to repeated-measures factors. Data were 
screened for skewed variance with arcsine transformations applied to skewed data 
88 
 
(percentage data in particular) to obtain a normal distribution. Behaviour on all 
anxiety assays was followed-up by correlation analysis (Pearsons r). 
 
4.3 Results 
4.3.1 Zfp804a C59X line 
4.3.1.1 Elevated plus-maze 
Analysis of the data from EthoVision showed that as expected, on average, all C59X 
subjects made significantly more entries on to the protected closed arms than the 
exposed open arms (Fig. 4.1A, main effect of ZONE, F1,27= 5.5, p=0.03, 
ZONE*GENOTYPE, F1,27= 1.9, p=0.18), and spent significantly longer on the closed 
arms than the open arms (Fig. 4.1B, main effect of ZONE, F 1,27= 14.1, p=0.001, 
ZONE*GENOTYPE, F1,27= 3.2, p=0.08). As is common with these tests (Lister, 1990), 
analysis was then focused on open arm behaviour, revealing that the C59X 
homozygous ENU-mutant mice made significantly more entries on to the open arms 
than their WT littermate controls (t27= 2.2, p=0.04). This pattern, consistent with a 
reduced level of anxiety, was also seen in the overall length of time spent on the 
open arms of the maze, with C59X homozygous ENU-mutant mice spending longer 
on the open arms than their WT littermate controls, both in duration and percentage 
of time, although these measures were not found to be significant (Fig. 4.1B and 
4.1C, t27= 1.9, p=0.07, t27= 1.9, p=0.07, respectively).   
In contrast to behaviour on the open arms, no genotype differences were 
found for entries on to the closed arms (t27= 0.6, p=0.58) or duration of time spent 
on the closed arms (t27= -1.4, p=0.16), suggesting, a priori, that the genotype 
differences seen with respect to behaviour on the open arms were not simply the 
result of underlying differences in activity (since if this was the case one might 
anticipate changes in behaviour that were common to both the open and closed 
arms).  
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Figure 4.1: Entries made and duration of time spent on the open and closed arms 
of the EPM for the C59X line  
 
  
 
 
Subjects of the C59X line made more entries on to the closed arms than the open arms, with the 
C59X homozygous ENU-mutant mice making significantly more entries on to the open arms than 
their WT littermate controls (A). Similarly, all C59X subjects, independent of genotype, also spent 
longer on the closed arms than the open arms. Despite the C59X homozygous ENU-mutant mice 
spending more time on the open arms (raw data (B), percentage of time (C)) than their WT 
littermate controls (indicative of reduced anxiety) these differences were not significant. Data 
shows the mean values ±SEM, *p<0.05 for pairwise differences related to genotype. For subject N 
see Table 5.1. 
 
The latency to enter the open arms for the first time is sometimes considered 
an additional index of anxiety, but in this case there were no genotype differences 
with respect to this measure (t27= -0.8, p=0.45). There were however, a number of 
other ancillary behaviours consistent with a pattern of reduced anxiety in the C59X 
homozygous ENU-mutant mice, including increased rearing (t27= 2.5, p=0.02), stretch 
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attend postures (SAPs, t27= 3.0, p=0.006) and head dips (t27= 2.9, p=0.007) on the 
open arms, Table 4.2. 
 
Table 4.2: Ancillary parameters on the EPM for the C59X line 
Behavioural Parameter WT Homozygous 
Latency of first occurrence on the 
open arms (seconds) 
17.4 9 ± 7.1 11.7 ± 2.9 
Number of rears on the open arms 8 ± 1.5 13.6 ± 1.7 
Number of SAPs on the open arms 24.2 ± 2.7 38.9 ± 4.1 
Number of head dips on the open 
arms 
17.1 ± 2.9 32.2 ± 4.2 
Data shows mean ± SEM 
 
Confounding influences of activity on the pattern of data were unlikely as 
differences due to genotype were limited to activity monitored on the open arms. 
Hence, the C59X homozygous ENU-mutant mice moved greater distances and spent 
longer moving on the open arms than their WT littermate controls (t27= 2.7, p=0.01 
and t27= 2.9, p=0.007, respectively) but were no different to their WT counterparts 
when measuring activity in the maze as a whole in terms of the total distance moved 
and time spent moving (main effect of GENOTYPE, F1,27 = 1.6, p=0.22, and F1,27= 2.7, 
p=0.11, respectively); similarly, the averaged velocity (cm/sec) of locomotion was 
indifferent to genotype (main effect of GENOTYPE, F 1,27= 2.9, p=0.1, see Table 4.3).   
 
Table 4.3: Locomotor parameters on the EPM for the C59X line 
Behavioural Parameter WT Homozygous 
Total distance moved on the open 
arms (cm) 
181.6 ± 27.3 297.4 ± 32.8 
Total time spent moving on the 
open arms (seconds) 
32.1 ± 16.5 53.1 ± 21.4 
Total distance moved (cm, all 
arms) 
377.8 ± 35.5 440.3 ± 34.3 
Total time spent moving (seconds, 
all arms) 
60 ± 4.3 69.9 ± 4.2 
Averaged velocity (cm/s) 3.9 ± 0.3 4.5 ± 0.3 
Data shows mean ± SEM 
 
91 
 
4.3.1.2 Open field  
The area of the OF arena was subdivided into 2 virtual regions (outer and 
central) using the EthoVision tracking software. When anxious, rodents are expected 
to stay in close proximity to the walls of the open field arena (the outer zone). 
Generally, all subjects demonstrated this thigmotaxic behaviour by making more 
entries into (Fig. 4.2A, main effect of ZONE, F1,28= 15.2, p=0.001, ZONE*GENOTYPE, 
F1,28= 0.2, p=0.63) and spending longer in the outer area as opposed to the more 
anxiety-provoking central region of the OF (Fig. 4.2B, main effect of ZONE, F1,28= 
806.5, p=0.00, ZONE*GENOTYPE, F1,28= 2.4, p=0.13).  
 
Figure 4.2: Entries made and duration of time spent in the central and outer 
zones of the OF for the C59X line 
  
 
All C59X subjects demonstrated thigmotaxic behaviour by making more entries into the outer zone 
(A) and spending longer in the outer zone as opposed to the more anxiety-provoking central zone 
(B). Despite the C59X homozygous ENU-mutant mice making more entries into the central zone and 
spending longer in the central zone than their WT littermate controls, these differences were not 
found to be significant. C59X homozygous ENU-mutant mice made significantly more entries into 
the outer zone than their WT littermate controls, but duration of time spent in the outer zone was 
equivalent between genotypes. Data shows the mean values ±SEM. For subject N see Table 5.1. 
 
Despite C59X homozygous ENU-mutant mice making more entries into the central 
zone and spending longer in the central zone than their WT littermate controls (Fig. 
4.2A and Fig. 4.2B), these differences were not found to be significant (t22.8= 2.0, 
0 
10 
20 
30 
40 
50 
60 
70 
Central Outer 
En
tr
ie
s 
0 
100 
200 
300 
400 
500 
600 
Central Outer 
D
u
ra
ti
o
n
 (
s)
 
 
A. B. 
92 
 
p=0.053, and t28= 1.4, p=0.16, respectively), although they do indicate an anxiolytic 
tendency in the C59X homozygous ENU-mutants. Inspection of outer zone behaviour 
revealed that despite the C59X homozygous ENU-mice making significantly more 
entries into the outer zone than their WT littermate controls (t28= 2.3, p=0.03), 
duration of time spent in the outer zone was equivalent between groups (t28= -1.7, 
p=0.11), suggesting that the C59X homozygous ENU-mutants display a more 
exploratory phenotype in the OF than their WT littermate controls. 
As seen on the EPM, there were no genotype differences in terms of the 
latency of first occurrence into the central zone of the OF (t28= -1.3, p=0.21), 
however, consistent with a reduced anxiety phenotype, C59X homozygous ENU-
mutant mice made more rears in both the central and outer zones than their WT 
littermate controls (t28= 3.2, p=0.003 and t28= 3.1, p=0.005, respectively), Table 4.4. 
 
Table 4.4: Ancillary parameters in the OF for the C59X line 
Behavioural Parameter WT  Homozygous 
Latency of first occurrence in the 
central zone (seconds) 
33.3 ± 15.2 12.7 ± 5.1 
Number of rears in the central 
zone 
24.3 ± 2.7 37.5 ± 3.1 
Number of rears in the outer zone 44.8 ± 4.1 64.1 ± 4.8 
Data shows mean ± SEM 
 
Confounding influences of activity on the pattern of data were unlikely as 
there were no genotype differences on locomotion (Table 4.5), this included the 
total distance moved, time spent moving and the average velocity in the OF as a 
whole (main effect of GENOTYPE, F1, 28= 0.01, p=0.93, and F1, 28= 0.3, p=0.6, F1,28= 0.2, 
p=0.64, respectively). Further analysis on locomotion in the more anxiety-provoking 
central zone also revealed no differences between the two genotypes in terms of 
total distance moved in the central zone and time spent moving in the central zone 
(t23.9= 2.0, p=0.06, and t28= 1.8, p=0.08, respectively). 
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Table 4.5: Locomotor parameters in the OF for the C59X line 
Behavioural Parameter WT  Homozygous 
Total distance moved (cm, all 
zones) 
3798.8 ± 260.5  3766.2 ± 260.5 
Total time spent moving (seconds, 
all zones) 
270.3 ± 5.5 274.5 ± 5.5 
Averaged velocity (cm/s) 16.1 ± 1.2 15.3 ± 1.2 
Total distance moved in the central 
zone (cm) 
1320.6 ± 12.1 1705.1 ± 9.7 
Total time spent moving in the 
central zone (seconds) 
70.8 ± 10.8 97 ± 9.3 
Data shows mean ± SEM 
 
4.3.1.3 Elevated zero-maze  
Analysis of the data showed that as expected, on average, all C59X subjects 
made significantly more entries into the protected closed zones than the exposed 
open zones (Fig. 4.3A, main effect of ZONE, F1,27= 25.4, p=0.00, ZONE*GENOTYPE, 
F1,27= 1.6, p=0.22), however, subjects spent an equivalent amount of time in both 
zones (Fig. 4.3B, main effect of ZONE, F1,27= 3.8, p=0.06). A significant interaction 
(ZONE*GENOTYPE, F1,27= 4.4, p=0.045), revealed that C59X homozygous ENU-mutant 
mice spent more time in the open zone (p=0.048) and less time in the closed zone 
(p=0.042) than their WT littermate controls, indicating a reduced level of anxiety in 
these mice. C59X homozygous ENU-mutant mice made significantly more entries 
into the open zones (t27= 3.2, p=0.003) and spent longer in the open zones than their 
WT littermate controls, both in duration and percentage of time (Fig. 4.3B and Fig. 
4.3C, t27= 2.1, p=0.048, t27= 2.1, p=0.044, respectively), consistent with a reduced 
level of anxiety, providing further support that the C59X homozygous ENU-mutants 
displayed an anxiolytic phenotype in these anxiety paradigms.  
Inspection of closed zone behaviour revealed that the C59X homozygous 
ENU-mutant mice made more entries into the protected closed zone than their WT 
littermate controls (t27= 3.5, p=0.002) but as expected from their open arm 
behaviour, the duration of time spent in the closed zone was significantly less for the 
C59X homozygous ENU-mutants than their WT littermate controls (t27= -2.1, p=0.04), 
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again pointing towards an anxiolytic phenotype in the C59X homozygous ENU-
mutants. 
Figure 4.3: Entries made and duration of time spent in the open and closed zones 
of the EZM for the C59X line 
 
 
 
 
All subjects from the C59X line made significantly more entries into the protected closed zones 
than the exposed open zones (A), however, subjects spent an equivalent amount of time in both 
zones (B). The C59X homozygous ENU-mutant mice made significantly more entries into the open 
zone and spent longer in the open zone than their WT littermate controls, both in terms of duration 
(B) and percentage of time spent in the open zones (C). The C59X homozygous ENU-mutant mice 
also spent significantly less time in the closed zones than their WT littermate controls, providing 
further support that the C59X homozygous ENU-mutants displayed an anxiolytic phenotype in 
these anxiety paradigms. Data shows the mean values ±SEM, **p<0.01 and *p<0.05 for pairwise 
differences related to genotype. For subject N see Table 5.1. 
 
As observed in the EPM and OF, there was no genotype difference in the 
latency to first enter the open zones in the EZM (t27= -0.8, p=0.41), there were 
however, a number of other ancillary behaviours consistent with reduced anxiety in 
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the C59X homozygous ENU-mutant mice, including increased rearing (t27= 4.0, 
p=0.001), SAPs (t27= 3.3, p=0.003) and head dips (t27= 3.4, p=0.002) on the open 
arms, Table 4.6. 
Table 4.6: Ancillary parameters on the EZM for the C59X line 
Behavioural Parameter WT  Homozygous 
Latency of first occurrence on the 
open arms (seconds) 
2.7 ± 0.8 1.9 ± 0.6 
Number of rears on the open arms 23.5 ± 2.4 35.1 ± 1.7 
Number of SAPs on the open arms 41.6 ± 5.3 63.1 ± 3.8 
Number of head dips on the open 
arms 
23.9 ± 3.2 38.7 ± 2.9 
Data shows mean ± SEM 
In terms of the locomotion of subjects from the C59X line during the EZM 
(Table 4.7), the total distance moved and time spent moving on the maze, were 
higher for C59X homozygous ENU-mutants than their WT littermate controls (main 
effect of GENOTYPE, F1,27= 13.7, p=0.001 and F1,27= 6.6, p=0.02, respectively), 
potentially reflecting hyperactivity in the C59X homozygous ENU-mutants on this 
assay, however, the averaged velocity (cm/sec) of locomotion was indifferent to 
genotype (F1,27= 3.6, p=0.07). A separate analysis of open zone  behaviour between 
genotypes revealed that the C59X homozygous ENU-mutant mice moved greater 
distances and spent longer moving in the open zone than their WT littermate 
controls (t27= 3.3, p=0.003 and t27= 2.2, p=0.04, respectively), behaviour which 
indicates more exploratory behaviour in the C59X homozygous ENU-mutants in the 
more exposed open zones. 
Table 4.7: Locomotor parameters on the EZM for the C59X line 
Behavioural Parameter WT  Homozygous 
Total distance moved (cm, all 
zones) 
851.5 ± 90 1282.7 ± 91.8 
Total time spent moving (seconds, 
all zones) 
74.7 ± 10.9 109.5 ± 10 
Averaged velocity (cm/s) 4.1 ± 0.3 4.9 ± 0.3 
Total distance moved in the open 
arms (cm) 
542.2 ± 0.3 842.1 ± 0.3 
Total time spent moving in the 
open arms (seconds) 
60 ± 9.2 88.5 ± 8.9 
Data shows mean ± SEM 
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4.3.2 Zfp804a C417Y line 
4.3.2.1 Elevated plus-maze 
Analysis of the data collected from EthoVision showed that, as expected, 
overall, all subjects made significantly more entries on to the protected closed arms 
than the exposed open arms (Fig. 4.4A, main effect of ZONE, F1,32= 76.2, p=0.00, 
ZONE*GENOTYPE, F1,32= 0.5, p=0.48) and spent significantly longer on the closed 
arms than the open arms (Fig. 4.4B, main effect of ZONE, F1,32= 90.6, p=0.00, 
ZONE*GENOTYPE, F1,32= 1.1, p=0.3). There were no significant differences between 
C417Y homozygous ENU-mutant mice and their WT littermate controls in the 
number of entries made on to the open arms (t32= 1.7, p=0.09) or total duration of 
time and percentage of time (Fig. 4.4C) spent on the open arms (t32= 1.7, p=0.09, t32= 
1.7, p=0.09, respectively) indicating an equivalent level of anxiety between the two 
genotype groups. Looking at closed arm behaviour also revealed no genotype 
differences for entries on to the closed arms (t32= 0.9, p=0.38) nor for the duration of 
time spent on the closed arms (t32= -0.4, p=0.7). 
When assessing the latency to first enter the open arms, there were again no 
genotype differences observed (t27= -0.8, p=0.44), nor were there any differences 
between genotypes in other ancillary measures of anxiety such as the number of 
rears, stretch attend postures and head dips in the open arms (t32= 1.9, p=0.07, t28.8= 
1.2, p=0.26, and t27.2= 1.9, p=0.06, respectively), Table 4.8. 
 
Table 4.8: Ancillary parameters on the EPM for the C417Y line 
Behavioural Parameter WT  Homozygous 
Latency of first occurrence on the 
open arms (seconds) 
30.2± 12.4 20.6 ± 4.9 
Number of rears on the open arms 3.9 ± 1 7.4 ± 1.5 
Number of SAPs on the open arms 17.5 ± 2 22.3 ± 3.3 
Number of head dips on the open 
arms 
8 ± 1.2 19 ± 3.2 
Data shows mean ± SEM 
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Figure 4.4: Entries made and duration of time spent on the open and closed arms 
of the EPM for the C417Y line 
 
  
  
 
All subjects from the C417Y line made more entries on to the closed arms than the open arms and 
spent significantly longer on the closed arms than the open arms. C417Y homozygous ENU-mutants 
and their WT littermate controls made an equivalent number of entries made on to the open arms 
(A) and spent an equivalent amount of time on the open arms, both in terms of duration (B) and 
percentage of time (C). Data shows the mean values ±SEM. For subject N see Table 5.1. 
 
In terms of the locomotion of the C417Y subjects on the EPM (Table 4.9), the 
total distance moved and time spent moving on the maze (as a whole) during the 
session was equivalent between C417Y homozygous ENU-mutants and WT littermate 
controls (main effect of GENOTYPE, F1,32= 2.0, p=0.17, and F1,32= 1.7, p=0.2, 
respectively), similarly, the averaged velocity (cm/sec) of locomotion was indifferent 
to genotype (main effect of GENOTYPE, F1,32= 1.1, p=0.31). A separate analysis of 
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open arm behaviour also revealed no differences between the C417Y homozygous 
ENU-mutants and their WT littermate controls in terms of total distance moved on 
the open arms and time spent moving on the open arms (t29.7= 1.6, p=0.13, and 
t28.03= 1.9, p=0.7, respectively), suggesting that locomotor activity was equivalent 
between genotypes on all regions of the maze, and unlikely to be a confounding 
influence on the pattern of data observed. 
 
Table 4.9: Locomotor parameters on the EPM for the C417Y line 
Behavioural Parameter WT  Homozygous 
Total distance moved (cm, all 
arms) 
352.9 ± 30.9 410.7 ± 27.4 
Total time spent moving (seconds, 
all arms) 
56.6 ± 4.5 64.6 ± 4 
Averaged velocity (cm/s) 3.7 ± 0.3 4.0 ± 0.2 
Total distance moved on the open 
arms (cm) 
128.2 ± 18.2 180.5 ± 27.9 
Total time spent moving on the 
open arms (seconds) 
22.5 ± 2.7 32.7 ± 4.7 
Data shows mean ± SEM 
 
4.3.2.2 Open field 
All subjects demonstrated the expected thigmotaxic behaviour by making 
more entries into the outer zone (Fig. 4.5A, main effect of ZONE, F1,32= 38.0, p=0.00, 
ZONE*GENOTYPE, F1,32= 0.01, p=0.91) and spending longer in the outer zone (Fig. 
4.5B, main effect of ZONE, F1,32= 772.2, p=0.00, ZONE*GENOTYPE, F1,32= 0.01, 
p=0.91) as opposed to the more anxiety-provoking central zone of the OF. All 
subjects made an equivalent number of entries into the central zone (t32= 1.4, 
p=0.16) but, perhaps reflecting a reduction in anxiety, C417Y homozygous ENU-
mutant mice spent significantly longer in the central zone than their WT littermate 
controls (t30.7= 2.3, p=0.03). There were no genotype differences in the number of 
entries into the outer zone and total time spent in the outer zone of the OF (t32= 1.3, 
p=0.21, and t32= 0.4, p=0.69, respectively). 
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Figure 4.5: Entries made and duration of time spent in the central and outer zones 
on the OF for the C417Y line 
  
 
 
All C417Y subjects demonstrated thigmotaxic behaviour by making more entries into the ‘safer’ 
outer zone (A) and spending longer in the outer zone as opposed to the more anxiety provoking 
central zone (B). All C417Y subjects made an equivalent number of entries into the central zone but 
the C417Y homozygous ENU-mutant mice spent significantly longer in the central zone than their WT 
littermate controls, perhaps reflecting a reduction in anxiety in the C59X homozygous ENU-mutants. 
Data shows the mean values ±SEM, p<0.05 for pairwise differences related to genotype For subject 
N see Table 5.1. 
 
The time taken to first enter the central zone was not significantly different 
between C417Y homozygous ENU-mutant mice and their WT littermate controls (t32= 
0.4, p=0.72), furthermore, there were no genotype differences in the number of 
rears in either the central or outer zones (t32= 0.9, p=0.37, and t32= 0.3, p=0.74, 
respectively), Table 4.10, again indicating equivalent levels of anxiety between C417Y 
homozygous ENU-mutants and their WT counterparts. 
Confounding influences of activity on the pattern of data were unlikely as 
there were no genotype differences in terms of the total distance moved or time 
spent moving in the OF as a whole, during the session (main effect of GENOTYPE, 
F1,32= 0.7, p=0.42, and F1,32= 0.7, p=0.4, respectively) similarly, the averaged velocity 
(cm/sec) of locomotion was indifferent to genotype (main effect of GENOTYPE, F1,32= 
0.3, p=0.59, Table 4.11). Further analysis on locomotion in the more anxiety-
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provoking central zone revealed no differences between the two genotypes in terms 
of total distance moved in the central zone (t23.9= 1.5, p=0.16) but C417Y 
homozygous ENU-mutants spent significantly longer moving in the central zone than 
their WT littermate controls (t28= 1.8, (t31.2= 2.2, p=0.04). 
 
Table 4.10: Ancillary parameters in the OF for the C417Y line 
Behavioural Parameter WT  Homozygous 
Latency of first occurrence on in 
the central zone (seconds) 
15.6 ± 4.7 21.8 ± 14.9 
Number of rears in the central 
zone 
17.9 ± 2.4 22.3 ± 3.9 
Number of rears in the outer zone 30 ± 4.9 32.4 ± 5.1 
Data shows mean ± SEM 
 
Table 4.11: Locomotor parameters in the OF for the C417Y line. 
Behavioural Parameter WT  Homozygous 
Total distance moved (cm, all 
zones) 
3029.6 ± 427.4 3499 ± 379.8 
Total time spent moving (seconds, 
all zones) 
252.2 ± 15 269.4 ± 13.3 
Averaged velocity (cm/s) 13.3 ± 1.9 14.7 ± 1.7 
Total distance moved in the central 
zone (cm) 
1017 ± 88.8 1330.3 ± 177.3 
Total time spent moving in the 
central zone (seconds) 
57.3 ± 4.3 73.3 ± 5.8 
Data shows mean ± SEM 
 
4.3.2.3 Elevated zero-maze 
 Analysis of the data showed that, unexpectedly, all C417Y subjects, in 
general, made significantly more entries into the exposed open zones than the 
protected closed zones (Fig. 4.6A, main effect of ZONE, F1,27= 11.4, p=0.002, 
ZONE*GENOTYPE, F1,27= 0.6, p=0.46), however, following a more typical pattern, all 
C417Y subjects spent significantly more time in the closed zones than in the more 
anxiety-provoking open zones (Fig. 4.6B main effect of ZONE, F1,27= 197.2, p=0.000, 
ZONE*GENOTYPE, F1,27= 2.4, p=0.13).  
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Figure 4.6: Entries made and duration of time spent in the open and closed zones 
of the EZM for the C417Y line 
 
 
 
 
All C417Y subjects unexpectedly made significantly more entries into the exposed open zones than 
the protected closed zones (A), however, as expected all C417Y subjects spent significantly more 
time in the closed zones than the open zones, both in terms of duration (B) and percentage of time 
(C) spent in the open zones. There were no genotype differences in the number of entries or time 
spent in the open zone. Data shows the mean values ±SEM. For subject N see Table 5.1. 
 
This could reflect a more exploratory phenotype by C417Y mice in general on the 
EZM as opposed to the EPM and OF; perhaps due to the loss of the ambiguous 
middle platform seen in the EPM. There were no genotype differences in the number 
of entries made into the open zones (t27= -0.9, p=0.437), or the duration and 
percentage of time (Fig. 4.6C) spent in the open zones (t27= -1.6, p=0.12, t27= -1.6, 
p=0.12, respectively), or entries and time spent in the closed zone (t27= -1.6, p=0.12, 
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t27= 1.5, p=0.15) suggesting equivalent levels of anxiety between C417Y mutant and 
WT mice. 
The time taken to first enter the open zone was not significantly different 
between the C417Y homozygous ENU-mutants and their WT littermate controls (t27= 
1.3, p=0.22), furthermore, there were no genotype differences in the number of 
rears, SAPs or head dips in the open zone (Table 4.12, t27= -1.6, p=0.12, t27= -1.3, 
p=0.21, and t27= -1.5, p=0.15, respectively), again indicating equivalent levels of 
anxiety between C417Y homozygous ENU-mutants and their WT counterparts. 
 
Table 4.12: Ancillary parameters on the EZM for the C417Y line 
Behavioural Parameter WT  Homozygous 
Latency of first occurrence on the 
open arms (seconds) 
3.8 ± 1 8.7 ± 3.6 
Number of rears on the open arms 20.8 ± 2.3 16.1 ± 1.8 
Number of SAPs on the open arms 28.3 ± 4.1 21.5 ± 3.3 
Number of head dips on the open 
arms 
15.6 ± 2 11.7 ± 1.8 
Data shows mean ± SEM 
 
 In terms of locomotion during the session, the total distance moved and time 
spent moving on the maze as a whole was equivalent between the C417Y 
homozygous ENU-mutants and WT littermate controls (Table 4.13, main effect of 
GENOTYPE, F1,27= 2.7, p=0.11, and F1,27= 2.5, p=0.13, respectively), similarly, the 
averaged velocity (cm/sec) of locomotion was indifferent to genotype (main effect of 
GENOTYPE, F1,27= 0.6, p=0.45). A separate analysis of open zone behaviour also 
revealed no differences between the C417Y homozygous ENU-mutants and their WT 
littermate controls in terms of total distance moved in the open zones and time 
spent moving in the open zones (t27=-1.6, p=0.13, and t27= -1.5, p=0.15, respectively), 
suggesting that locomotor activity was equivalent between genotypes on all regions 
of the maze, and unlikely to be a confounding influence on the pattern of data 
observed. 
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Table 4.13: Locomotor parameters on the EZM for the C417Y line 
Behavioural Parameter WT  Homozygous 
Total distance moved (cm, all 
zones) 
735.5 ± 79 578.3 ± 57.6 
Total time spent moving (seconds, 
all zones) 
51.4 ± 6.6 38.5 ± 5.3 
Averaged velocity (cm/s) 4.8 ± 0.3 4.5 ± 0.3 
Total distance moved in the open 
arms (cm) 
439.3 ± 45.3 340.8 ± 43.8 
Total time spent moving in the 
open arms (seconds) 
37.1 ± 4.8 27 ± 4.7 
Data shows mean ± SEM 
 
4.3.3 Comparison of EPM, OF and EZM performance for both Zfp804a mutant lines 
 Correlational analyses were carried out using subjects from both lines to 
determine if performances on the three anxiety measures were related. The 
parameters examined were entries onto the more anxiety-provoking open arms and 
time spent on the open arms in the EPM and EZM, as well as entries made into the 
more anxiety-provoking central zone and time spent in the central zone in the OF. 
 The results showed moderately strong positive correlations between entries 
made onto the EPM open arms and entries made into the central zone of the OF 
(r=0.34, p (two-tailed) =0.007, Appendix 3.1A), and entries made onto the open arms 
of the EZM (r=0.42, p (two-tailed) =0.001, Appendix 3.1B). Entries made onto the 
open arms of the EZM and entries made into the central zone of the OF were not 
significantly correlated (r=0.16, p (two-tailed) =0.22, Appendix 3.1C). The same 
pattern of results was seen with the duration of time spent in the exposed zones, 
with moderately strong positive correlations between the duration of time spent on 
the open arms in the EPM and the duration of time spent in the central zone of the 
OF (r=0.32, p (two-tailed) =0.01, Appendix 3.1D), and duration of time spent on the 
open arms of the EZM (r=0.38, p (two-tailed) =0.003, Appendix 3.1E). The duration of 
time spent on the open arms of the EZM and the duration of time spent in the 
central zone of the OF were not significantly correlated (r=0.23, p (two-tailed) = 0.08, 
Appendix 3.1F). These results suggest that performance on the EPM is significantly 
associated with performance on the OF and EZM, but that behaviour on the OF and 
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EZM were not related. This adds further weight to the idea that the paradigms may 
be measuring different aspects of emotionality, further highlighting the need for 
multiple assays to examine anxiety in rodents. 
 
4.4 Discussion 
WT littermate control mice of both the C59X and C417Y lines demonstrated 
the expected basic patterns of results for each of the assays used, generally showing 
avoidance behaviour of the most anxiety-inducing regions of each apparatus. C59X 
homozygous ENU-mutant mice demonstrated consistent findings across all the tests 
suggestive of reduced levels of anxiety. C417Y homozygous ENU-mutant mice, on the 
other hand, demonstrated equivalent levels of anxiety to their WT littermate 
controls. This pattern of results is consistent with a previous study using Zfp804a 
C59X mice on a <98% C57BL/6J background (Al-Janabi, 2012); G4i C59X homozygous 
ENU-mutant mice exhibited similar patterns to the current study of reduced anxiety 
on the EPM. This replication of findings on the EPM would therefore indicate that 
the reduced anxiety displayed is a result of the mutation of Zfp804a at the C59X 
locus, and not a consequence of mutations in other genes induced by ENU-
mutagenesis. Thus, in the current study C59X homozygous ENU-mutant mice spent 
less time in the periphery of the OF and made more entries into and spent more 
time on the open arms of the EPM and EZM; further corroborated by increased 
amounts of ethological behaviours such as SAP’s, rearing and head dips. In contrast, 
although C417Y homozygous ENU-mutant mice were found to have spent 
significantly longer in the central zone of the OF than their WT littermate controls, 
indicative of a reduced level of anxiety, this, appears to be an isolated result as none 
of the other ancillary measures, such as SAPs and rearing, support this suggestion 
and these mice did not differ from their WT littermates on the EPM or EZM. 
Therefore, it can be concluded that mutation of the Zfp804a gene in exon 2 (C59X 
mutation) leads to altered anxiety whereas the exon 4 mutation (C417Y) does not 
affect this function. The lack of effect in C417Y homozygous ENU-mutant mice, 
however, is consistent with other mouse models for schizophrenia, where equivalent 
behaviour between WT and mutant mice on the same assays used here has been 
found (Karl et al., 2007; O’Tuathaigh et al., 2008; Clapcote et al., 2007). Further 
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discussion about the mechanism of action will be addressed in the General 
Discussion chapter (Chapter VIII); however, the fact that there is dissociation 
between the two mutant lines is further evidence for causal effects of the targeted 
C59X mutation rather than co-segregating genes inherited alongside both mutations 
(Chapter III, Section 3.1).  
As mentioned, the WT littermate controls from both lines showed the 
expected patterns of behaviour, and were relatively consistent in each of the 
different tasks, suggesting that order effects or repeated testing did not affect 
performance and would not account for the differences between C59X homozygous 
ENU-mutant mice and their WT littermate controls. Prior exposure to any anxiety-
provoking task can make subsequent anxiety tasks less fear inducing and produce a 
more anxiolytic phenotype (Holmes, 2001); however this did not seem to be the case 
here. Similarly, it is well known that levels of motor activity can influence anxiety-
related behaviours (Lister, 1990). As demonstrated in Chapter III (Section 3.3.3.2) 
there were no significant differences between C59X homozygous ENU-mutant mice 
and their WT littermates in a specific test of locomotion, with the trend actually 
pointing towards hypoactivity. In the anxiety tests used here, of much shorter 
duration (5-10 minutes), C59X homozygous ENU-mutant mice also showed 
equivalent levels of motor activity to their WT counterparts, including, measures of 
the total distance moved, time spent moving and mean velocity of movement on the 
EPM and OF tests, although on the EZM the C59X homozygous ENU-mutants moved 
greater distances and spent longer moving than their WT littermates. However, the 
locomotor results from the EZM were mainly driven by behaviour in the open zones 
(Table 4.7) illustrating that the C59X homozygous ENU-mutants were not hyperactive 
across all the maze per se, but spent longer moving and moved greater distances in 
the open zones, indicating an exploratory (not hyperactive) phenotype in the EZM 
for these mice. Therefore, it would appear that differences in locomotion were not 
influencing anxiety in these tests and that the differences in behaviour shown by 
C59X homozygous ENU-mutant mice were due to alterations in innate anxiety 
responsiveness. 
Anxiety is a multi-faceted construct; therefore the different tests used here 
may tax different, or partially overlapping, components of emotionality (Ramos, 
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2008; Sousa et al, 2006). For example, the OF and EPM did not produce a common 
anxiety-related factor in a principal component analysis (Trullus & Skolnick, 1993; 
Ramos et al., 1998), however, this premise was not supported by the current data 
where entries and durations in the EPM were significantly correlated with entries 
and durations in the OF. Furthermore, entries and durations in EZM correlated with 
EPM behaviour but not the OF, suggesting (a priori) that the EPM was measuring the 
same component of anxiety as the OF and EZM, but that the OF and EZM were 
measuring separate forms of anxiety and that the consistent differences shown by 
C59X homozygous ENU-mutant mice reflect altered anxiolytic effects by these mice 
across a range of anxiety sub-types. 
Decreased anxiety, or anxiolysis, can occur in animal models using a variety of 
different paradigms, e.g. treatment with benzodiazepines (Treit et al., 2010), 
amygdaloidal lesions, local infusions into the amygdala (Davis, 1992) or other parts 
of the brain, such as the hippocampus (Bannerman et al., 2003). In terms of genetic 
approaches there has been a focus on serotonin receptor overexpression and 
knockout models (Jennings, Loder, Sheward et al., 2006; Holmes, Yang, Lesch et al., 
2003) perhaps due to the link between serotonin and anxiety, and it’s role in the 
treatment of certain anxiety disorders (Baldwin & Rudge, 1995; Ballenger, 1999). 
Anxiolytic behaviour has also been observed in knockout mouse models of dopamine 
receptor 3 (Steiner, Fuchs & Accili, 1997), Corticotropin releasing factor receptor 1 
(Smith, Aubry, Dellu et al., 1998; Contarino, Dellu, Koob et al., 1999), Protein kinase 
Cε (Hodge, Raber, McMahon et al., 2002) and Neurabin (Kim, Wang, Li et al., 2011). 
Thus, there are a variety of neurobiological mechanisms through which the Zfp804a 
C59X mutation could be mediating effects on anxiety-related behaviours.   
Although not widely reported, many patients with schizophrenia also report 
altered levels of anxiety (Braga et al., 2004; Pokos & Castle, 2006) including 
symptoms of OCD, PTSD, phobias and panic attacks (Pilkonis et al., 1980; Fenton & 
McGlashan, 1986; Argyle, 1990; Penn et al., 1994; Eisen et al., 1997; Meyer et al., 
1999; Braga et al., 2005). Furthermore, one study (Steinberg et al., 2011) has found a 
copy number variant, in the form of a deletion of ZNF804A, in both a schizophrenia 
patient and an anxiety disorder patient and the link between ZNF804A variants and 
bipolar disorder (Owen et al., 2007; O’ Donovan et al., 2008; Steinberg et al. 2011) 
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suggests that emotional functionality could be affected in these individuals, if 
investigated.  Bipolar disorder is characterised by deficits in emotional regulation 
(Townsend & Altshuler, 2012); consequently, we might expect to see phenotypes 
relating more to the symptomology of bipolar disorder in the Zfp804a mutant mouse 
lines. 
The effects observed are consistent and relevant to both schizophrenia and 
bipolar disorder, but it is difficult to directly predict the effects found in the Zfp804a 
mutants to clinical studies. However, this should not obscure the key finding that 
disruption of normal Zfp804a functionality leads to consistently altered anxiety in 
C59X mutant mice. 
 
 
4.4.1. Summary of key results from Chapter IV 
 WT littermate controls of both mutant lines showed the expected basic 
pattern of behaviour in response to anxiety-provoking stimuli. 
 C59X homozygous ENU-mutant mice demonstrated a consistent anxiolytic 
phenotype, in comparison to their WT littermates, in three different anxiety 
assays. 
 Overall, C417Y homozygous ENU-mutant mice showed equivalent anxiety-
related behaviour in comparison to their littermate WT controls. 
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Chapter V: Assessment of motivational and hedonic function in the 
Zfp804a mutant lines; progressive ratio and lick cluster analysis 
 
5.1 Introduction 
Schizophrenia and other major mental illnesses, such as bipolar disorder, have a very 
complex variety of symptoms, including a range of emotional and motivational 
deficits, sometimes termed ‘negative symptoms’ (Bleuler, 1911), manifesting as 
avolition, withdrawal and a reduced ability to experience pleasure (anhedonia). 
These emotional and motivational deficits have been linked to the cognitive 
impairments seen in schizophrenia, with the suggestion that perhaps a general lack 
of motivation in these patients contributes to the cognitive dysfunction observed in 
psychometric tests (Barch, 2005). Avolition has long being described as a core 
symptom of schizophrenia (Kraepelin, 1919), however, there have been relatively 
few studies examining motivation in mental disorders, with one possible reason 
being that motivation is seen as difficult to quantify and is a complex notion to study 
empirically (Barch, 2008). Notwithstanding these difficulties, recent research has 
found that avolition, and other negative symptoms in schizophrenia patients, are 
strong predictors of functional outcome and quality of life (Rabinowitz et al., 2012), 
and that self-generated motivation can promote cognitive improvement, and 
therefore contribute to the positive relationship between cognition and psychosocial 
functioning in schizophrenia (Nakagami, Xie, Hoe & Brekke, 2008). 
 Deficits in motivation in schizophrenia have been linked to the dopamine 
system (Berridge, 2004), with the idea that dopamine is involved with ‘wanting’ 
(working towards achieving a desirable goal; thought to be part of motivational 
processes) but not necessarily ‘liking’ (the pleasurable consummatory response). 
Hence, abnormalities in dopamine function may lead to changes in incentive 
motivation towards achieving a goal, but when the goal is achieved, the hedonic 
response remains unaltered (Barch, 2005). A progressive ratio task (PRT) can be used 
to measure the motivation of rodents to continue to work for a reward, when the 
effort required to earn the reward is progressively increased (Hodos, 1961). This task 
was originally developed for use with rats, utilising lever presses as the ‘work’ 
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element of the task. Since then, the PRT has been adapted for use with mice 
incorporating an increasing schedule of nose-pokes. Eventually the mouse will reach 
a ratio at which it will no longer nose-poke, and it is this ‘breakpoint’ that is held to 
index the subject’s incentive motivational drive to obtain the reinforcer. In the 
current work we used a mouse version of the PRT to assess motivation in the 
Zfp804a ENU-mutant lines. To our knowledge, there have been no previous mouse 
models based on manipulations of confirmed psychiatric risk genes that have utilised 
the PRT. However, one study looking at dopamine receptor subtypes found that 
mutants that over-expressed subcortical D2 receptors exhibited lower incentive 
motivation on a progressive ratio schedule (Drew, Simpson, Kellendonk et al., 2007).  
 The second task described in this chapter was a lick cluster analysis designed 
to assess the hedonic reactions of mice to various solutions. Anhedonia, defined as a 
diminished ability to experience pleasure, is also a common symptom of 
schizophrenia (Kraepelin, 1919), with research showing that patients with 
schizophrenia report experiencing lower levels of pleasure in general than controls in 
both interviews and self-report questionnaires (reviewed in Horan, Kring & 
Blanchard, 2006b). However, other research has also shown that patients report 
similar experiences of positive and negative emotions, in comparison to controls, in 
response to evocative emotional stimuli (Berenbaum & Oltmanns, 1992; Kring & 
Neale, 1996). This discrepancy in the research findings has led to the idea that, 
arguably,  schizophrenia patients experience normal levels of pleasure when actually 
engaged in an enjoyable activity (consummatory pleasure) but experience anhedonia 
in anticipation of future pleasurable activities (anticipatory pleasure), an idea which 
has received some support (Gard, Kring, Gard-Germans, Horan & Green, 2007). Gard 
et al. (2007) examined daily reports of consummatory and anticipatory pleasure, 
finding that patients anticipated less joy from goal-directed activities than controls, 
but reported similar consummatory pleasure as controls. However, yet another 
study has found the opposite pattern, with the main differences between patients 
and controls being seen in reported consummatory pleasure (Strauss, Wilbur, 
Warren, et al., 2011). Clearly, the exact nature of the hedonic deficits in 
schizophrenia remains to be established, especially as much of the data is obtained 
from self-report questionnaires which are notoriously noisy and subject to bias. 
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 Lick cluster analyses have been used previously in a number of settings to 
index ‘pleasure’ in rodent models. It is important to appreciate that other assays, 
which merely measure consumption, are limited in their ability to reflect hedonic 
function. Typically in consumption-based tests, total consumption of a solution is 
taken as a measure of palatability; however, the inverted-U shaped function for 
consumption of palatable solutions confounds this approach (since the same 
amounts of solution can be consumed at low and high concentrations of, say, 
sucrose). Consequently, this approach has been criticised as providing an insufficient 
method for analysing the hedonic reactions of animals (Dwyer, 2012).  
An alternative approach to monitor hedonic components of behaviour is to 
exploit automated technical approaches that allow fine-grained analysis of licking 
behaviour. This approach, first established in rat models, has demonstrated that 
rodents produce rhythmic sets of licks that can be grouped into lick clusters based on 
the interval between licks; critically, the microstructure of the licking behaviour, in 
particular the size of the lick cluster (licks per cluster) provides an indication of the 
perceived palatability and concentration of the solution (Davis, 1973; Davis & Levine, 
1977; Davis & Smith, 1992). Thus, lower lick cluster sizes have been found for 
unpalatable solutions such as quinine, and higher lick cluster sizes have been found 
for palatable solutions such as sucrose (Hsiao & Fan, 1993), suggesting that lick 
cluster size provides a valid index related to hedonic components of behaviour. 
Importantly, measurements of lick cluster size and the total amount of solution 
consumed are dissociable, with maximal levels of consumption at moderate 
concentrations of palatable solutions, but maximum lick cluster sizes at high 
concentrations, illustrating that despite consuming less of the higher concentrations 
of sucrose, they actually like it more; this cannot be discerned from the consumption 
data alone (Dwyer, 2012). 
 There are several examples in the literature where lick cluster analysis has 
been used to examine behavioural changes in relation to factors that may be of 
relevance to vulnerability for brain disorders. One attempt was to use 16 days of 
psychosocial cage-change stressor treatment in rats to model the predisposing 
effects of chronic stress. Every day, rats from the stress treatment group were either 
placed in a new cage alone, a cage with one other rat or a cage of two other rats, 
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with bedding soiled by another groups of rats. The stressor treatment group gained 
weight but also demonstrated anhedonia as evidenced by reduced lick cluster size in 
response to a 5% sucrose solution (Dwyer, 2012). In contrast, systemic dosing with 
the NMDA antagonist phencyclidine (PCP), either acutely or sub-chronically in rats, 
had no reliable effects on hedonic reactivity to sucrose (Lydall, Gilmour & Dwyer, 
2010). These unexpected findings could be due to PCP treatment modelling more of 
the positive symptoms of schizophrenia than the negative (Dwyer, 2012).  
 
5.2 Materials and Methods 
5.2.1 Subjects and animal husbandry 
In total, 55 adult male mice were used in this series of experiments (age 
range 7 to 12 months at beginning of testing, see Table 5.1). The progressive ratio 
task (PRT) was run first followed by lick cluster analysis (LCA) two months later. 
 
Table 5.1: Sample size and genotype of each cohort-subset of mice assayed on 
paradigms of hedonic and motivational function 
Behavioural  
Task 
C59X line C417Y line 
 WT Homozygous WT Homozygous 
Progressive Ratio 
Task (PRT) 
13/13 14/14 13/13 14/15 
Lick cluster 
Analysis (LCA) 
13/13 14/14 13/13 15/15 
 
Mice were housed in littermate groups of two to five animals per cage, under 
standard temperature- and humidity controlled conditions, with a 12-hour light: 12-
hour dark cycle (lights on at 07:30). All subjects had ad libitum access to standard 
laboratory chow and water until behavioural procedures commenced. For the PRT 
mice were on a partial water restriction schedule, allowing ad libitum access to 
laboratory chow and 2 hours access to water per day following testing. For the LCA 
experiment, subjects were on a standardised feeding schedule of 8 hours access/day, 
with water freely available, which ensured that the subjects had not eaten for 16 
hours prior to testing. For both schedules, food or water was presented following 
testing. Mice were weighed on a regular basis and any subjects losing greater than 
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10% of their body weight were removed from the experiment. For details of the 
restrictions schedules used see below. All experimental procedures were conducted 
under licenses issued by the Home Office (U.K.) in compliance with the Animals 
(Scientific Procedures) Act 1986. 
 
5.2.2 General Behavioural methods 
All testing took place between the hours of 09:00 and 18:00, with equal 
distribution of testing for subject of different genotypes throughout the day. Prior to 
testing, mice were habituated to the test rooms for at least 10 minutes. 
 
5.2.3 Progressive ratio task 
Mouse nine-hole operant chambers were used for this experiment (Humby et 
al., 1999), with eight of the nine nose-poke holes in the response array covered, 
leaving just the central aperture open. A more detailed description of the apparatus 
can be found in Chapter II, Section 2.4.9. The main measures of interest were the 
number of rewards collected, the breakpoint of nose poking (the maximum number 
of nose-pokes a mouse would perform for a single food delivery), the overall session 
duration, the average latency to make the first nose-poke for each reward, the 
latency to collect a reward and the intra nose-poke duration. 
 
5.2.3.1 Restriction procedure 
Before any behavioural procedures, subjects had to complete a water 
restriction schedule to motivate behaviour in the PRT (See Chapter II, Section 2.3.4). 
This schedule lasted 6 days, encompassing 4 days of 4hr access/day and 2 days of 2 
hr access/day. Mice were weighed daily during this schedule, as were their drinking 
bottles to ensure they were drinking during the water access. After these 6 days, 
mice were maintained on a 2hr access/day schedule. 
 
5.2.3.2 Habituation to the reinforcer 
Habituation to the condensed milk reinforcer used in the PRT took place as 
previously described in Chapter II, Section 2.3.5. Subjects not reaching a 70% 
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preference for the condensed milk (CM) reward over water (on the last day of 
testing) were not used in the PRT.  
 
5.2.3.3 Initial behavioural shaping 
Mice were given one training session per day at approximately the same time 
of day, and mice were always tested individually in the same operant boxes each 
day.  Following habituation to the test chambers and shaping to learn that reward 
was available in the apparatus, the mice were trained over 5 sessions whereby they 
had to make a single nose-poke to initiate delivery of the CM reward (22μl, 10% 
concentration). These continuous reinforcement schedule (CRF) sessions terminated 
after collection of 100 rewards or if 30 minutes had elapsed. In the analysis of these 
CRF sessions, the last 3 days at CRF were averaged together. 
 
5.2.3.4 Progressive ratio schedule  
After the 5 sessions at CRF, subjects were moved to a progressive ratio (PR) 
schedule of reinforcement. Under this schedule, the nose-poke requirement for food 
delivery was increased with the following progression: 1, 2, 4, 6 (then further 
incrementing by 2 nose-pokes/ratio) with two trials at each ratio. The progression 
continued until the subject failed to complete the ratio requirements, determined by 
the failure to make a further nose-poke within 4 minutes of the previous response 
(timed out). Sessions could also be terminated if 100 rewards had been delivered or 
if 30 minutes had elapsed, as per the CRF sessions. This PR schedule was 
administered for 3 consecutive days, with performance averaged across the 3 
sessions (See Appendix 4.1-4.3). After these 3 PR sessions, subjects were returned to 
the CRF schedule for 2 days (CRF2); performance here was averaged over the 2 days. 
 
5.2.3.5 Task manipulations 
To assess the impact of different levels of reward on the motivation to 
perform the PRT, a series of probe tests were performed, counter-balanced with 
standard PR sessions.  Thus, the concentration of the 22l condensed milk reward 
was decreased from 10% to 0%. Table 5.2 illustrates the different reward 
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manipulations used.  Mice were tested on alternate days with a single session per 
day. 
 
Table 5.2: The amount and concentration of the reward manipulation. 
Session Reward type Amount 
Concentration of 
condensed milk 
Standard Condensed Milk 22μl 10% 
Decreased 
concentration 
Water 22μl 0% 
 
5.2.4 Lick cluster analysis  
For the LCA experiment, subjects were on a standardised feeding schedule of 
8 hours access/day, with water freely available, which ensured that the subjects had 
not eaten for 16 hours prior to testing. For all testing subjects were placed in a cage 
similar to their home cage, modified to incorporate the lick cluster analysis 
equipment (as previously described in Chapter II, Section 2.4.7) with the 
experimental rooms illuminated. Subjects were placed individually into the test 
cages and given 10 minutes to drink the available solutions from bottles (maximum 
volume: 50 ml). Each chamber was equipped with a single test bottle, which was 
attached to a lickometer. The lickometer accurately detected any contact made with 
the spout of the bottle, and allowed the measurement of parameters such as the 
total number of licks, lick clusters (>single lick/cluster), single lick clusters, average 
inter-lick interval and volume consumed/1000 licks. In the current experiment, a lick 
cluster was defined as a series of licks where the intra-lick interval did not exceed 
500ms, therefore any lick occurring >=500ms after the previous would be recorded 
in a new lick cluster.  Other parameters such as total consumption of sucrose and lick 
cluster size were also derived from these initial measures. Sucrose consumption was 
normalised to body weight using the following equation:  VolNor=Vol/weight0.75 
(Schmidt-Nielsen, 1990). 
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5.2.4.1 Training to baseline performance 
Mice were given 6 sessions, with a single session each day, to habituate to 
the test environment and learn to drink from the lickometer apparatus. In each of 
these sessions, 8% sucrose solution was present in the drinking bottles, and the mice 
could consume as much of the solution as they would like (ca.1-2ml). As was 
expected, the size of the lick clusters was low (typically 0-15) and the inter-lick 
interval quite high (ca.150ms), but on consuming a similar amount of the solution for 
3 days running and achieving less than 40 single lick clusters, subjects were moved 
on to the next stage of testing. Performances across the final 3 sessions of training 
were averaged together for analysis. Data from sessions where delivery of the 
sucrose had been impaired by blockage of the spout or leaking from the bottle was 
removed from the analysis. 
 
5.2.4.2 Test phases 
To test the sensitivity of the pattern of drinking to the palatability of the 
reward solution, animals were tested with 2 further sucrose solutions at 4% and 16% 
(baseline training was at 8% sucrose concentration). As during baseline sessions, 
subjects were placed in the testing cages and given 10 minutes to lick the sucrose 
solution from the testing bottles. Consumption of each solution was assessed over 4 
consecutive days, with a single 10 minute session each day, and performance was 
averaged across these sessions. Days where bottles had leaked or where bottles 
were blocked were taken out of the analysis. The order of presentation of the 2 
sucrose solutions was counter-balanced, hence, some subjects received the lower 
concentration first, and the higher concentration second, and others in the reverse 
order. As before, days where bottles had leaked or where the drinking spouts had 
blocked were removed from the analysis. 
 
5.2.5 Statistical analysis 
The experimental data was analysed using SPSS 18.0. Behavioural data are 
presented as mean values (M) along with the standard error of the mean (SEM), 
unless stated otherwise. All data were analysed by either ANOVA or t tests. All 
significance tests were performed at alpha level of 0.05 and where significant 
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interactions were identified in the main ANOVA, post-hoc tests using appropriate 
pair-wise comparisons were performed. Greenhouse-Geisser degrees of freedom 
(df) corrections were applied as required to repeated-measures factors. Data were 
screened for skewed variance with arcsine transformations applied to skewed data 
(percentage data in particular) to obtain a normal distribution. Each parameter (see 
above for the PRT and LCA) was analysed separately for each strain, with between 
subjects factor of GENOTYPE (homozygous ENU-mutant vs. WT littermate control) 
and within subject factors as appropriate (i.e. SESSION, REWARD TYPE and REWARD 
CONCENTRATION). 
 
5.3 Results 
5.3.1 Zfp804a C59X Line 
5.3.1.1 Progressive Ratio Task 
 Mice were initially trained to respond on a continuous reinforcement (CRF) 
schedule that allowed the animals to collect a maximum of 100, 20l rewards within 
each 30min test session. Mice of both genotypes readily achieved high levels of 
performance, collecting >75 rewards (out of 100 available) per session from the 
onset of training (Fig. 5.1, main effect of SESSION, F3.1,78.4= 1.8, p=0.13). As the C59X 
homozygous ENU-mutant mice showed higher levels of nose-poke responding, they 
consequently earned significantly more rewards than their WT littermate controls in 
this initial phase of training, which did not explicitly tax motivation (main effect of 
GENOTYPE, F1,25= 4.5, p=0.04). There were similar patterns of behaviour for other 
parameters during the CRF training phase, with no significant session, genotype 
differences or interactions in the overall session duration (main effect of SESSION, 
F4,100= 0.6, p=0.65, main effect of GENOTYPE, F1,25 = 0.9, p=0.36, SESSION*GENOTYPE, 
F4,100 = 0.5, p=0.74) or the latency to collect the reward (main effect of SESSION, 
F1.5,36.5  =2.0, p=0.11, main effect of GENOTYPE, F1,25= 0.9, p=0.36, 
SESSION*GENOTYPE, F4,100 = 0.3, p=0.87). The latency to make the first nose-poke for 
each reward did not significantly differ between CRF sessions (main effect of 
SESSION, F2.94,73.5 = 0.8, p=0.51), however, C59X homozygous ENU-mutants were 
significantly quicker to initiate the first nose-poke than their WT littermate controls 
117 
 
(main effect of GENOTYPE, F1,25= 6.0, p=0.02, SESSION*GENOTYPE, F4,100 = 1.4, 
p=0.26). 
 
Figure 5.1: Acquisition of CRF behaviour by C59X mice. 
 
 
All mice from the C59X line readily learnt to make a single nose-poke to earn a 22l delivery of 10% 
CM solution, reaching near the maximum of 100 available rewards within the 30min session. C59X 
homozygous ENU-mutant mice completed more trials and therefore earned significantly more 
rewards than their WT littermate controls during this initial phase of training. Data shows the mean 
values ±SEM, *p<0.05 for pairwise differences related to genotype. For subject N see Table 5.1. 
 
Following CRF training the mice were switched to the  progressive ratio 
schedule (PR), where  the number of nose-pokes required to initiate a 22l reward 
delivery was gradually increased throughout the session (see Section 5.2.3.4 for 
details). Performance across the 3 PR sessions was averaged together, and to 
demonstrate the effects of the imposition of this schedule, PR performance was 
compared with the average of the last 3 CRF sessions prior to, and the average of 3 
CRF sessions following PR testing (See Appendix 4.4 and 4.6). Imposition of the PR 
schedule led to a significant reduction in the number of rewards earned within a 
session (Fig. 5.2A, main effect of SESSION, F2,50= 382.5, p=0.000); this reduction was 
equivalent between the C59X genotypes (main effect of GENOTYPE, F1,25= 3.9, 
p=0.06) although a significant interaction (SESSION*GENOTYPE, F2,50= 7.8, p=0.001) 
revealed that the C59X homozygous ENU-mutant mice (as before) earned 
significantly more rewards than their WT littermate during the CRF sessions before 
the PR schedule (p=0.04) and the CRF sessions after the PR schedule (CRF2, p=0.02). 
0 
20 
40 
60 
80 
100 
1 2 3 4 5 
N
u
m
b
e
r 
o
f 
re
w
ar
d
s 
e
ar
n
e
d
 
Session 
* 
118 
 
The decrease in rewards earned during the PR sessions was not due to the 
mice running out of time to collect all the available rewards, as the average PR 
session did not run for the full 30 minutes available, and there were no significant 
differences in session duration between the PR and CRF sessions (main effect of 
SESSION, F1.3, 33.0= 0.9, p=0.42). In fact, most mice were timed out midway through a 
PR session by the failure to make a further nose-poke within 5 minutes of the 
previous response as a result of the increased number of nose-pokes required to 
earn a reward, as illustrated by the maximum breakpoint achieved by the mice (Fig. 
5.2B).  
 
Figure 5.2:  C59X performance in CRF and PR sessions 
 
  
   
                        
Imposition of the PR schedule led to a large reduction in the rewards earned (A), as a result of the 
mice having to make increased numbers of nose-pokes for each reward (B). There were no 
differences in the number of rewards delivered or maximum number of nose-pokes/reward 
(breakpoint) or in the intra nose-poke latency (C) between the C59X homozygous ENU-mutants and 
their WT littermate controls. However, the C59X homozygous ENU-mutant mice were quicker to 
make the first nose-poke in each ratio (D). Data shows the mean values ±SEM. For subject N see 
Table 5.1. 
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There was no significant genotype differences in the PR breakpoint (t25= -0.4, 
p=0.66), suggesting an equivalent level of motivation between C59X homozygous 
ENU-mutant mice and their WT littermate controls as indexed by this key measure. 
In addition to the main breakpoint measure, further evidence for a lack of genotype 
effects on motivational processes in the PRT was shown by equivalent intra nose-
poke latencies between the C59X homozygous ENU-mutant mice and their WT 
littermate controls (Fig. 5.2C, t25= 1.4, p=0.18). Imposition of the PR schedule did, 
however, lead to a general slowing of performance compared to the speed of 
responding in CRF sessions, with an increase in the latency to make the first nose-
poke of each ratio sequence (Fig. 5.2D, main effect of SESSION, F1.4, 34.7) = 14.9, 
p=0.000). C59X homozygous ENU-mutant mice were quicker overall than their WT 
counterparts to make this first response (main effect of GENOTYPE, F1,25= 8.1, 
p=0.009, SESSION*GENOTYPE, F1.4, 34.7= 0.2, p=0.8); the precise interpretation of 
these effects in the homozygous ENU-mutants is unclear,  though it is unlikely they 
were the  result of being more motivated to earn the reward given the previous 
pattern of data. As expected, there was also an increase in the total number of nose-
pokes made in the PR session, compared to the CRF sessions (main effect of 
SESSION, F1.02,25.4 = 13.3, p=0.000, See Appendix 4.6). 
Overall, the data were consistent with there being no reliable differences in 
the motivation to earn reward between C59X homozygous ENU-mutants and their 
WT littermate controls. However, to test this further we additionally compared PR 
performance under differing reward conditions (Hodos, 1961). This was done over 2 
sessions (the order counter-balanced between genotypes), where the concentration 
of reward was altered (see Table 5.2). As anticipated, when the concentration of the 
reward was decreased to 0% CM (water), the breakpoints of all the C59X mice, both 
homozygous ENU-mutants and their WT littermate controls, were significantly 
reduced (Fig. 5.3A, main effect of SESSION, F1,17= 10.3, p=0.003), illustrating that 
devaluing the reward reduces motivation to work. Importantly, in terms of the 
breakpoint reduction, both the C59X homozygous ENU-mutants and their WT 
counterparts responded equally to this manipulation (main effect of GENOTYPE, 
F1,17= 0.03, p=0.87, SESSION*GENOTYPE, F1,17= 0.2, p=0.68). Furthermore, there was 
no effect of reward type on the pattern of nose poking, as illustrated by the intra 
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nose-poke latency (Fig. 5.3B, main effect of SESSION, F1,17= 0.1, p=0.74, 
SESSION*GENOTYPE, F1,17= 3.6, p=0.08), and the latency to initiate the 1
st nose-poke 
(Fig. 5.3C, main effect of SESSION, F1,17= 1.1, p=0.31, SESSION*GENOTYPE, F1,17= 1.2, 
p=0.29), with no genotype differences in these measures (main effect of GENOTYPE, 
F1,17= 0.04, p=0.85, F1,17= 1.3, p=0.27, respectively). There was also no effect of 
reward type on the latency to collect the reward (main effect of SESSION, F1,17= 1.1, 
p=0.14), nor were there any genotype differences in this measure (main effect of 
GENOTYPE, F1,17= 0.04, p=0.45, SESSION*GENOTYPE, F1,17= 0.2, p=0.65). The data 
from the reward manipulation sessions confirmed the lack of genotype effects on 
motivation in the C59X mice as assayed in the PRT.   
 
Figure 5.3: C59X PR performances under differing reward conditions. 
   
                               
Decreasing the reward concentration to 0% CM decreased the breakpoint value (A). This effect was 
indifferent to genotype, suggesting that when less motivated to receive the reward, all of the C59X 
mice, both ENU-mutants and their WT littermate controls, worked less. There were also no differences 
between the C59X homozygous ENU-mutants and their WT littermate controls in the maximum 
amount of nose-pokes made to earn a reward delivery, or in the pattern of nose poking, as shown by 
the intra nose-poke latency (B) and the latency to make the 1
st
 nose-poke of each ratio (C). Data shows 
the mean values ±SEM. For subject N see Table 5.1. 
 
5.3.1.2 Lick Cluster Analysis  
For the LCA, the mice were first trained to drink from the lickometers over 6 
initial sessions with 8% sucrose solution available. As performance was stabilised by 
the final 3 sessions, parameters from these sessions were averaged together so that 
the behaviour of the C59X homozygous ENU-mutants and their WT littermate 
controls could be compared (Table 5.3).   
0 
5 
10 
15 
20 
25 
30 
10% 0% 
B
re
ak
p
o
in
t 
0 
5 
10 
15 
20 
10% 0% 
In
tr
a 
n
o
se
-p
o
ke
 la
te
n
cy
 (
s)
 
0 
5 
10 
15 
20 
10% 0% 
La
te
n
cy
 t
o
 1
st
 n
o
se
-p
o
ke
 (
s)
 
C. A. B. 
Concentration of CM 
 
121 
 
Table 5.3: C59X performance in the 8% sucrose solution training stage of 
the LCA 
Behavioural Parameter WT Homozygous 
Total Consumption (normalised) 0.13 ± 0.005 0.13 ± 0.009 
Total single lick clusters 14 ± 2.2 25.7 ± 6.1 
Average Inter-lick interval 135.4 ± 2 142.2 ± 2.6 
Lick cluster size 16.7 ± 1.8 11 ± 0.67 
Data shows mean ± SEM 
 
There was no genotype effects in the amount of sucrose consumed in this 
initial phase of training (t18.58= 0.6, p=0.53), with mean volumes consumed in the 10 
minute session between 1.5 and 1.7ml. There were also no differences due to 
genotype in the total number of single licks made (t24= 1.8, p=0.09), but the C59X 
homozygous ENU-mutants did show a longer inter-lick latency than their WT 
littermate controls (t24= 2.1, p=0.048). During the initial training phase there were 
indications of reduced lick cluster size in the C59X homozygous ENU-mutant mice 
(t15.2= -3.0, p=0.007). Overall, the average inter-lick intervals for all mice ranged from 
135 to 145ms, which meant that they had met the predefined criteria (see Section 
5.2.4.1) and were moved on to the main test phase of the LCA with 4% and 16% 
sucrose solutions. The order of presentation of the 4% and 16% sucrose tests was 
counter-balanced between the different groups of mice, and data from the 4 
sessions of each concentration were averaged together. To ensure that differences 
in bodyweight could not bias data analysis, the volumes of the different solutions 
consumed were normalised to body weight on each day of testing (see Section 
5.2.4).  
In the main test phase there was no difference between C59X homozygous 
ENU-mutants and their WT littermate controls in the total amount of sucrose 
consumed (Fig. 5.4A, main effect of GENOTYPE, F1,24= 0.4, p=0.56) or in consumption 
of the different sucrose solutions presented (main effect of CONCENTRATION, F1,24= 
0.1, p=0.82, CONCENTRATION*GENOTYPE, F1,24= 0.002, p=0.96). The C59X 
homozygous ENU-mutants did show an increased level of consumption per lick (Fig. 
5.4B, main effect of GENOTYPE, F1,24= 13.1, p=0.001), drinking more sucrose/1000 
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licks than their WT littermate controls. This effect was consistent for both sucrose 
solutions (main effect of CONCENTRATION, F1,24= 2.2, p=0.15, 
CONCENTRATION*GENOTYPE, F1,24= 2.6, p=0.12), although the effect appeared to be 
driven mainly by the  4% sucrose solution. Both C59X genotype groups made 
equivalent overall numbers of licks in each session (Fig. 5.4C, main effect of 
GENOTYPE, F1,24= 0.3, p=0.12), and again sucrose concentration did not affect this 
behaviour (main effect of CONCENTRATION, F1,24)= 0.5, p=0.49, 
CONCENTRATION*GENOTYPE, F1,24= 0.9, p=0.32). As expected, lick cluster sizes were 
significantly greater for the 16% sucrose as opposed to the 4% (main effect of 
CONCENTRATION, F1,24= 20.8, p=0.000, CONCENTRATION*GENOTYPE, F1,24= 2.9, 
p=0.1). Importantly, the C59X homozygous ENU-mutants exhibited reduced lick 
cluster sizes in comparison to their WT littermate controls (Fig. 5.4D, main effect of 
GENOTYPE, F1,24= 5.4, p=0.03). Post-hoc tests showed the genotype effect to be a 
stronger when the 4% sucrose solution was present (p=0.016), although they still 
showed smaller lick cluster sizes with the 16% solution (p=0.045). Lick cluster size is 
the main index of perceived palatability (Davis & Smith, 1992); therefore, these data 
are consistent with a mutation-related reduction in hedonic reactivity to the 
palatable solution.  
 There was no significant difference in the number of single lick clusters made 
by the mice, although there was a strong tendency for C59X homozygous ENU-
mutants to make more single lick clusters than their WT littermate controls (Fig. 
5.4E, main effect of GENOTYPE, F1,24= 3.5, p=0.075), as might be expected in relation 
to the overall reduced size of their lick clusters. This pattern of licking was consistent 
for both sucrose solutions (main effect of CONCENTRATION, F1,24= 1.7, p=0.21, 
CONCENTRATION*GENOTYPE, F1,24= 0.06, p=0.8). The average inter-lick interval was 
found to be significantly increased when the 16% sucrose solution was available (Fig. 
5.4F, main effect of CONCENTRATION, F1,24= 8.4, p=0.008, 
CONCENTRATION*GENOTYPE, F1,24= 0.9, p=0.37), which may be a result of increased 
viscosity of the 16% sucrose solution, and so may be more difficult to drink at speed 
than the 4% sucrose. Importantly, there were no genotype differences for the 
average inter-lick interval at either concentration (main effect of GENOTYPE, F1,24= 
0.2, p=0.63). 
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Figure 5.4:  C59X mice LCA at 4% and 16% sucrose concentrations 
 
 
 
                              
                                                     
There was no significant difference in the total amount of different sucrose solutions consumed by 
the C59X homozygous ENU-mutants and their WT littermate controls (A, normalised to 
bodyweight
0.75
), but the C59X homozygous ENU-mutant mice showed an increased volume per 1000 
licks for each solution (B). Similarly, although there was no overall difference in the total number of 
licks made by the mice (C), the C59X homozygous ENU-mutants had significantly reduced lick cluster 
sizes (D), and a related increase in single lick clusters (E) relative to their WT littermate controls. 
There were no genotype differences in the intra-lick latency with either 4% or 16% sucrose solutions 
(F). Data shows the mean values ±SEM, **p<0.01 and *p<0.05 for pairwise differences related to 
genotype. For subject N see Table 5.1.
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5.3.2 Zfp804a C417Y Line 
5.3.2.1 Progressive ratio task 
 As with the C59X line, the C417Y line achieved high levels of performance 
during CRF training sessions, acquiring approximately 85% of the maximum available 
number of 22l rewards in each session (Fig. 5.5). All the mice operated at these high 
levels (main effect of SESSION, F2.1,53.5= 1.3, p=0.27, SESSION*GENOTYPE, F2.1,53.5= 
0.3, p=0.89) and performance between C417Y homozygous ENU-mutants and their 
WT  littermate controls was equivalent during this initial phase of training which did 
not explicitly tax motivation (main effect of GENOTYPE, F1,25= 0.3, p=0.58). Other 
parameters such as the overall session duration, latency to make the first nose-poke 
for each reward and the latency to collect the reward also showed no genotype 
differences (main effect of GENOTYPE, F1,25 = 0.3, p=0.6, F1,25 = 0.002, p=0.97, F1,25 = 
0.8, p=0.78, respectively).  
Figure 5.5: Acquisition of CRF behaviour by C417Y mice.   
 
                          
Both the C417Y homozygous ENU-mutants and their WT littermate controls collected near maximum 
numbers of the 22ml 10% CM solution reward in each 30min session of the CRF training period. 
Performance of C417Y mice during these sessions was equivalent. Data shows the mean values 
±SEM. For subject N see Table 5.1. 
 
Following CRF training, subjects were moved on to the PR schedule, where 
the number of nose-pokes required for each reward steadily increased through the 
sessions. For comparison, averages of the final 3 CRF sessions before PR testing, the 
3 PR sessions and 3 CRF sessions were calculated (See Appendix 4.5-4.6). As 
expected, imposition of the PR led to a significant decrease in the amount of rewards 
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earned by the mice, in comparison to CRF responding (Fig. 5.6A, main effect of 
SESSION, F2,50= 387.8, p=0.000, SESSION*GENOTYPE, F2,50= 0.4, p=0.69). Consistent 
with the C59X line, this is most probably due to the increased load of increasing 
nose-pokes to earn reward during the PR schedule.  
 
Figure 5.6: : C417Y performance in CRF and PR sessions.   
  
  
                                                      
Imposition of the PR schedule led to a significant decrease in the amount of rewards earned by the 
mice (A) in comparison with CRF responding. The C417Y homozygous ENU-mutants showed a strong 
tendency for increased motivation to work in PR sessions, as shown by a propensity to make more 
nose-pokes to earn a reward, reaching higher breakpoints than their WT littermate controls (B). 
There was no difference in the intra nose-poke latency (C), although there was a general slowing to 
make the first nose-poke of each ratio in PR sessions (D). Data shows the mean values ±SEM. For 
subject N see Table 5.1. 
 
There was no genotype difference for the number of rewards earned between the 
CRF, PR and CRF2 sessions (main effect of GENOTYPE, F1,25= 0.9, p=0.35). Again, 
similar to the C59X mice, PR sessions were more likely to be terminated by the mice 
discontinuing their nose poking behaviour rather than reaching the end of the 30 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
CRF PR CRF2 
R
e
w
ar
d
s 
e
ar
n
e
d
 
Session 
A. 
0 
5 
10 
15 
20 
25 
30 
B
re
ak
p
o
in
t 
0 
2 
4 
6 
8 
10 
In
tr
a 
n
o
se
-p
o
ke
 la
te
n
cy
 (
s)
 
0 
2 
4 
6 
8 
10 
12 
14 
16 
CRF PR CRF2 
La
te
n
cy
 t
o
 1
st
 n
o
se
-p
o
ke
 (
s)
 
Session 
              
C. D. 
B. 
 
        C417Y WT    C417Y Homozygous 
        C417Y WT    C417Y Homozygous 
126 
 
minute sessions, with a mean PR session duration of 24 minutes (data not shown). 
CRF sessions lasted on average 21 minutes, with no significant difference in session 
duration between CRF and PR (main effect of SESSION, F1.39,34.7= 2.9, p=0.06). 
Importantly, and in contrast to the C59X mice, there was a strong tendency (t25= 
2.04, p=0.053) for the C417Y homozygous ENU-mutant mice to achieve higher 
breakpoints in the PR sessions than their WT littermate controls (Fig. 5.6B), 
suggesting that these mice may be more motivated to work for a reward, at least as 
indexed by this baseline measure. Intra nose-poke latencies (Fig. 5.6C, t25= 0.1, 
p=0.9) and the latency to make the first nose-poke (Fig. 5.6D, main effect of 
GENOTYPE, F1,25= 0.2, p=0.67) did not differ between the C417Y homozygous ENU-
mutant mice and their WT littermate controls, although there was a significant 
decrease in the speed with which they started each ratio in the PR sessions 
compared to CRF sessions (main effect of SESSION, F1.6,40.5= 8.2, p=0.001, 
SESSION*GENOTYPE, F1.6,40.5= 0.8, p=0.48). As expected, overall the C417Y mice 
made significantly more nose-pokes in the PR session than in CRF sessions (main 
effect of SESSION, F1.01, 25.2= 20.0, p=0.000) for the reasons outlined previously. 
 These initial data suggested that the C417Y homozygous ENU-mutants may 
have had a higher level of motivation to work for a reward, but to assess this further 
the mice were then tested under different reward conditions (see Table 5.2). This 
was done over 2 sessions (the order counter-balanced between genotypes), where 
the concentration of reward was altered. As expected, when the concentration of 
the reward was decreased to 0% CM (water), the breakpoints of the C417Y mice 
were, in general, reduced, albeit not quite significantly (Fig. 5.7A, main effect of 
SESSION, F1,19= 4.3, p=0.052, SESSION*GENOTYPE, F1,19= 0.2, p=0.68). Importantly, 
the C417Y homozygous ENU-mutants maintained their significantly increased 
breakpoints, in comparison to WT littermate controls, across both reward conditions 
(main effect of GENOTYPE, F1,19= 11.6, p=0.003), providing further evidence that that 
these animals were more willing to work for a reward, even when the reward was 
devalued, as indexed by this key measure of motivation. It should be noted that, a 
priori, several factors may have been contributing to the rewarding properties of the 
two reinforcers used in this part of the study (in addition to palatability), including 
degree of thirst and rate of satiation. However, it is unlikely that gross effects on 
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thirst or satiation could explain the effects on breakpoints seen in the C417 
homozygous ENU-mutant mice since the CRF performance data (where animals 
consumed much larger volumes of liquid reinforcer compared to the PR sessions) did 
not show any effects due to genotype. This issue will be discussed further in the 
Discussion section below. 
The intra nose-poke latency was not affected by reward type (Fig. 5.7B, main 
effect of SESSION, F1,19= 0.02, p=0.9, SESSION*GENOTYPE, F1,19= 1.6, p=0.22) nor by 
C417Y genotype (main effect of GENOTYPE, F1,19= 3.6, p=0.07). However, the latency 
to initiate the 1st nose-poke in each ratio was significantly increased for the 0% CM 
reward condition (Fig. 5.7C, main effect of SESSION, F1,19= 5.6, p=0.03, 
SESSION*GENOTYPE, F1,19= 0.0, p=0.99), perhaps indicating a reduced motivation to 
initiate trials when the reward is devalued. C417Y homozygous ENU-mutants and 
their WT littermate controls had equivalent initiation latencies (main effect of 
GENOTYPE, F1,19= 1.1, p=0.3).  
 
Figure 5.7: C417Y PR performances under differing reward conditions. 
    
                            
Altering the reward conditions by reducing the reward concentration to 0% CM reduced the amount of 
nose-pokes subjects were will to make to earn a reward (A). During these manipulation sessions, the 
C417Y homozygous ENU-mutants were more motivated, having significantly higher breakpoints than 
their WT littermate controls. There were no differences in the intra nose-poke latency (B), but latency 
to make the first nose-poke of each ratio was significantly slowed when the concentration of reward 
was reduced (C). Data shows the mean values ±SEM. For subject N see Table 5.1. 
 
There was no effect of reward type on the latency to collect the reward (main effect 
of SESSION, F1,19= 2.7, p=0.12, SESSION*GENOTYPE, F1,19= 3.4, p=0.08, data not 
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shown), nor were there any genotype differences on this measure (main effect of 
GENOTYPE, F1,19= 0.13, p=0.72). There were also no differences in the way in which 
these different reward sessions were terminated with all C417Y subjects of both 
genotypes being timed out for not making consecutive nose-pokes within the criteria 
time, and equivalent session durations for both reward types (main effect of 
SESSION, F1,19= 2.5, p=0.13, SESSION*GENOTYPE, F1,19= 0.2, p=0.67, data not shown) 
and genotype (main effect of GENOTYPE, F1,19= 0.6, p=0.46). In general, the data 
from the reward manipulation sessions tended to confirm that the C417Y 
homozygous ENU-mutants showed evidence of increased motivation to work for 
reward relative to their WT littermate controls, as assayed in the PRT.   
 
5.3.2.2 Lick cluster analysis  
Mice were trained over 6 initial sessions with 8% sucrose solution available, 
data from the final 3 sessions were averaged together and used for comparison 
(Table 5.4). There was no differences in this initial phase of training between C417Y 
homozygous ENU-mutants and their WT littermate controls in the consumption of 
sucrose in the 10 minute sessions (t25= -0.7, p=0.5), with average volumes consumed 
ranging between 1.5 to 1.6ml in 10 minutes. All mice of the C417Y line also made a 
similar amount of single lick clusters (t18.8= -0.6, p=0.53), and took an equivalent 
amount of time between licks (t25= 0.8, p=0.42), with inter-lick intervals ranging from 
136 to 141ms.  
Table 5.4: C417Y performance in the 8% sucrose solution training stage of 
the LCA 
Behavioural Parameter WT Homozygous 
Total Consumption (normalised) 0.13 ± 0.005 0.13 ± 0.008 
Total single lick clusters 16.3 ± 3.5 13.8 ± 1.9 
Average Inter-lick interval 137.7 ± 2.7 140.6 ± 2.3 
Lick cluster size 20.8 ± 2.1 18.6 ± 1.7 
Data shows mean ± SEM 
 
As the values for these parameters were within criteria (see Section 5.2.4.1), all of 
the mice were moved on to the main test phase of the LCA with 4% and 16% sucrose 
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solutions, the order of which was counter-balanced between different genotype 
groups. Drinking of each solution was averaged across 4 consecutive days, and any 
session where the drinking spout was blocked or the reservoir had leaked was 
removed from the analysis. As previously, to ensure that differences in bodyweight 
could not bias data analysis, the volumes of solution consumed were normalised to 
the individual bodyweight of each mouse (see Section 5.2.4).  
In the main test phase of the LCA, there was no difference in the total 
amount of 4% and 16% sucrose consumed by the mice (Fig. 5.8A, main effect of 
CONCENTRATION, F1,25= 0.6, p=0.44, CONCENTRATION*GENOTYPE, F1,25= 0.02, 
p=0.9) or in consumption between C417Y homozygous ENU-mutants and their WT 
littermate controls (main effect of GENOTYPE, F1,25= 0.1, p=0.77). There were also no 
differences in the amount of sucrose consumption per lick between the different 
solutions (Fig. 5.8B, main effect of CONCENTRATION, F1,25= 1.1, p=0.3, 
CONCENTRATION*GENOTYPE, F1,25= 1.1, p=0.3), although C417Y
 homozygous ENU-
mutant mice consumed more sucrose/1000 licks than their WT counterparts (main 
effect of GENOTYPE, F1,25= 4.7, p=0.04); this effect appeared to be driven mainly by 
the 16% sucrose solution. The total number of licks performed by the mice at each 
concentration were also not found to be significantly different (Fig. 5.8C, main effect 
of CONCENTRATION, F1,25= 0.4, p=0.54, CONCENTRATION*GENOTYPE, F1,25= 0.1, 
p=0.75) and again, there were no significant genotype differences (main effect of 
GENOTYPE, F1,25= 0.9, p=0.635). As expected, the lick cluster size was found to be 
significantly higher when the mice were drinking the 16% sucrose solution as 
opposed to the 4% sucrose solution (Fig. 5.8D, main effect of CONCENTRATION, 
F1,25= 52.2, p=0.000, CONCENTRATION*GENOTYPE, F1,25= 0.7, p=0.42), as the 16% 
solution is thought of as more palatable. Importantly, there were no differences in 
lick cluster size between C417Y homozygous ENU-mutant mice and their WT 
littermate controls (main effect of GENOTYPE, F1,25= 0.8, p=0.37), suggesting that, in 
contrast to the C59X mutants, hedonic reactivity to a palatable solution was 
equivalent in the C417Y mice. Furthermore, the number of single lick clusters did not 
differ between C417Y homozygous ENU-mutants and their WT littermate controls 
(Fig. 5.8E, main effect of GENOTYPE, F1,25= 0.25, p=0.63) or between the different 
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sucrose solutions (main effect of CONCENTRATION, F1,25= 2.5, p=0.13, 
CONCENTRATION*GENOTYPE, F1,25= 0.04, p=0.84).  
Figure 5.8: C417Y mice LCA at 4% and 16% sucrose concentrations. 
   
 
                
                                               
There was no significant differences in the total amount of the different sucrose solutions consumed 
by the C417Y homozygous ENU-mutants and their WT littermate controls (A, normalised to 
bodyweight
0.75
), or in the rate of licking for each solution (B). There was also no overall difference in 
the total number of licks made by the mice (C), with all C417Y
 
mice showing increased lick cluster 
size for the more palatable 16% sucrose solution (D). The number of single licks did not differ 
between genotypes (E), nor did the intra-lick latency (F). Data shows the mean values ±SEM, 
*p<0.05 for pairwise differences related to genotype. For subject N see Table 5.1. 
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When the 16% sucrose solution was available the mean intra-lick interval was 
increased, relative to when the mice were drinking the 4% solution, (Fig. 5.8F, main 
effect of CONCENTRATION, F1,25= 7.98, p=0.009, CONCENTRATION*GENOTYPE, F1,25= 
0.04, p=0.85) although this was behaviour was not affected by C417Y genotype 
(main effect of GENOTYPE, F1,25=0.01, p=0.92). 
 
5.4 Discussion 
5.4.1 Motivation, assessed by the progressive ratio task 
In general all mice in the C59X and C417Y lines demonstrated the expected 
basic patterns of behaviour in the progressive ratio task (PRT), achieving high levels 
of performance in the initial continuous reinforcement phase (where a reward was 
earned after every nose-poke), with approximately 90 rewards earned, and a 
reduction in the number of rewards earned (ca.25) following the subsequent 
imposition of the progressive ratio (PR) schedule. In other words when the number 
of nose-pokes required to earn a reward increased the subjects became less inclined 
to work, reaching breakpoints in the 15-25 nose-pokes/reward range. As anticipated, 
devaluing the reward by reducing the concentration led to a reduction in the 
breakpoints achieved, although the attenuation in breakpoints was not as large as 
might be expected. This could be explained by the water restriction schedule the 
mice were placed on, potentially causing these mice to work equally for any liquid 
reinforcement, however concentrated. Taken together, this pattern of behaviour 
would demonstrate that PRT performance in WT mice was governed by the 
motivation to earn a reward, either in terms of the effort required or by the value of 
the reward given.  
There were no significant effects of C59X genotype in PRT performance, with 
the only consistent difference being that C59X homozygous ENU-mutant mice were 
significantly quicker to make the first nose-poke in each ratio than their WT 
counterparts. The precise interpretation of these effects is unclear, though it is 
unlikely they were the result of being more motivated to earn the reward as the 
breakpoint data demonstrated that C59X homozygous ENU-mutants and their WT 
littermate controls worked equally hard to achieve rewards, even in the face of 
reward devaluation. Overall, this would suggest that the C59X mutation does not 
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lead to demonstrable changes in motivation. In contrast, C417Y homozygous ENU-
mutant mice demonstrated near significant tendencies to achieve higher breakpoints 
than their WT littermate controls during the PRT schedule at standard reward 
conditions (p=0.053). This increased level of motivation became significantly 
different to their WT littermate controls when the reward was devalued (p<0.01). 
There were no latency differences between C417Y homozygous ENU-mutants and 
their WT counterparts under any test condition. Together, these data are consistent 
with the conclusion that the C417Y mutation was associated with increased 
motivation to work for liquid reinforcers.  
The breakpoints obtained in the progressive ratio task are generally taken as 
a measure of motivation to earn rewards. Of interest was the fact that the C417Y 
homozygous ENU-mutants maintained their increased breakpoints across both 
reward conditions (10% condensed milk and water). This raises the possibility that 
the pattern of effects could have been influenced by thirst per se. However, the idea 
that the consistently increased breakpoints could have been due to the C417Y 
homozygous ENU-mutants simply being thirstier than their WT littermate controls is 
unlikely, as under free drinking conditions (i.e. no requirement to work for the 
reinforcer, See Chapter III, Section 3.3.4.3) consumption was equivalent between the 
ENU-mutants and WT littermate controls. Another possibility that may also have led 
to general effects across the two reinforcers was that the C417Y homozygous ENU-
mutants could have been less sated, perhaps due to having larger stomachs than 
their WT littermate controls. However, confounds due to  satiation would also seem 
unlikely as the much greater amount of reinforcer consumed in general during the 
initial continuous reinforcement sessions, compared to the PR sessions, showed that 
satiation was not a factor controlling behaviour in the PR sessions. 
It would seem, therefore, that an increased motivation to work for liquid 
reinforcers remains the most plausible explanation for the increase in breakpoints 
demonstrated by the C417Y homozygous ENU-mutant mice. This is contrary to what 
might be expected in a mouse model for schizophrenia, where decreased motivation 
(avolition) is the more common observation (Barch, 2008) and in the few studies 
utilising animal models (e.g. Drew et al., 2007). The neural mechanism(s) mediating 
the changes in motivation remain unknown but, as mentioned previously, one study 
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has found that mice over-expressing subcortical striatal D2 receptors had lower 
incentive motivation on a progressive ratio schedule (Drew et al., 2007). 
Furthermore, dopamine has been put forward as an important neurotransmitter in 
motivation (Berridge, 2004). It is possible that altered dopaminergic functioning in 
the C417Y homozygous ENU-mutant mice is somehow contributing to the increased 
level of motivation seen in the progressive ratio task, an idea discussed further in the 
General Discussion (Chapter VIII). 
 
5.4.2 Hedonia, assessed by lick cluster analysis 
Mice of both the C59X and C417Y lines demonstrated the expected basic 
patterns of results in the licking assay, with equivalent consumption of sucrose at 
both the 4% and 16% concentrations, and greater lick cluster sizes at 16% than 4% 
(due to the greater palatability of the 16% sucrose solution), although the total 
number of licks made did not differ. Changes in the size of lick clusters, based on 
prescribed intra-lick intervals, have been shown to be sensitive to the consumption 
of more or less palatable solutions (e.g. Hsiao & Fan, 1993), which suggests that lick 
cluster size is the main determinant of palatability and can therefore provide an 
index related to hedonic components of behaviour (Davis & Smith, 1992). This can be 
further demonstrated in terms of the dissociation between total consumption and 
lick cluster size, where subjects may consume greater amounts of low concentration 
solutions with smaller lick cluster sizes than more concentrated rewards (lower total 
consumption, larger lick cluster sizes, Dwyer, 2012). In the current study, the fact 
that consumption of 4% and 16% sucrose was equivalent would suggest that these 
concentrations were at approximately equivalent positions on the ascending and 
descending limbs of the inverted-U shaped function for consumption of palatable 
solutions, indicating that simple consumption tests would not be sensitive enough to 
dissociate differences in palatability, and hence hedonia, further supporting the 
efficacy of lick cluster analysis in assessing rodent palatability (Dwyer, 2012). 
Lick cluster analysis did not reveal any significant genotype differences within 
the C417Y mice, with both C417Y homozygous ENU-mutant mice and their WT 
littermate controls demonstrating equivalent lick cluster sizes at both sucrose 
concentrations. (Note, these data add further evidence that the effects seen in the 
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PRT were not the results of general effects on thirst, satiety or other physiological 
changes in the C417Y homozygous ENU-mutant mice). In contrast, the C59X 
homozygous ENU-mutants displayed reduced lick cluster sizes at both 
concentrations of sucrose in comparison to their WT littermate controls. Lick cluster 
size has been discussed as the main determinant of palatability (Davis & Smith, 
1992). Hence, these effects might be interpreted as the C59X homozygous ENU-
mutant mice showing an anhedonic phenotype. To our knowledge, this is the first 
time such effects have been demonstrated in animal models probing genetic risk 
factors for mental disorder and would be consistent with findings of anhedonia in 
both schizophrenia (Horan et al., 2006b; Gard et al., 2007) and bipolar disorder 
(Serretti & Olgiati, 2004). The specificity of these effects to negative symptoms is 
underlined by previous data showing that PCP treatment in rats, thought to model 
the positive symptoms of schizophrenia more than the negative (Dwyer, 2012), did 
not affect hedonic responding as indexed by lick cluster sizes (Lydall et al., 2010a). 
There was some evidence of motoric changes in the C59X homozygous ENU-
mutants, insofar as they displayed increased volume per lick for both of the 4% and 
16% sucrose solutions in comparison to their WT counterparts. Although total 
consumption and the total number of licks made for each sucrose solution was 
equivalent (suggesting that overall motivation to collect and consume the rewards 
was the same, it was just the manner in which the C59X homozygous ENU-mutant 
mice drank the sucrose that differed) the possibility that the reduced lick cluster size 
may have been confounded by altered buccal/tongue physiology as a result of the 
C59X mutation has to be considered. However, there is strong evidence to refute this 
possibility due to the dissociation between the increased volume per lick, which was 
only present at 4% sucrose, and reduced lick cluster size, which was observed at both 
4% and 16% sucrose. This pattern of effects is consistent with the C59X mutation 
affecting licking behaviour in a manner that reflects anhedonia, rather than any 
motoric consequence of the mutation (D. Dwyer, personal communication).  
A number of possible mechanisms might underlie the anhedonia observed 
with the C59X homozygous ENU-mutants. Chronic stress, for example, leads to 
anhedonia in rats using lick cluster analysis (Dwyer, 2012), but the extent to which 
these effects may overlap with changes in brain function in the mutants is unknown. 
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Much of the research into hedonic reactivity has focused on opiate systems in the 
brain (Peciña, Smith & Berridge, 2006). Systemic treatment with opiate agonists in 
humans and animals increases affective (oro-facial liking) hedonic reactions to 
palatable sucrose (Parker, Maier, Rennie et al., 1992) and infusions into the nucleus 
accumbens shell or the ventral pallidum increase the hedonic reactions to sucrose in 
rats (Peciña & Berridge, 2005; Peciña et al., 2006). GABA blockade in the ventral 
pallidum was also found to stimulate eating but was not accompanied by enhanced 
‘liking’ behaviours (Smith & Berridge, 2005a). Dopamine antagonists also lead to 
reduced lick cluster sizes (D’Aquila, 2010) suggesting a role for dopamine in the 
‘liking’ of rewards as well as the ‘wanting’, despite Berridge’s argument to the 
contrary (Berridge, 2004). It would appear that mutation-related changes in several 
neurotransmitter systems may be of potential relevance to the behavioural findings 
in this chapter, as discussed further in the General Discussion (Chapter VIII).   
 
 
5.4.3. Summary of key results from Chapter V 
 WT littermate control mice from both lines showed the expected basic 
patterns of behaviour on the progressive ratio task and lick cluster analysis. 
 The results suggest that the C59X mutation caused a dissociation between 
pleasure and motivation, whereby the C59X homozygous ENU-mutant mice 
were equally driven to earn rewards on the progressive ratio task but did not 
find them as pleasurable as their WT littermate controls. 
 The C417Y mutation also hinted at a dissociation between pleasure and 
motivation, but in the opposite direction to the C59X mice, whereby the 
C417Y homozygous ENU-mutant mice were more motivated to earn rewards 
but found them equally as pleasurable as their WT littermate controls. 
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Chapter VI: Assessment of sensorimotor gating in Zfp804a mutant 
mice; acoustic startle and prepulse inhibition of startle 
 
6.1 Introduction 
The startle response is the result of brainstem reflexes elicited by sudden intense 
stimuli, which can facilitate an escape from a potentially dangerous situation (Geyer 
& Swerdlow, 2001). It has been used as a behavioural measure of central nervous 
system activity, and can be measured in many species via acoustic, tactile or visual 
stimuli; the most common methodology employed in the clinic being the eye-blink 
response to an air puff (Geyer & Swerdlow, 2001). Startle magnitude can be 
attenuated when the startle stimulus is preceded by a weaker non-startling pre-
stimulus (a prepulse), with startle stimuli not needing to be in the same modality 
(Hoffman & Searle, 1968; Ison, McAdam & Hammond, 1973). This inhibition of a 
motor response, termed prepulse inhibition (PPI), has been held to reflect the 
operation of low level attentional processes required to filter out extraneous 
information (Braff, Geyer & Swerdlow, 2001).  
 PPI deficits are seen in a number of disorders, including conditions in which 
frontal brain regions are affected, such as schizophrenia (for reviews see Geyer, 
Krebs-Thomson, Braff & Swerdlow 2001; Braff et al., 2001) and bipolar disorder 
(Giakoumaki, Roussos, Rogdaki et al., 2007; Perry, Minassian, Feifel, & Braff, 2001). 
However it should be emphasised that PPI deficits are also seen in other conditions 
such as Huntington’s disease (Swerdlow, Paulsen, Braff et al., 1995b), obsessive 
compulsive disorder (Swerdlow, Benbow, Zisook et al., 1993) and ADHD (Ornitz, 
Hanna, & de Traversay, 1992), so effects on PPI can be sensitive to pathology but are 
not selective. Most of the studies conducted on schizophrenia patients have found a 
reduction in PPI (in percentage terms) regardless of what modality the startle 
response and prepulse are generated in (Braff et al., 2001). Furthermore, a possible 
link between PPI deficits and schizophrenia is suggested by the finding that 
antipsychotics drugs (e.g. dopamine D2 receptor antagonists), which are used 
clinically to attenuate the primary symptoms of schizophrenia, also reduce the PPI 
deficiency in patients (for a review see Geyer et al., 2001). Interestingly, one study 
not only found reduced PPI in schizophrenia patients, but also in the unaffected first 
137 
 
degree relatives of the schizophrenia (Cadenhead, Swerdlow, Shafer, Diaz & Braff, 
2000) and bipolar (Giakoumaki et al., 2007) probands, suggesting a genetic element 
to the PPI deficits seen in both disorders. Patients with schizophrenia have also 
demonstrated slower rates of habituation to repeated administrations of the startle 
stimulus than normal controls (Geyer & Braff, 1982; Braff, Grillon & Geyer, 1992,), 
perhaps suggesting a generalised habituation deficit to startling stimuli. 
 The startle response and PPI are relatively easily modelled in rodents with 
common methodologies employing acoustic startle and prepulse stimuli, and an 
assessment of the whole body startle response. Furthermore, it is possible to use 
stimuli parameters in animals that are directly comparable to human studies, such as 
acoustic startle amplitude and prepulse interval manipulations (Swerdlow, Weber, 
Qu, et al., 2008). In attempting to develop plausible animal models for schizophrenia, 
a deficit in PPI has become a recognised endophenotype (Turetsky, Calkins, Light, et 
al., 2007). Thus, animal models have sought to recapitulate the deficits seen in 
schizophrenic patients. Pharmacological challenges such as dopamine agonists, 5-HT2 
agonists, and NMDA antagonists all impair PPI in rodents, revealing some degree of 
overlap between neurotransmitter systems important in mediating prepulse 
inhibition and the robust effects on PPI seen in schizophrenia (for a review see Geyer 
et al., 2001). Furthermore, the rat social isolation model of early life deprivation, a 
putative neurodevelopmental model for schizophrenia, also causes a reduction in PPI 
(Geyer et al., 1993; Wilkinson, Kilcross, Humby, et al., 1994) in addition to altered 
forebrain dopaminergic systems (Wilkinson et al., 1994), further suggesting that 
early life stressors may have important repercussions on brain function and 
behaviour in later life. Studies involving specific brain lesions have implicated the 
hippocampus, the medial prefrontal cortex and the striatum as brain regions thought 
to be important in mediating PPI in rodents (see Swerdlow, Geyer & Braff, 2001 for a 
review); these regions have also been implicated in the pathophysiology of 
schizophrenia (Swerdlow et al., 2001). 
Sensorimotor gating effects have been found in a number of genetic mouse 
models for psychiatric disorders. For example, mice carrying an ENU-induced 
missense mutation of DISC1 showed a reduced startle response as well as displaying 
PPI deficits which were reversed by antipsychotic treatment (Clapcote et al., 2007). 
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PPI deficits, although less pronounced than the ENU-induced mutant strain, were 
observed in another DISC1 mutant over expressing a truncated form of DISC1 under 
the control of the CaMKII promoter (Hikida et al., 2007). Similarly, other mouse 
models of candidate genes for schizophrenia and other mental conditions have 
shown PPI impairments (e.g. NRG1, Stefansson, et al., 2002), although the findings 
are not always clear cut (e.g. NRG1, Karl, Burne, Van den Buuse & Chesworth, 2011 
and others). These differences in results are not due to any debate about the 
reliability of the PPI deficit in schizophrenia and other conditions per se, which is fully 
accepted, but are more likely due to the differences between the creation of the 
different mouse lines and variable testing methods. In the case of the present work, 
the experiments in this chapter examined acoustic startle and prepulse inhibition of 
acoustic startle in the two Zfp804a ENU mutant lines to further investigate 
endophenotypes of possible relevance to the pathogenicity of ZNF804A variants in 
people. 
 
6.2 Materials and Methods 
Full methodological descriptions can be found in the relevant sections of the 
General Methods (Chapter II, Section 2.4.8). 
 
6.2.1 Subjects and animal husbandry 
In total, 50 adult male mice were used in these experiments (mean age 13 ± 
0.21 months). Details of specific mouse numbers per genotype can be seen in Table 
6.1. Mice were housed in littermate groups of two to five animals per cage, under 
temperature and humidity controlled conditions, with a 12-hour light: 12-hour dark 
cycle (lights on at 07:30). All subjects had ad libitum access to standard laboratory 
chow and water. Mice were weighed on a regular basis and any mice dropping 10% 
of their body weight or more were removed from the experiment. All experimental 
procedures were conducted under licenses issued by the Home Office (U.K.) in 
compliance with the Animals (Scientific Procedures) Act 1986. 
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Table 6.1: Sample size and genotype of each cohort of mice assayed on acoustic 
startle response and PPI. 
Behavioural  
Task 
C59X line C417Y line 
 WT  Homozygous WT Homozygous 
Startle/PPI 14 12 11 13 
 
6.2.2 General behavioural methods 
All testing took place between the hours of 09:00 and 18:00, with equal 
distribution of testing for subjects of different genotypes throughout the day. 
Subjects were habituated to an adjacent holding room at least 30 minutes before 
testing. Subjects were then collected from the holding room just prior to testing, and 
immediately placed into the startle apparatus. Following testing the mice were 
weighed and returned to their home cage. 
 
6.2.3 Acoustic startle and prepulse inhibition 
The acoustic startle response (ASR) and prepulse inhibition (PPI) were 
assayed using SR-Lab apparatus (San Diego Instruments, U.S.A), according to 
previous methods (Geyer & Dulawa, 2003). ASR and PPI were measured in a single 
session lasting 30 minutes where subjects were placed in the sound attenuating 
chambers described in Chapter II, Section 2.4.8. In brief, mice were placed into a 
35mm diameter, Perspex tube mounted on a Perspex plinth. Directly beneath the 
centre of the tube was a piezoelectric sensor that detected flexion in the plinth: the 
measure of startle reactivity. Above the animal enclosure (12cm) a loud speaker was 
mounted, through which all white-noise stimuli were presented. The apparatus was 
thoroughly cleaned with 1% glacial acetic acid solution between subjects to remove 
any aversive odour cues. 
A startle session consisted of exposure to 49 acoustic stimuli, presented in a 
pseudorandom manner every 10s, against a background noise of 70dB (A scale, (A)). 
Sessions started with a 5 minute acclimatisation period at background followed by 2 
blocks of acoustic stimuli. The first block of 20 trials (See Appendix 5.1) consisted of a 
pseudorandom distribution of pulse-alone (startle) trials of different amplitude (3 
each at 80, 90, 100, 110 and 120 dB and 5 no-stimulus trials). The second block (29 
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trials), consisted of a pseudorandom distribution of pulse-alone (at 120dB), 
prepulse+pulse-alone (prepulses at 8 and 16dB above background) and no-stimulus 
trials. There were 13 pulse-alone trials, and 6 trials for each prepulse+pulse-alone 
combination and 4 no-stimulus trials. All pulse-alone trials consisted of a 30ms 
startle stimulus.  Prepulse+pulse-alone trials consisted of a 20ms prepulse followed 
by a 30ms startle stimulus, 70ms after the prepulse stimulus offset. Responses were 
monitored for 65ms following the onset of the startle stimulus. The whole body 
startle response to the pulse-alone trials and the inhibition of responding due to the 
presentation of prepulse stimuli was recorded (as arbitrary startle units, ASU, related 
to the voltage change detected by the piezoelectric sensor). 
 
6.2.4 Statistical analysis 
The experimental data was analysed using SPSS (Version 18.0). Behavioural data are 
presented as mean values (M) along with the standard error of the mean (SEM), unless 
stated otherwise. Data for each strain were analysed separately, and separate ANOVAs were 
performed with between subject’s factor of GENOTYPE (homozygous ENU-mutant vs. WT 
littermate control) and within subject factors as appropriate. The mean startle amplitude for 
each trial type was calculated for trials from the first block and analysed with factor 
STIMULUS INTENSITY (no-stimulus trials and pulse-alone trials at 80, 90, 100, 110 and 120 
dB). Data from the second block were analysed with within subject factors of TRIAL NUMBER 
(13x 120dB pulse-alone stimuli), TRIAL TYPE (mean pulse-alone, 8dB and 16dB prepulse 
trials) and amount of PPI (8dB and 16dB prepulse trials). PPI was calculated from data 
collected in the second block; as the percentage reduction in mean startle amplitude 
between prepulse trials and pulse-alone trials for each prepulse intensity (at 8 and 16dB 
prepulse amplitude above background), using the following calculation: 
 
% prepulse inhibition = 100 x (mean pulse-alone trial – mean prepulse trial) 
          (mean pulse-alone trial) 
 
All significance tests were performed at alpha level of 0.05 and where significant 
interactions were identified in the main ANOVA, post-hoc tests using appropriate 
pair-wise comparisons were performed. Greenhouse-Geisser degrees of freedom 
(df) corrections were applied as required to repeated-measures factors.  Outliers 
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which were 2 standard deviations or more from the mean were removed from the 
analysis. 
 
6.3 Results 
6.3.1 Zfp804a C59X line 
6.3.1.1 Startle reactivity 
To assess startle reactivity, the mice were tested with a range of increasing 
levels of stimulus amplitude, ranging from 70dB to 120dB, against a background 
noise of 70db, thus the lowest stimulus volume was equivalent to background (Fig. 
6.1A). Background activity was also assessed by recording movement in the absence 
of a specific stimulus presentation (No stim trials). As expected, both C59X 
homozygous ENU-mutants and WT littermate controls showed an appropriate 
increase in startle reactivity as the stimulus intensity increased (main effect of 
STIMULUS INTENSITY, F2.2,43.9= 15.5, p=0.000, STIMULUS INTENSITY*GENOTYPE, 
F2.2,43.9= 1.9, p=0.11). There were no overall differences in the startle response 
between C59X homozygous ENU-mutants and their WT littermate controls (main 
effect of GENOTYPE, F1,20= 0.7, p=0.41), suggesting that auditory sensitivity was 
equivalent between C59X subjects. 
In the second block of trials, 13 pulse-alone trials at 120dB were interspersed 
with 12 prepulse/pulse-alone trials (6 trials each with 8dB and 16dB prepulse stimuli 
above background) in the sequence of stimuli presentations. Within this timeframe 
there was no overall change in the startle response to these stimuli, with all mice 
maintaining good levels of reactivity throughout the session (Fig. 6.1B, main effect of 
TRIAL NUMBER, F5.9,117.6= 1.5, p=0.12, TRIAL NUMBER*GENOTYPE, F5.9,117.6= 0.5, 
p=0.89). Examination of the pattern of startle reactivity at a constant 120dB pulse 
suggested that C59X homozygous ENU-mutant mice startled less to the 120dB 
stimuli than their WT littermate controls, although this did not quite reach statistical  
significance (main effect of GENOTYPE, F1,20= 4.2, p=0.054). A priori analysis 
excluding the first 5 120dB pulse trials, where the startle response was greatest and 
most anxiogenic (t20= -1.6, p=0.12), demonstrated that the average startle response 
for C59X homozygous ENU-mutants was indeed significantly reduced in comparison 
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to their WT littermate controls (Fig. 6.2A, t20= -2.2, p=0.04), perhaps indicating 
reduced startle reactivity in the C59X homozygous ENU-mutants.  
 
Figure 6.1. Startle reactivity in C59X mice 
   
  
                         
C59X homozygous ENU-mutant mice and their WT littermate controls showed an increased startle 
response with increasing pulse alone intensity (A). On the 13 120dB pulse alone trials (B) both the 
C59X homozygous ENU-mutants and their WT littermates showed consistent responding across 
multiple presentations of the 120dB pulses; the C59X homozygous ENU-mutant mice appeared to 
startle less than their WT littermate controls, although this did not reach significance. Data shows 
the mean values ±SEM. For subject N see Table 6.1. 
 
6.3.1.2 PPI 
In the presence of prepulse stimuli at either 8 or 16dB, the startle response to 
120dB stimuli was significantly reduced from pulse-alone levels (Fig. 6.2A, main 
effect of TRIAL TYPE, F2,40= 17.0, p=0.000). C59X homozygous ENU-mutant mice 
showed reduced levels of startle for each type of trial in comparison to their WT 
littermate controls, but this was not found to be significant (main effect of 
GENOTYPE, F1,20= 1.8, p=0.2). PPI was calculated as the difference in mean startle 
reactivity between pulse-alone and prepulse trials and, as expected, all subjects 
showed significantly greater PPI when the prepulse was at 16dB than at 8dB above 
background (Fig. 6.2B, main effect of PREPULSE INTENSITY, F1,20= 12.1, p=0.002, 
PREPULSE INTENSITY*GENOTYPE, F1,20= 1.5, p=0.24). Importantly, C59X homozygous 
ENU-mutant mice showed reduced levels of PPI compared to their WT counterparts 
(main effect of GENOTYPE, F1,20= 5.2, p=0.03), which may reflect an impairment in 
sensorimotor gating in these mice. As the PPI calculation takes into account baseline 
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startle levels, it was important to show that the PPI deficits found with the C59X 
homozygous ENU-mutants was not confounded by the reduced acoustic startle 
response found with these mice. The results of an ANCOVA with baseline startle 
levels as the covariate showed no interaction between baseline startle and PPI 
(p=0.166), although the overall significant difference between C59X homozygous 
ENU-mutant mice and their WT littermate controls was reduced from the previous 
analysis (main effect of GENOTYPE, F1,19= 3.7, p=0.07).  
 
Figure 6.2. Startle reactivity and PPI in the C59X mice. 
   
   
                
The C59X homozygous ENU-mutant mice showed significantly reduced startle when all the 120dB 
pulse alone trials were averaged together, as compared to their WT littermate controls (A). All C59X 
mice showed an equivalent amount of startle in trials with 8dB and 16dB prepulses (A). All subjects 
showed a significantly greater percentage PPI when the prepulse was at 16dB than at 8dB above 
background (B), however, C59X homozygous ENU-mutant mice show reduced PPI compared to their 
WT littermate controls at both prepulse amplitudes. Data shows the mean values along with the 
±SEM, *p<0.05 for pairwise differences related to genotype. For subject N see Table 6.1. 
 
6.3.2 Zfp804a C417Y line 
6.3.2.1 Startle reactivity 
 In response to increasing startle stimuli intensities, all subjects showed the 
expected increase in startle response (Fig. 6.3A, main effect of STIMULUS INTENSITY, 
F2.7,51.3= 24.8, p=0.000, STIMULUS INTENSITY*GENOTYPE, F2.7,51.3= 0.6, p=0.7). C417Y
 
homozygous ENU-mutants and WT littermate controls showed comparable levels of 
startle to these stimuli (main effect of GENOTYPE, F1,19= 0.5, p=0.48), suggesting that 
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auditory sensitivity is equivalent for all the C417Y subjects. In the second block of 
trials, 13 120dB pulse alone trials were distributed randomly between the prepulse 
trials. There was no overall change in the startle response to these stimuli, with all 
mice maintaining good levels of reactivity throughout the session (Fig. 6.3B, main 
effect of TRIAL NUMBER, F5.4,102.7= 1.8, p=0.12, TRIAL NUMBER*GENOTYPE, F5.4,102.7= 
0.5, p=0.78) with no difference in startle responses between C417Y homozygous 
ENU-mutants and their WT littermates (main effect of GENOTYPE, F1,19= 0.1, p=0.75). 
Comparison of startle reactivity between mice of the C417Y line for the first 5 120dB 
pulse alone trials (t19= 0.3, p=0.75) and the average of all 120dB pulse alone trials 
(t19= 0.96, p=0.35) showed no significant differences, suggesting that all C417Y 
subjects startled at equivalent levels throughout the session and habituated to the 
pulse alone trials at an equivalent rate.   
 
Figure 6.3. Startle reactivity in C417Y mice. 
   
  
                     
C417Y homozygous ENU-mutant mice and WT littermate controls showed an increased startle 
response with increasing pulse alone intensity (A). On the 13 120dB pulse alone trials (B) both the 
C417Y homozygous ENU-mutants and their WT littermate controls showed consistent responding 
across multiple presentations of the 120dB pulses, with no genotype differences. Data shows the 
mean values ±SEM. For subject N see Table 6.1 
 
6.3.2.2 PPI 
Sensorimotor gating was assessed using 2 different levels of prepulse 
amplitude, 8 and 16dB above background and compared to the mean startle pulse 
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alone response to 120dB stimuli. As expected there was a significant attenuation in 
startle reactivity when a prepulse stimulus was present (Fig. 6.4A, main effect of 
TRIAL TYPE, F2,38= 12.7, p=0.000) with no difference between C417Y homozygous 
ENU-mutant mice and their WT littermate controls in these measures (main effect of 
GENOTYPE, F1,19= 1.1, p=0.31). This reduction in startle was greatest following the 
presentation of a 16dB prepulse than an 8dB prepulse (p=0.018), with higher PPI 
following the 16dB prepulse than the 8dB prepulse (Fig. 6.4B, main effect of PRE 
PULSE INTENSITY, F1,19= 7.9, p=0.01, PREPULSE INTENSITY*GENOTYPE, F1,19= 3.4, 
p=0.08). There were no significant differences in PPI between the C417Y 
homozygous ENU-mutants and their WT littermate controls under both prepulse 
conditions (main effect of GENOTYPE, F1,19= 0.09, p=0.77).   
 
Figure 6.4. Startle reactivity and PPI in the C417Y mice. 
   
  
             
C417Y homozygous ENU-mutant mice startle at an equivalent rate to their WT littermate controls 
when all the 120dB pulse alone trials were averaged together (A). They also startle at an equivalent 
rate to both 8dB and 16dB prepulses (A). All subjects showed a significantly greater % PPI when the 
prepulse was at 16dB than at 8dB above background (B), with no genotype differences observed in 
percentage PPI. Data shows the mean values ±SEM. For subject N see Table 6.1. 
 
 
6.4 Discussion 
 WT littermate control mice of both the C59X and C417Y lines demonstrated 
the expected basic pattern of results, showing increasing startle responses to 
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increasing acoustic startle stimulus amplitudes (in pulse-alone trials). They also 
showed reduced startle responses (prepulse inhibition, PPI), when presented with 
prepulse trials in which an acoustic prepulse stimulus 8dB or 16dB above background 
noise preceded the 120dB startle stimulus. Responses to pulse-alone or prepulse 
trials were equivalent between C417Y homozygous ENU-mutant mice and their WT 
littermate controls. Responses to increasing startle amplitudes, habituation to 120dB 
pulse-alone stimuli and the degree of PPI shown with 8dB and 16dB prepulse stimuli 
were also equivalent between C417Y homozygous ENU-mutant mice and their WT 
littermates. In contrast, C59X homozygous ENU-mutant mice showed reduced levels 
of startle at 120dB pulse-alone stimuli and, importantly, reduced PPI, although 
startle reactivity to increasing startle intensities was equivalent to their WT 
littermate controls. This pattern of results would suggest, a priori, an altered acoustic 
startle response and impaired sensorimotor gating in the C59X homozygous ENU-
mutant mice. 
 The pattern of data could potentially be influenced by a number of factors. 
Firstly, as all the stimuli used in the current study were acoustic, hearing 
impairments could, in theory, be accountable for the reduced levels of startle shown 
by the C59X homozygous ENU-mutant mice. However, deafness can be discounted 
as the C59X homozygous ENU-mutant mice demonstrated equivalent startle 
responses (in relation to their WT littermate controls) to increasing amplitudes of the 
startle stimuli, especially at the lower end of the range used (80 to 100dB, Fig. 6.1A) 
suggesting a degree of sensitivity to these stimuli that was equivalent to their WT 
counterparts. Likewise, data from the next series of experiments in the stop-signal 
reaction time task would further support this, where C59X homozygous ENU-mutant 
mice demonstrated improved responding to the 105dB white noise stimuli used to 
indicate a stop trial, see Section 7.3.1.3. Startle responses and PPI can also be 
induced using visual and tactile stimuli alone, or in combination with acoustic stimuli, 
and it would therefore be of benefit to assess startle reactivity and PPI in C59X mice 
in other sensory modalities, in particular a tactile modality, which is thought to be 
optimum for rodent models (Geyer & Swerdlow, 2001).  
 The PPI calculation is not independent of baseline startle responding and 
therefore the reduced pulse alone startle response of the C59X homozygous ENU-
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mutants may have influenced the PPI deficits shown in these mice. However, there is 
no agreement on how the startle response and PPI levels are correlated, and as such, 
reduced startle effects could be accompanied by PPI deficits or PPI enhancements 
(Csomor, Yee, Vollenweider, et al, 2008). Furthermore, the reduced startle response 
in the C59X homozygous ENU-mutant mice was not found to co-vary with the PPI 
deficits shown.  
 There might have also been a possible ‘floor effect’ in the startle response of 
the C59X homozygous ENU-mutant mice. As mentioned previously, these mice 
showed a significantly reduced startle response in 120dB pulse-alone trials, as 
compared to their WT littermate controls. It could therefore be a possibility that any 
further reductions in startle responding could not be reliably measured either due to 
the sensitivity of the apparatus and/or some biological minimum response in these 
mice, hence their reduced percentage PPI (in comparison to their WT littermate 
controls) could have been a result of this potential floor effect. To counteract this 
idea, it can be shown that the C59X homozygous ENU-mutant mice were capable of 
lower startle responses than those generated when prepulses were present; with 
Fig. 6.2A showing that even further reduced startle could be reliably assessed in 
these mice when 70, 80 and 90dB stimuli were presented. 
  Attenuated PPI is considered an endophenotype of schizophrenia (Geyer et 
al., 2001; Braff et al., 2001) but is also seen in bipolar patients (Giakoumaki et al., 
2007; Perry et al., 2001). This impairment in sensorimotor gating can also be 
demonstrated as a result of specific brain lesions related to the pathophysiology of 
schizophrenia and bipolar disorder, such as the prefrontal cortex and hippocampus 
(Swerdlow et al., 2001), but also manipulation of the major forebrain 
neurotransmitter systems and by NMDA receptor blockade (Geyer et al., 2001) and 
altered early life experience (Geyer et al., 1993; Wilkinson et al., 1994). Thus, there 
are a number of different mechanisms by which the effects of the C59X Zfp804a 
mutation could give rise to the PPI deficit observed, occurring from prenatal 
differences through to altered adult brain function.  
Reduced startle reactivity is not commonly observed in schizophrenia, 
instead patients are more likely to show reduced rates of habituation to repeated 
administrations of the startle stimulus than normal controls (Geyer & Braff, 1982; 
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Braff et al., 1992), an effect that was not observed in the current study, most likely 
due to the reduced number of presentations of the startle stimuli and the 
interpolation of the prepulse trials. This blunted startle response is also seen in post-
traumatic stress disorder, depression and bipolar disorder (Beck & Catuzzi, 2013), 
suggesting a potential similarity between the sensory reactivity of these mice to 
patients with certain psychiatric disorders. In animal models startle reactivity and 
anxiety have previously been shown to be correlated (Mikaelsson, Constância, Dent 
et al., 2013), thus, the reduced startle reactivity demonstrated by C59X homozygous 
ENU-mutant mice could also be related to the reduced anxiety phenotype shown by 
these mice, (Chapter IV).  
The data in this chapter indicate PPI deficits that are specific to the C59X line, 
providing evidence of an endophenotype that may prove to be of relevance to the 
risk for mental disorder associated with ZNF804A gene variants (Turetsky et al., 
2007). As with work done in other models, such as DISC1 mutants (Clapcote et al., 
2007; Hikida et al., 2007) and NRG1 mutants (Stefansson et al., 2002) it would be 
interesting to see if the PPI deficits could be reversed with antipsychotic drugs. 
Additionally, these data may point to underlying neurobiology that are common to 
startle and PPI, and pathways sensitive to ZNF804A function/dysfunction, in 
particular modulatory effects of the monoaminergic pathways on limbic and cortical 
circuitries (Powell, Zhou & Geyer, 2009); ideas which are discussed further in the 
General Discussion (Chapter VIII). 
 
6.4.1. Summary of key results from Chapter VI 
 WT littermate controls both mutant lines demonstrated the expected startle 
and PPI responses. 
 C59X homozygous ENU-mutant mice displayed attenuated startle reactivity 
and reduced PPI in comparison to their WT littermate controls, indicating an 
impairment of sensorimotor gating in these mice. 
 The C417Y mutation did not have an effect on the mutant’s ability to startle, 
habituate or attenuate to a startling stimulus. 
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Chapter VII: Assessment of response control in Zfp804a mutant mice: 
stop-signal reaction time task (SSRTT) 
7.1 Introduction 
The ability to inhibit thoughts and actions when they are no longer in keeping with 
current goals is an essential requirement of human behaviour (Logan & Cowan, 
1984). Impulsivity on the other hand, is a lack of behavioural inhibition, where 
actions are ‘poorly conceived, prematurely expressed, unduly risky, or inappropriate 
to the situation and that often result in undesirable outcomes’ (Evenden, 1999a). 
Maladaptive deficits in response control are found in several psychiatric illnesses 
including schizophrenia, bipolar disorder, attention-deficit hyperactivity disorder 
(ADHD) and OCD. 
Response control forms part of the umbrella of cognitive processes known as 
‘executive functioning’, which essentially act in unison to monitor the world, 
generate and assess appropriate responses and co-ordinate actions accordingly 
(Badcock, Michie, Johnson & Combrinck, 2002). Patients with schizophrenia show 
deficits in elements of executive functioning in areas such as attention (Braff, 1993; 
Heinrichs & Zakzanis, 1998), impulsivity (Newman et al., 1985; Heerey et al., 2007) 
and working memory (Goldman-Rakic, 1994; Barch, 2006) and perform poorly on 
tasks that place a heavy load on executive functioning such as the Wisconsin Card 
Sorting Test and the Tower of Hanoi problem (Fey, 1951; Bustini, Stratta, Daneluzzo, 
et al., 1999; Badcock et al., 2002). Patients with bipolar disorder also show similar 
deficits in executive function, with reduced attention, impairments in working 
memory and increased impulsivity (Swann, 2010). 
Impulsivity is not a unitary concept. It has been proposed that impulsivity 
actually encompasses a variety of phenomena that may yet have separate biological 
mechanisms (Evenden, 1999b). Measuring behavioural inhibition in the laboratory 
has benefitted from this definition, with tasks measuring impulsivity divided into two 
major categories; those measuring impulsive choice and those measuring impulsive 
action (Winstanley, Eagle, Robbins, 2006). Impulsive choice paradigms involve 
measuring impulsive decisions and have, for example, utilised delay-discounting 
tasks which measure intolerance (or otherwise) to delay-of-gratification, typically 
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offering subjects a choice between smaller immediate rewards or larger delayed 
rewards (Ainslie, 1975). Picking the smaller immediate reward is seen as an impulsive 
choice. Impulsive action paradigms usually measure the ability to withhold making a 
pre-potent response, such as, for example, in go/no-go paradigms and the stop-
signal reaction time task (SSRTT, Logan & Cowan, 1984). In go/no-go tasks, subjects 
learn to make a response when cued to do so by a ‘go’ signal, however on some 
trials a ‘no-go’ signal is presented simultaneously or just prior to the ‘go’ signal  
indicating to subjects to withhold their response. The SSRTT is an elaboration of the 
go/no-go task with the difference being that the stop- (no-go) signal is presented 
after the presentation of the go signal, thus measuring the ability to inhibit a 
response once it has already been initiated, in other words the ability to stop 
(Winstanley et al., 2006). The stop-signal can be presented close to the start of the 
go response, making stopping easy, whereas presentation later in the go response 
would make stopping more difficult (Logan & Cowan, 1984). It is hypothesised that 
the go and stop responses are independent processes, which compete to control the 
final behavioural output, described as the ‘horse-race’ model (Logan & Cowan, 
1984).  Thus, a key consideration is the point where competition is greatest, i.e. at 
50% stopping where it is presumed the go and stop responses are equal. 
A main measure of interest in the SSRTT is the stop-signal reaction time 
(SSRT); the time required to successfully stop. This is a calculated measure as it is 
impossible to accurately measure the latency of a response that never occurs, 
however estimations of the SSRT can be generated from the race model, using the 
subjects’ mean go reaction time and the stop-signal delay when correct stopping is 
at 50%. In human studies adult SSRTs are close to 200ms (Logan & Cowan, 1984) but 
these have been found to be around 200ms longer (slower) for children (Schachar & 
Logan, 1990) and the elderly (Kramer, Humphrey, Larish et al., 1994). Research has 
also found that children with ADHD tend to take longer to respond to the stop-signal 
and as such have SSRTs which are around 100ms slower than normal children 
(Oosterlaan, Logan, & Sergeant, 1998; Overtoom, Kenemans, Verbaten, et al., 2002). 
Frontostriatal brain systems, thought to be involved in the pathophysiology of 
schizophrenia and bipolar disorder have been implicated in the neural substrates of 
response inhibition (Rubia, 2002; Rubia, Russell, Bullmore et al., 2001; Rubia, Smith, 
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Brammer & Taylor, 2003; Townsend, Bookheimer, Foland-Ross et al., 2012), with 
lesions to the right inferior frontal gyrus (Aron, Fletcher, Bullmore et al., 2003), the 
frontal lobes and the basal ganglia (Rieger, Gauggel & Burmeister, 2003) all 
producing slower SSRTs in schizophrenia patients on the SSRTT. 
 While there have been few investigations into the response control of 
schizophrenia and bipolar patients using the SSRTT, this task has been proposed as a 
potential biomarker for schizophrenia (Barch et al., 2009). There is debate as to the 
consistency of findings when schizophrenia patients are tested on the SSRTT, with 
some evidence showing that subjects have slower inhibitory processes, achieving 
SSRTs of around 245ms compared to 191ms for controls (Enticott, 2008; Huddy, 
Aron, Harrison et al., 2009), But other research showing no differences between 
patients and controls in inhibitory performance (Rubia et al., 2001) or only showing a 
lateralised deficit in response inhibition (Bellgrove, Chambers, Vance et al., 2005). 
One study suggests that there are indeed impairments in the triggering of inhibitory 
processes in schizophrenia patients, but that speed of inhibitory processes (when 
triggered) are relatively unaffected (Badcock et al., 2002). With bipolar disorder 
patients, response inhibition, as measured by the SSRTT, was poorer in patients 
versus normal controls (Strakowski, Fleck, DelBello et al., 2010), but more research 
using the SSRTT is needed to confirm this finding. 
 The SSRTT paradigm has also been developed for use in rats (Eagle & 
Robbins, 2003a,b), using a double lever press as the go response. The rat SSRT has 
been found to be around 300ms (Eagle & Robbins, 2003a); similar to results in 
humans. We have recently developed the SSRTT for mice (Humby, Eddy, Reichelt et 
al., 2013), using a double nose-poke methodology, which, as expected, 
demonstrated systematic changes in stopping ability as the stop-signal position was 
altered; and also  SSRTs in keeping with data from humans (350ms), illustrating a 
degree of translational relevance of the mouse SSRTT to clinical settings. Stopping in 
the mice was improved using drugs known to improve inhibition in humans, i.e. 
methylphenidate (a dopamine reuptake inhibitor) and atomoxetine (a noradrenaline 
reuptake inhibitor), whilst lesions to the medial prefrontal cortex (mPFC) impaired 
stopping (Humby et al., 2013). Consistent with our data in mice, studies in rats have 
also found that stopping in the SSRTT is affected by lesions to the orbitofrontal 
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cortex and the subthalamic nucleus (Eagle, Baunez, Hutcheson et al., 2008), and that 
amphetamine and methylphenidate improved stopping in animals with poor 
baseline inhibitory performance, including rats with medial striatal lesions (Eagle & 
Robbins, 2003a,b; Eagle, Tufft, Goodchild & Robbins, 2007). The SSRTT has, 
therefore, been shown to be a useful translational tool for studying impulsive action 
in animal models including very recently (and uniquely in our own laboratory) mice, 
and hence was used in the present chapter to assess whether the Zfp804a mutant 
lines showed any evidence of changes in response control. 
 
7.2 Materials and Methods 
Full methodological descriptions can be found in the relevant sub-sections of the 
General Methods (Chapter II). 
 
7.2.1 Subjects and animal husbandry  
In total, 58 adult male Zfp804a mice were used in these experiments (mean 
age of 7 months). Details of specific mouse numbers per genotype can be seen in 
Table 7.1. 
 
Table 7.1: Sample size and genotype of each cohort-subset of mice assayed on the 
Stop-signal reaction time task (SSRTT). 
Behavioural 
Task 
C59X line C417Y line 
WT Homozygous WT Homozygous 
SSRTT 14 15 14 15 
 
All mice were housed in littermate groups of two to five animals per cage, 
under temperature and humidity controlled conditions, with a 12-hour light: 12-hour 
dark cycle (lights on at 07:30). All subjects had ad libitum access to standard 
laboratory chow but only 2hrs access to water per day during testing. Mice were 
weighed on a regular basis. Any mice dropping 10% of their body weight or more 
were removed from the experiment. All experimental procedures were conducted 
under licenses issued by the Home Office (U.K.) in compliance with the Animals 
(Scientific Procedures) Act 1986. All testing took place between the hours of 09:00 
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and 14:00, with equal distribution of testing for subjects of different genotypes 
throughout the day. Prior to testing, mice were habituated to the test rooms for at 
least 40 minutes. 
 
7.2.2 General behavioural methods  
 All testing took place between the hours of 07:00 and 13:00, with equal 
distribution of testing for subjects of different genotypes throughout the day. Prior 
to testing, mice were habituated to the test rooms for at least 20 minutes. 
 
7.2.3 Reinforcer habituation 
Habituation to the condensed milk (CM) reinforcer used to motivate 
performance in the SSRTT took place as previously described in Chapter II, Section 
2.3.5. Once body weight had stabilised on the water restriction schedule (ca.10 days) 
the mice were habituated to the reinforcer (10% condensed milk solution, Nestle 
Ltd, U.K.). This was done so that any neophobic (fear of the novel) responses to the 
solution could be reduced before SSRTT testing got underway, and also to assess any 
pre-existing individual subject differences in reinforcer preference. Any subjects 
failing to reach 70% preference for the CM on the final day of preference or failing to 
consume CM on the milk vs. milk day were excluded from the SSRTT. 
 
7.2.4 The stop-signal reaction time task (SSRTT) 
Testing was carried out in “9-hole” operant chambers (Cambridge Cognition 
Ltd, U.K.) based on a design first used in rats (Carli et al., 1983) and tailored for use in 
mice (Humby et al., 1999). A full description of the SSRTT apparatus can be found in 
Chapter II, Section 2.4.9. In the SSRTT, the presentation of a stop-signal indicated 
that the response had to be cancelled. As described in detail below, the task (Fig. 7.1 
allowed an explicit behavioural measure of stopping performance (successful 
stopping) and a calculated determination of the latency to stop (SSRT). In addition, 
the task provided a wide range of ancillary behaviours that, importantly, allowed 
dissociations between stopping and going behaviours, and also gave some within-
task indications of sensorimotor and motivational functions. Subjects performed one 
20-minute session per day, with a maximum of 100 trials per session. In sessions 
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where stopping was assessed a minority of stop trials (20%) were randomly 
distributed amongst the majority go trials (80%).  
 
Figure 7.1: The stop-signal reaction time task (SSRTT) procedure. 
    
 
 
The left stimulus light is illuminated signaling the beginning of the trial (A). The mouse makes a left 
nose-poke (B) which in Go trials triggers the right stimulus light to be illuminated for a limited time 
(the limited hold) and the mouse to make a right nose-poke (C), which is then rewarded with a food 
delivery (D). In stop trials, a burst of white noise was played after the left nose-poke, indicating to 
subjects that they should withhold their response at the right aperture (E) in order to be rewarded. 
Incorrect responses (failing to nose poke on Go trials or going on Stop trials) incurred both a timeout 
period and a lack of reward. 
 
7.2.4.1 Initial behavioural training 
Initial training involved animals being trained to push the food magazine 
panel to retrieve the CM reinforcer. These training sessions occurred consecutively 
over 5 days, with mice consistently allocated to the same chamber over the course 
of the SSRTT testing duration. During the first three sessions of this training, the 
panel to the food magazine was wedged open, and the apertures in the response 
array were blocked with clear plastic film. Subjects were presented with 22μl of 
condensed milk in the food magazine every 30 seconds for twenty minutes, 
indicated by the illumination of the tray light coincident to the food delivery. After 
the session, food magazines were checked to see whether subjects had been 
       B 
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E 
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drinking. During the last 2 days of shaping, the food magazine panels were not 
wedged open, so subjects had to learn to panel push to gain access to the food. Mice 
that failed to panel-push or had not collected the reward were given additional 
training. Once all subjects had learnt to panel-push, they were moved onto the single 
nose poke phase of the SSRTT training.  
 
7.2.4.2 Initial shaping of behaviour for the SSRTT  
In the first phase of SSRTT training, subjects were trained to make a single 
nose-poke response, the ‘initiation nose-poke’, at the initiation stimulus location (3rd 
aperture from the left of the nose-poke array). Each session began with a 22μl 
condensed milk delivery into the food magazine.  On collection of this reward, a trial 
was started with the illumination of the initiation stimulus. When a nose-poke was 
made into this illuminated aperture, the light stimulus was extinguished and the 
reward was delivered; on collection the next trial was started. The initiation stimulus 
duration was initially set to 30s, and failure to make a nose-poke within this period 
was punished with a time-out period of 5 seconds indicated by illumination of the 
house-light, and those trials were recorded as non-started. As subjects became 
quicker at responding to the initiation stimulus, the presentation time was reduced 
until stimuli durations of 20s were achieved. Within a session following 4 consecutive 
responses the stimulus duration was reduced by 5s, and new sessions started with 
the final value achieved in the previous session for each individual mouse (minimum 
duration was 20s). Subjects moved to the next stage of training when they 
completed >70% of trials with a 20s initiation stimulus duration, for 3 consecutive 
sessions. 
In the second phase of training, the subjects had to make a second nose-poke 
(the ‘go’ response) after the initiation nose-poke to earn reward. Thus, following a 
correct initiation nose-poke, the go stimulus aperture (6th aperture from the left of 
the nose-poke array) was illuminated. A correct nose-poke at this location now 
initiated delivery of the reward. Failure to make an initiation nose-poke or a go nose-
poke were punished by a 5s time-out. The initiation stimulus duration was fixed at 20 
seconds, and the initial go stimulus duration was set to 30s. Within a session 
following 4 consecutive correct go responses the go stimulus duration was reduced 
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by 5s, until it was equivalent to the go response latency (the go reaction time, Go-RT) 
of each individual mouse, plus 0.3s. New training sessions started with the final value 
achieved in the previous session for each individual mouse. Subjects moved to the 
next stage of training when they completed >70% of trials and made >70% correct go 
responses with a Go stimulus duration equivalent to their Go-RT, for 3 consecutive 
sessions.  
7.2.4.3 Shaping stopping behaviour 
During shaping of stopping behaviour a stop-signal (65 decibels of white 
noise for 0.3s) was presented after the initiation nose-poke on 20% of the trials (the 
other 80% being go trials) and the mice had to learn to cancel their ongoing response 
and wait for a set amount of time in order to earn a reward. In this phase of training 
stopping was relatively easy since the stop-signal was presented very close to the 
initiation nose-poke, i.e. at the start of the go response and was classed as a 0% 
stop-signal position. The initiation stimulus duration was fixed at 20s, the Go 
stimulus duration was equivalent to the individual mouse’s Go-RT and the initial stop 
limited hold (LH) period was set to 0.35s, a period slightly longer than the duration of 
the white noise burst, enabling the mice to hear the reward delivery.  The stop LH 
was increased in 0.1s increments following 4 consecutive correctly performed stop 
trials, and new sessions started with the final value achieved in the previous session 
for each individual mouse. Subjects moved to the next stage of testing when they 
completed >70% of trials, made >70% correct go responses with a Go stimulus 
duration equivalent to their Go-RT and made >70% correct stop trials, for 3 
consecutive sessions.  
 
7.2.4.4 Manipulation of the stop-signal delays 
Baseline was determined as stable performance for 3 consecutive sessions at 
the following criteria: >70% of trials initiated, >70% correct go responses with a Go 
stimulus duration equivalent to individual Go-RTs and >70% correct stop trials at a 
stop LH equivalent to the Go stimulus duration with 0% stop-signal presentations. To 
further assess stopping behaviour, the mice were tested in probe sessions where the 
stop-signal was presented at different positions within the individual Go-RT of each 
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subject. Thus, stopping was made increasingly more difficult by presenting the stop-
signal 10, 20, 30, 40, 50, 60, 70, 80 and 90% of the way through the Go-RT; the 
nearer the stop-signal was to the execution of the go response, the harder it would 
be to stop the response. The SSRTT study utilised software that provided an on-line 
monitoring of the Go-RT for each mouse and calculated the stop-signal position as a 
percentage of the mean on-going Go-RT for each individual subject. Therefore, if the 
subject’s Go-RT changed during the session then the stop-signal position was 
recalculated for the next stop trial. Stop-signal positions were changed between 
sessions but not within them. Each probe session was implemented following a 
baseline session where subjects had performed to criterion. 
 
7.2.4.5 Calculating the stop-signal reaction time (SSRT) 
SSRTs were estimated using the procedure described in Logan & Cowan 
(1984) from data where the correct stopping of each subject was 50±10% (a worked 
example is given in Appendix 6.1). Individual data for each subject from the sessions 
where the stop-signal position was altered were ranked and individual means 
calculated from sessions where the mice performed 50% correct stopping ±10%; any 
subject with mean % correct stopping which were greater than ±10% from 50% were 
excluded from further analysis of the SSRT. The stop-signal delay (SSD) was 
calculated for each subject as the stop-signal position*Go-RT, where the mean stop-
signal position was calculated for the different sessions specified above. To calculate 
the SSRT, Go-RTs were rank ordered and the nth Go-RT was obtained (where n was 
the number obtained by multiplying the number of Go-RTs in the distribution by the 
probability of responding on stop trials at that stop-signal delay). This value was the 
estimated time where the stopping process finished, relative to the onset of the go 
stimulus. The SSRT (the time where the stopping process finished relative to the 
stop-signal) was then obtained by subtracting the stop-signal delay (SSD) from this 
value (see Humby et al., 2013). 
 
7.2.4.6 Behavioural measures 
Task acquisition of the SSRTT was determined by the number of sessions 
required for each subject to reach SSRTT baseline performance, and the number of 
158 
 
sessions needed to complete each of the SSRTT training phases. A number of 
different behavioural measures were recorded for each session: correct go 
responses, Go-RT, correct stop responses, percentage of trials initiated (indexing 
levels of motivation), the latency to initiate a trial and latency to collect reward. The 
final initiation and go stimuli durations, and the stop LH, were also assessed as 
overall SSRTT performance could be affected by differences in these parameters. The 
SSD and the SSRT were also calculated when the mice showed 50% correct stopping, 
according the rationale of Logan & Cowan (1984).  
 
7.2.5 Statistical analysis 
The experimental data was analysed using SPSS (Version 18.0). Behavioural 
data are presented as mean values (M) with the standard error of the mean (SEM), 
unless stated otherwise. As the key point of interest was whether the Zfp804a 
mutant mice demonstrated altered behavioural information, particular focus was 
placed upon the point at which the go and stop responses were at maximal 
competition (Logan & Cowan, 1984); i.e. where stopping was ~50%. Data for each 
strain were analysed separately, and separate ANOVAs were performed with 
between subjects factor of GENOTYPE (homozygous ENU-mutant vs. WT littermate 
control) and within subject factors as appropriate, i.e. SESSION (first, last) for 
acquisition data, STOP-SIGNAL POSITION (Baseline, 50%) for stop-signal position 
manipulations and SESSION (baseline, 50%) for the comparison of 50% stop 
responding. All significance tests were performed at alpha level of 0.05 and where 
significant interactions were identified in the main ANOVA, post-hoc tests using 
appropriate pair-wise comparisons were performed. Data were screened for skewed 
variance with arcsine transformations applied to skewed data (percentage data in 
particular) to obtain a normal distribution. Greenhouse-Geisser degrees of freedom 
(df) corrections were applied as required to repeated-measures factors. Outliers 
which were 2 standard deviations or more from the mean were removed from the 
analysis. 
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7.3 Results 
7.3.1 Zfp804a C59X line 
7.3.1.1 Task acquisition 
There was no difference in the final  CM preference between C59X 
homozygous ENU-mutants (86%) and their WT littermate (88%) controls (t27= 0.3, 
p=0.81). Of the 29 C59X subjects that commenced the SSRTT, 28 subjects managed 
to complete the task, with only one C59X homozygous ENU-mutant mouse failing to 
reach training criteria performance (Section 7.2.4.2). There were no differences 
between the genotype groups of C59X mice in terms of the number of sessions (ca.7) 
required to reach stable baseline performance at criteria responding (t26= -0.4, 
p=0.71). During the initial shaping stages of training when the mice were learning to 
make the initiation nose-poke, the number of completed trials increased by almost 
20% (main effect of SESSION, F1,27= 12.3, p=0.002, SESSION*GENOTYPE, F1,27= 0.04, 
p=0.84), and the latency to initiate a trial was over 100% quicker between the first 
and last sessions (main effect of SESSION, F1,27= 189.5, p=0.000, SESSION*GENOTYPE, 
F1,27= 0.002, p=0.96). There were no differences between C59X homozygous ENU-
mutant and WT littermate control mice for either of these measures at this stage of 
training (main effect of GENOTYPE, F1,27= 0.5, p=0.61, and F1,27= 0.3, p=0.51, 
respectively).  
In the next stage of training, the go response was introduced, whereby the 
mice had to make a 2nd nose-poke after the initiation nose-poke in order to earn a 
reward. Both C59X homozygous ENU-mutants and their WT littermate controls 
completed this stage of training in ca.9 sessions (t26= 1.3, p=0.21), acquiring the go 
response readily (Table 7.2), and reaching high levels of correct responding (main 
effect of SESSION, F1,26= 0.00, p=0.99, SESSION*GENOTYPE, F1,26= 0.003, p=0.96). As 
might be expected, and reflecting the increasing stimulus control as training 
progressed, the speed of responding improved through training for the first (M= 
5267ms) and last (M= 859ms) sessions respectively, main effect of SESSION, F1,25= 
73.7, p=0.000, SESSION*GENOTYPE, F1,25= 1.1, p=0.3), although no difference was 
observed between the two C59X genotype groups of mice (main effect of 
GENOTYPE, F1,25= 0.69, p=0.41).  
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 In the final stage of training, the stop-signal was introduced at the start of the 
go response (i.e. 0% position) in 20% of the trials. It took all mice from the C59X line 
ca.10 sessions to reach stable performance criteria and again there were no 
significant differences between C59X homozygous ENU-mutants and their WT 
littermate controls (t26= 0.3, p=0.77). There was a reduction in the percentage of 
correct stopping during training, with C59X mice achieving 100% correctly stopped 
trials in the first sessions compared to 85% correctly stopped trials on average in the 
last session through training (Table 7.2, main effect of SESSION, F1,26= 49.14, 
p=0.000), most likely as a result of the increase in stop LH. A significant interaction 
between SESSION and GENOTYPE (F1,26= 7.93, p=0.009) demonstrated that C59X 
homozygous ENU-mutant mice achieved higher levels of performance than their WT 
counterparts by the end of training (p=0.009). As predicted by the theory that going 
and stopping are dissociable but competing processes (Logan & Cowan, 1984), the 
introduction of the stop-signal stimulus in training had no effect on go responding, 
which remained unchanged from the previous training stage and at high levels of 
correct performance (main effect of SESSION, F1,26= 0.02, p=0.89, 
SESSION*GENOTYPE, F1,26= 0.4, p=0.55), although there was a further increase in the 
speed of go responding by all of the mice (main effect of SESSION, F1,25= 10.35, 
p=0.004, SESSION*GENOTYPE, F1,26= 0.4, p=0.53). These patterns of behaviour were 
equivalent between C59X homozygous ENU-mutants and WT littermate controls 
(main effect of GENOTPYE, F1,26= 3.33, p=0.08, and F1,25= 0.12, p=0.73, for correct go 
responses and Go-RTs, respectively). Taken together, the data from the training to 
baseline of the SSRTT indicated no differences between C59X homozygous ENU-
mutants and their WT littermate controls in the way that they acquired criteria 
performance for the different components of the SSRTT. 
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Table 7.2: Task acquisition in Zfp804a C59X mice. 
Behavioural Parameter C59X Genotype 
Single nose-poking Double nose-poking Learning to stop 
First Last First Last First Last 
End Initiation stimulus duration 
(s) 
WT 24.6 ± 1.5 11 ± 0.7 20 ± 0 20 ± 0 20 ± 0 20 ± 0 
Homozygous 23.9 ± 1.4 10 ± 0.7 20 ± 0 20 ± 0 20 ± 0 20 ± 0 
Number of trials initiated (%) 
WT 44.3 ± 5.7 
43/5 
62.0 ± 4.5 
75.5 
60.8 ± 4.6 67.9 ± 4.0 67.8 ± 2.9 75.4 ± 3.8 
Homozygous 32.6 ± 5.3 54.0 ± 6.2 61.6 ± 5.4 67.2 ± 3.4 67.3 ± 3.3 73.5 ± 3.5 
Latency to initiate a trial (s) 
WT 13.3 ± 0.9 
13.6 
4.4 ± 0.3 3.5 ± 0.4 7.7 ± 0.8 6.5 ± 0.5 5.2 ± 0.4 
Homozygous 13.6 ± 0.9 4.8 ± 0.3 4.7 ± 0.4 7.0 ± 0.7 7.6 ± 0.4 6.6 ± 0.4 
End Go stimulus duration (s) 
WT . . 8.4 ± 2.1 1.2 ± 0.05 9.5 ± 0.4 9.5 ± 0.4 
Homozygous . . 11.7 ± 1.9 1.1 ± 0.04 9.6 ± 0.4 9.6 ± 0.4 
Correct go trials (%) 
WT . . 80.8 ± 3.1 79.1 ± 2.4 77.7 ± 3.2 79.3 ± 3.8 
Homozygous . . 78.7 ± 3.6 82.3 ± 2.0 78.7 ± 3.2 77.7 ± 2.3 
Correct go reaction time (Go-RT, 
ms) 
WT . . 4765 ± 791 904 ± 43.1 852 ± 31.7 760 ± 32.4 
Homozygous . . 5768 ± 708 813 ± 38.5 823 ± 30.5 762 ± 31.2 
Latency to collect the reward (s) 
WT . . 1.9 ± 1.1 3.1 ± 0.8 2.5 ± 1.5 2.6 ± 0.6 
Homozygous . . 3.3 ± 1.0 2.7 ± 0.7 5.5 ± 1.4 2.7 ± 0.6 
End stop limited hold (ms) 
WT . . . . 504 ± 24.9 712 ± 28.8 
Homozygous . . . . 497 ± 23.2 680 ± 26.8 
Correct stop trials (%) 
WT . . . . 100 ± 0.0 86.7 ± 3.8 
Homozygous . . . . 100 ± 0.0 82.3 ± 3.5 
Data shows mean ± SEM 
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7.3.1.2 SSRTT performance at baseline 
Baseline performance was calculated by averaging parameter values across 
all sessions which preceded each of the stop-signal manipulation sessions. During 
baseline sessions, the stop-signal was played concurrently with the onset of the go 
response (i.e. 0% of the individual Go-RT for each subject). There were no significant 
differences between C59X homozygous ENU-mutant mice and their WT littermate 
controls in terms of the key task parameters which dictated how the mice performed 
the SSRTT, such as the duration of the initiation and go stimuli and the stop LH (Table 
7.3).  
 
Table 7.3: Baseline SSRTT performance in Zfp804a C59X mice. 
 WT Homozygous   
Behavioural 
Parameter 
Mean Mean T statistic p-value 
Initiation stimulus 
duration (s) 
20.00±0.00 20.00±0.00 n.a. n.a. 
Go stimulus 
duration (ms) 
997.01±32.65 919.33±41.59 t26=1.4 p=0.16 
Stop limited hold 
(ms) 
676.92±30.28 673.33±21.75 t26=0.1 p=0.92 
Number of trials 
initiated (%) 
82.75±2.25 87.35±1.66 t26=-1.7 p=0.11 
Latency to initiate 
a trial (s) 
5.47±0.40 4.36±0.30 t26=-2.3 p=0.03 
Correct go trials 
(%) 
85.88±1.12 84.90±1.35 t26=0.4 p=0.67 
Correct stop trials 
(%) 
86.47±2.19 88.42±2.04 t26=-0.6 p=0.54 
Correct go reaction 
time (Go-RT, ms) 
726.19±20.22 650.48±17.46 t26=2.9 p=0.008 
Latency to collect 
the reward (s) 
1.67±0.25 1.48±0.17 t26=0.6 p=0.53 
Initiation nose-
pokes/trial (n) 
0.97±0.03 0.97±0.02 t26=0.01 p=0.10 
Go nose-
pokes/trial (n) 
0.78±0.04 0.76±0.02 t26=0.6 p=0.58 
Panel-pushes/trial 
(n) 
1.57±0.29 1.00±0.06 t26=2.03 p=0.053 
Beam-breaks/trial 
(n) 
7.63±0.70 8.26±0.71 t26=-0.6 p=0.54 
Data shows mean ± SEM 
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In general both genotypes of the C59X line initiated the same amount of trials within 
each session, but homozygous ENU-mutant mice were noticeably quicker to do this 
than their WT littermates (t26=-2.3, p=0.03). Likewise there were no differences in 
the amount of correct go (t26=0.4, p=0.67) and stop trials (t26= -0.6, p=0.54), but 
again, C59X homozygous ENU-mutant mice had shorter response latencies when 
making the go response (t26=2.9, p=0.008). There were no genotype-related 
differences in other task measures, such as the latency to collect the reward, 
numbers of nose pokes or number of beam breaks suggesting that there were no 
differences in motivation or locomotion between C59X homozygous ENU-mutant 
mice and WT littermate controls at baseline in the SSRTT. 
 
7.3.1.3 The effects of varying the stop-signal delay on SSRTT performance 
Once the mice had attained a stable baseline performance, where the stop-
signal was presented at the start of the go response, they were then moved onto 
sessions where the stop-signal was presented at different positions to assess the 
ability to stop the response. As expected, there was a systematic decrease in the 
amount of correctly stopped trials made by all genotype of the C59X line as the stop-
signal position was moved progressively into the individualised Go-RTs of the mice 
(Fig. 7.2A, main effect of STOP-SIGNAL POSITION, F5.2,133.1= 18.7, p=0.000, STOP-
SIGNAL POSITION*GENOTYPE, F5.2,133.1= 0.8, p=0.57). The specificity of this 
manipulation to stopping was confirmed by an absence of any significant effects on 
the proportion of correct go trials (Fig. 7.2B, main effect of STOP-SIGNAL POSITION, 
F5,130.2=0.7, p=0.66, SIGNAL POSITION*GENOTYPE, F5,130.2= 1.0, p=0.45), and the 
latency of correct go responding (Fig. 7.2C, main effect of STOP-SIGNAL POSITION, 
F5.3,136.7=2.1, p=0.07).  
 Consistent with the pattern of behaviour shown at baseline, C59X 
homozygous ENU-mutant mice were quicker at making go responses than their WT 
littermate controls (main effect of GENOTYPE, F1,26=7.6, p=0.01), but overall 
responding in go trials was not different (main effect of GENOTYPE, F1,26=0.1, 
p=0.71). By observation, C59X homozygous ENU-mutant mice appeared to better at 
stopping (Fig. 7.2A, however, this apparent effect did not reach significance (main 
effect of GENOTYPE, F1,26=1.1, p=0.31). 
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Figure 7.2. Effect of varying the stop-signal position on SSRTT performance in 
Zfp804a C59X mice. 
  
    
 
 
Moving the position of the stop-signal within the individualised go responses of each subject led to a 
systematic decrease in the ability of the mice to withhold responding, as shown by the proportion of 
correctly stopped trials (A), however this manipulation did not significantly affect correct responding 
in go trials (B). Although there was a tendency for C59X homozygous ENU-mutant mice to show 
better stopping behaviour, this was not significant, nor was the percentage of correct go trials made 
by the two groups of mice. However, C59X homozygous ENU-mutant mice were quicker than their 
WT littermate controls to make a response in go trials (C). Data shows the mean values ±SEM, 
*p<0.05 for pairwise differences related to genotype. For subject N see Table 7.1 and text. 
 
As mentioned previously, a key consideration in interpreting the SSRTT was 
to assess performance of this task at the point where competition between the go 
and stop responding was at its greatest, estimated to be where the proportion of 
correct responses were equal to 50%, which also permits calculation of the latency 
to stop responding (SSRT). To determine this, the data for each subject from the 
sessions in which the stop-signal position was moved was ranked by the proportion 
of correct responses and those between 40% and 60% (i.e. 50%±10%) were 
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averaged. Any subject outside of this range was removed from the analysis. One 
C59X homozygous ENU-mutant mouse (mean stopping of 71%) and one WT mouse 
(mean stopping of 74%) were therefore removed leaving final subject numbers of 14 
and 12 for the C59X homozygous ENU-mutant (mean stopping = 51.63±1.38%) and 
WT (mean stopping = 47.63±2.51%) groups, respectively. C59X homozygous ENU-
mutant mice had significantly shorter SSRTs than their WT littermate controls (Fig. 
7.3A, t24=2.3, p=0.03) which would be consistent with improved inhibitory control by 
these mice (increased SSRTs are associated with worse stopping, e.g. Humby et al., 
2013). When the mice were showing 50% stop responding, there were still no 
differences in the proportion of correct responding between C59X homozygous ENU-
mutant and WT mice (Fig. 7.3B, main effect of GENOTYPE, F1,24= 0.7, p=0.4) and 
performance did not differ from baseline (main effect of SESSION, F1,24= 0.5, p=0.49, 
SESSION*GENOTYPE, F1,24= 1.5, p=0.23). C59X homozygous ENU-mutant mice, 
however, were consistently quicker in making go responses than their WT littermate 
controls (Fig. 7.3C, main effect of GENOTYPE, F1,24= 9.3, p=0.005), although response 
speed did not differ from baseline (main effect of SESSION, F1,24=0.3, p=0.62, 
SESSION*GENOTYPE, F1,24= 0.6, p=0.44).  
There were no differences between the two groups of C59X mice in a number 
of ancillary behaviours including the amount of trials initiated (Fig. 7.3D, main effect 
of GENOTYPE, F1,24=2.9, p=0.1) or the latency to collect the reward (Fig. 7.3F, main 
effect of GENOTYPE, F1,24=1.6, p=0.23), but C59X homozygous ENU-mutant mice 
were significantly quicker to initiate a trial than their WT counterparts (Fig. 7.3E, 
main effect of GENOTYPE, F1,24=5.5, p=0.03). These measures did not differ between 
baseline performance and when the mice were showing 50% stop responding (main 
effect of SESSION, F1,24=0.07, p=0.8, F1,24=0.04, p=0.85, and F1,24=0.03, p=0.86, for 
proportion of trials initiated, latency to initiate a trial and latency to collect reward, 
respectively). There were no significant differences between C59X homozygous ENU-
mutant mice and WT littermate controls for other task measures such as the number 
of initiation and go nose-pokes, food magazine panel-pushes and locomotion in the 
test chambers, measured as infra-red beam breaks (data not shown). 
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Figure 7.3. SSRTT performance in C59X mice at 50% stopping. 
  
    
 
 
 
Normalising performance to 50% correct stopping, where the go and stop responses were 
equivalent, allowed calculation of the SSRT; the latency to stop a response. C59X homozygous ENU-
mutant mice had significantly shorter SSRTs than their WT littermate controls (A), suggesting 
improved stopping, i.e. enhanced response inhibition. There was no difference in the go response 
(B), and going was equivalent to baseline responding. There was also no difference in the Go-RT (C), 
amount of trials started (D), latency to initiate trials (E) or latency to collect the reward (F) between 
baseline and performance at 50% stopping. The pattern of C59X homozygous ENU-mutant mice 
making quicker go responses was maintained, however, and these mice were also faster to initiate a 
trial than their WT littermate controls. Data shows the mean values ±SEM, *p<0.05 for pairwise 
differences related to genotype. For subject N see Table 7.1 and text. 
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7.3.2 Zfp804a C417Y line 
7.3.2.1 Task acquisition 
There was no difference in the final  CM preference between C59X 
homozygous ENU-mutants (83%) and their WT littermate (87%) controls (t28= -0.8, 
p=0.42). Of the 29 C417Y subjects that commenced the SSRTT, 28 mice managed to 
complete the task, with a single C417Y homozygous ENU-mutant subject failing to 
reach baseline. There was no differences between the genotype groups of C417Y 
mice in terms of the number of sessions (ca.7) required to reach stable baseline 
performance at criteria responding (t26= 0.3, p=0.74). The overall percentage of trials 
that were completed increased between the first and last session of this phase of 
training (Table 7.4), although this increase was not found to be significant (main 
effect of SESSION, F1,27= 2.4, p=0.13, SESSION*GENOTYPE, , F1,27= 0.1, p=0.73), but 
the latency to initiate a trial had significantly decreased (main effect of SESSION, 
F1,27= 61.5, p=0.000, SESSION*GENOTYPE, , F1,27= 0.001, p=0.97). C417Y homozygous 
ENU-mutant mice and their WT littermate controls did not significantly differ for 
either of these measures (main effect of GENOTYPE, F1,27= 0.2, p=0.63, and F1,27= 1.3, 
p=0.26, respectively). 
All mice from the C417Y line achieved criteria and completed the double 
nose-poke phase, 2nd stage, of training in ca.9 sessions, with no significant difference 
observed between genotypes (t26= -0.3, p=0.77). Although C417Y homozygous ENU-
mutants made significantly less correct go responses than their WT counterparts 
(main effect of GENOTYPE, F1,26= 4.7, p=0.04), overall performance by both groups 
was consistently greater than criteria (ca.78%) from the first session of this stage of 
training (main effect of SESSION, F1,26= 0.03, p=0.87, SESSION*GENOTYPE, , F1,26= 0.4, 
p=0.55). There was a significant reduction in the latency to make a correct go 
response between the first (M= 5628ms) and the last session (M= 854ms) of this 
phase of training (main effect of SESSION, F1,22= 65.7, p=0.000, SESSION*GENOTYPE, , 
F1,22= 0.8, p=0.39, Table 7.4), although no difference was observed between the 
different C417Y genotype groups of mice (main effect of GENOTYPE, F1,22= 0.5, 
p=0.49). There were also no group differences in the amount of trials initiated during 
this stage of training (main effect of GENOTYPE, F1,26= 0.13, p=0.72), although all 
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mice from the C417Y line showed an increase in the number of trials completed 
(main effect of SESSION, F1,26= 5.05, p=0.03, SESSION*GENOTYPE, F1,26= 0.2, p=0.69).  
Once at criteria responding, the mice were moved to the final stage of 
training where a stop-signal was presented at the start of the go response (i.e. 0% 
position) for 20% of the trials. C417Y homozygous ENU-mutant and WT littermate 
controls demonstrated good stopping behaviour from the first to the last session, 
with consistently high correct stop responses (~86%) throughout training (main 
effect of SESSION, F1,26= 3.5, p=0.07, SESSION*GENOTYPE, F1,26= 0.6, p=0.46), with no 
significant differences between genotypes (F1,26= 1.5, p=0.24). The amount of correct 
go responses made by the C417Y mice continued to increase (main effect of 
SESSION, F1,26= 4.9, p=0.04, SESSION*GENOTYPE, F1,26= 1.71, p=0.2) and the speed of 
go responding increased (main effect of SESSION, F1,24= 15.4, p=0.001), although the 
previous difference in correct go responses between C417Y homozygous ENU-
mutants and WT littermate controls had now disappeared (main effect of 
GENOTYPE, F1,26= 0.2, p=0.65); go reaction times were not different between the 
groups of mice (main effect of GENOTYPE, F1,24= 0.5, p=0.48). All mice from the 
C417Y line (t26= 1.3, p=0.21) completed the learning to stop stage of SSRTT in ca.11 
sessions. Therefore, there were no fundamental differences between C417Y 
homozygous ENU-mutant and WT littermate controls in the way that they acquired 
criteria performance for the different components of the SSRTT. 
 
7.3.2.2 SSRTT performance at baseline 
 As before, baseline performance was calculated by averaging parameter 
values across all sessions which preceded each of the stop-signal manipulation 
sessions. During baseline sessions, the stop-signal was played concurrently with the 
onset of the go response (i.e. 0% of the individual Go-RT for each subject). There 
were no significant differences between C417Y homozygous ENU-mutants and their 
WT littermate controls in terms of the critical task parameters which dictated how 
the mice performed the SSRTT, the initiation and go stimuli as well as the stop LH 
(Table 7.5). Mice from the C417Y line initiated the same amount of trials, with 
equivalent latencies, but C417Y homozygous ENU-mutant mice made more correct 
go response than their WT littermate controls (t26=-2.2, p=0.04).  
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Table 7.4: Task acquisition in Zfp804a C417Y mice. 
Behavioural Parameter C417Y Genotype 
Single nose-poking Double nose-poking Learning to stop 
First Last First Last First Last 
End Initiation stimulus duration 
(s) 
WT 22.9 ± 1.5 11.1 ± 0.8 20 ± 0 20 ± 0 20 ± 0 20 ± 0 
Homozygous 22.4 ± 1.5 10.3 ± 0.7 20 ± 0 20 ± 0 20 ± 0 20 ± 0 
Number of trials initiated (%) 
WT 47.4 ± 5.7 
32.6 
60.1 ± 3.7 62.1 ± 3.9 71.9 ± 2.7 69.5 ± 3.1 75.3 ± 3.4 
Homozygous 48.9 ± 6.4 52.3 ± 5.2 56.7 ± 4.9 64.0 ± 3.8 64.4 ± 4.0 71.9 ± 3.7 
Latency to initiate a trial (s) 
WT 13.6 ± 0.9 6.0 ± 0.8 5.7 ± 0.8 6.7 ± 0.5 7.1 ± 0.4 6.1 ± 0.6 
Homozygous 12.7 ± 0.9 5.2 ± 0.8 4.9 ± 0.7 6.9 ± 0.4 7.1 ± 0.7 6.2 ± 0.5 
End Go stimulus duration (s) 
WT . . 9.8 ± 1.8 1.1 ± 0.08 9.8 ± 0.8 9.8 ± 0.8 
Homozygous . . 10.0 ± 2.0 1.2 ± 0.09 9.9 ± 0.5 9.9 ± 0.5 
Correct go trials (%) 
WT . . 81.0 ± 2.5 80.7 ± 3.0 64.6 ± 6.6 79.7 ± 2.6 
Homozygous . . 74.3 ± 5.5 80.4 ± 1.9 79.2 ± 3.8 81.2 ± 2.8 
Correct go reaction time (Go-
RT, ms) 
WT . . 6110 ± 925 814 ± 84.3 781 ± 50.3 723 ± 26.0 
Homozygous . . 5146 ± 782 893 ± 71.3 870 ± 46.5 700 ± 24.1 
Latency to collect the reward 
(s) 
WT . . 1.6 ± 1.1 2.7 ± 0.7 3.5 ± 0.7 2.5 ± 0.6 
Homozygous . . 3.7 ± 1.0 3.1 ± 0.6 2.5 ± 0.6 2.8 ± 0.6 
End stop limited hold (ms) 
WT . . . . 473 ± 35.1 650 ± 23.1 
Homozygous . . . . 483 ± 32.7 710 ± 21.5 
Correct stop trials (%) 
WT . . . . 92.9 ± 7.1 85.7 ± 3.5 
Homozygous . . . . 91.4 ± 7.2 75.0 ± 6.0 
Data shows mean ± SEM    
 
 
 
 
There were no differences in the speed of responding to the go stimuli or in the amount of 
correctly stopped trials. Other task measures, such as the latency to collect the reward, 
numbers of nose pokes and beam breaks also did not differ between the different genotype 
groups of the C417Y line, suggesting that there were no differences in motivation or 
locomotion between C417Y homozygous ENU-mutants and their WT littermate controls at 
baseline in the SSRTT. 
 
Table 7.5: Baseline SSRTT performance in Zfp804a C417Y mice. 
 WT Homozygous   
Behavioural 
Parameter 
Mean Mean T statistic p-value 
Initiation stimulus 
duration (s) 
20.00±0.00 20.00±0.00 n.a. n.a. 
Go stimulus duration 
(ms) 
917.69±49.20 1037.33±78.29 t26=-1.3 p=0.22 
Stop limited hold 
(ms) 
657.69±15.86 690.00±22.47 t26=-1.2 p=0.25 
Number of trials 
initiated (%) 
81.64±2.74 84.18±2.11 t26=-0.7 p=0.49 
Latency to initiate a 
trial (s) 
4.89±0.41 4.96±0.51 t26=-0.1 p=0.92 
Correct go trials (%) 81.91±1.57 86.16±1.24 t26=-2.2 p=0.04 
Correct stop trials (%) 87.28±2.26 85.92±2.59 t26=0.4 p=0.71 
Correct go reaction 
time (Go-RT, ms) 
671.73±33.89 668.79±17.13 t26=0.08 p=0.94 
Latency to collect the 
reward (s) 
1.54±0.15 1.46±0.14 t26=0.4 p=0.71 
Initiation nose-
pokes/trial (n) 
0.95±0.03 0.97±0.03 t26=-0.6 p=0.58 
Go nose-pokes/trial 
(n) 
0.72±0.03 0.79±0.03 t26=-1.8 p=0.09 
Panel-pushes/trial (n) 0.88±0.06 1.30±0.19 t26=-2.0 p=0.06 
Beam-breaks/trial (n) 7.26±0.67 7.41±0.66 t26=-0.2 p=0.87 
Data shows mean ± SEM 
 
7.3.2.3 The effects of varying the stop-signal delay on SSRTT performance 
Once mice from the C417Y line had attained stable baseline performance in the 
SSRTT, their ability to stop the go response was assessed in sessions where the stop-signal 
was presented at different positions within the individualised Go-RTs of the mice. As 
expected, moving the stop-signal position led to a systematic decrease in the amount of 
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correctly stopped trials made (Fig. 7.4A, main effect of STOP-SIGNAL POSITION, 
F5.5,141.9=22.9, p=0.000, STOP-SIGNAL POSITION*GENOTYPE, F5.5,141.9= 0.8, p=0.55), without 
affecting the go response in terms of the amount of correct go trials (Fig. 7.4B, main effect 
of STOP-SIGNAL POSITION, F5.2,134.6=0.9, p=0.5, STOP-SIGNAL POSITION*GENOTYPE, F5.2,134.6= 
1.5, p=0.18), nor speed of responding (Fig. 7.4C, main effect of STOP-SIGNAL POSITION, 
F5.3,137.1=0.9, p=0.51, STOP-SIGNAL POSITION*GENOTYPE, F5.3,137.1= 1.96, p=0.09).  
Figure 7.4: Effect of varying the stop-signal position on SSRTT performance in 
Zfp804a C417Y mice. 
  
    
 
 
Moving the position of the stop-signal within the individualised go responses of each subject led to a 
systematic decrease in the ability of the mice to withhold responding, as shown by the proportion of 
correctly stopped trials (A), however this manipulation did not significantly affect correct responding 
in go trials (B) or in the time required to make the go response (C). There was no significant 
genotype difference in the number of correctly stopped trials nor in the time required to make a go 
response, however, C417Y homozygous ENU-mutants made significantly more correct go responses 
than their WT littermate controls across the range of manipulation sessions. Data shows the mean 
values ±SEM, *p<0.05 for pairwise differences related to genotype. For subject N see Table 7.1 and 
text. 
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Moving the stop-signal position did not generate any specific differences between C417Y 
homozygous ENU-mutants and WT littermate controls, a finding consistent with baseline 
performance. Thus, there were no genotype-related differences in stopping (main effect of 
GENOTYPE, F1,26=1.8, p=0.19), or the latency to make a go response (main effect of 
GENOTYPE, F1,26=0.004, p=0.95). However, C417Y homozygous ENU-mutant mice made 
significantly more correct go responses than their WT littermate controls across the range of 
manipulation sessions (main effect of GENOTYPE, F1,26=5.3, p=0.03). 
 To investigate stopping performance at the point where competition between the go 
and stop responding was at its greatest (i.e. where the proportion of correct responses were 
equal to 50%), the data for each subject from the sessions in which the stop-signal position 
was moved was ranked by the proportion of correct responses and those between 40% and 
60% (i.e. 50%±10%) averaged, any subject outside of this range was removed from the 
analysis. One C417Y homozygous ENU-mutant mouse (mean stopping of 33%) and two WT 
mice (mean stopping of 78% and 38%) were therefore removed from the analysis leaving 
final Ns of 14 and 11 for the C417Y homozygous ENU-mutant (mean stopping = 
51.18±1.21%) and WT (mean stopping = 49.07±1.12%) groups, respectively. There was no 
difference between the two groups of mice in the SSRT, the latency to stop a response, 
when the mice were showing 50% correct stopping, (Fig. 7.5A, t23=0.9, p=0.37) suggesting 
that there was no difference in inhibition between C417Y homozygous ENU-mutants and 
their WT littermate controls. 
When C417Y mice were showing 50% stop responding, there were no differences in 
the go response in terms of the proportion of correct responding (Fig. 7.5B, main effect of 
GENOTYPE, F1,23=0.33, p=0.57) nor the speed of responding (Fig. 7.5C, main effect of 
GENOTYPE, F1,23=0.27, p=0.61) and performance did not differ from baseline for either of 
these measures (main effect of SESSION, F1,23=0.6, p=0.47, and F1,23=0.1, p=0.77, for 
percentage go correct and Go-RT, respectively). There were no differences between the two 
groups of C417Y mice in the amount of trials initiated (Fig. 7.5D, main effect of GENOTYPE, 
F1,23=0.5, p=0.48), the latency to initiate a trial (Fig. 7.5E, main effect of GENOTYPE, F1,24=0.2, 
p=0.69) or the latency to collect the reward (Fig. 7.5F, main effect of GENOTYPE, F1,23=0.1, 
p=0.72).  
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Figure 7.5: SSRTT performance in C417Y mice at 50% stopping. 
  
    
 
 
 
Normalising performance to 50% correct stopping, where the go and stop responses were 
equivalent, allowed calculation of the SSRT; the latency to stop a response. C417Y homozygous ENU-
mutants and their WT littermate controls had equivalent SSRTs, and therefore comparable inhibitory 
control (A). There was no difference in the go response (B), and going was equivalent to baseline 
responding. There was no difference in the Go-RT (C), latency to initiate trials or latency to collect 
the reward (F) between baseline and performance at 50% stopping, although a significantly greater 
number of trials were initiated when performance was at 50% stopping (D). There were also no 
significant genotype differences on any of these measures. Data shows the mean values ±SEM. For 
subject N see Table 7.1 and text. 
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There was also no difference in the latency to initiate a trial and the latency to collect a 
reward between baseline performance and when the mice were showing 50% stop 
responding (main effect of SESSION, F1,23=1.6, p=0.22, and F1,23=1.4, p=0.25, respectively) 
but there was a small but significant increase in the proportion of trials initiated when the 
mice were showing 50% stop responding (main effect of SESSION, F1,24=8.4, p=0.008). There 
were no significant differences between C417Y homozygous ENU-mutants and their WT 
littermate controls for other task measures such as the number of initiation and go nose-
pokes, food magazine panel-pushes and locomotion in the test chambers, measured as 
infra-red beam breaks (data not shown). 
 
7.4 Discussion 
 WT mice from both the C59X and C417Y lines acquired and performed the SSRTT 
essentially as demonstrated in previous work using inbred C57BL/6J mice (Humby et al., 
2013). As expected, moving the stop-signal position progressively into the individualised go 
responses of each subject led to a systematic decrease in the ability of the mice to cancel 
the go response. This led to a reduction in the number of correctly stopped trials, 
supporting the ‘horse-race’ model’s assumption that the later the stop-signal delay is 
presented the less chance that the stopping process will win the race (Logan & Cowan, 
1984). 
 Analysis of stopping behaviour at the 50% stop-position, where the race is predicted 
to be at its greatest, yielded stop-signal reaction times (SSRT) of ca. 230ms; these were close 
to previous data in the C57BL/6J mouse strain (350ms, Humby et al., 2013) and rats (300ms, 
Eagle & Robbins, 2003a), and were also consistent with human studies using this task 
(200ms, Logan & Cowan, 1984), adding further weight to the translational potential of the 
murine SSRTT. Behaviour in the SSRTT was dissociable, in that responding in go trials 
(amount of correct go trials and the go reaction time), motivation (latency to collect reward, 
proportion of trials initiated, latency to initiate a trial) or locomotion (beam breaks) were 
not affected by stopping behaviour at the 50% (or any other) stop-signal position, further 
supporting the race-model which describes stopping and going as parallel, competing, 
independent processes (Logan & Cowan, 1984). 
 C59X and C417Y homozygous ENU-mutant mice acquired the task at the same rate 
as their respective WT littermate controls and demonstrated equivalent performance in 
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measures of motivation and locomotion throughout the different phases of testing.  There 
were also no genotype-related differences between mice of the C417Y line for any of the 
main measures of the SSRTT, such as proportion of correct go responses, initiation and go 
latencies and SSRT at baseline, as well as in sessions when the stop-signal position was 
altered, and also when the mice were showing 50% correct stopping. Thus, the C417Y 
mutation, at least within the task parameters used in the present work, does not appear to 
have an effect on response control assayed in the SSRTT.   
C59X homozygous ENU-mutant mice displayed improved stopping compared to their 
WT littermate controls, an indication the C59X mutation may actually give rise to enhanced 
response control. This effect was consistent, being apparent during acquisition when the 
stop-signal was first introduced, and when the stop-signal was moved to different positions 
within the individualised go responses of each subject. Furthermore, at 50% correct 
stopping, C59X homozygous ENU-mutant mice had significantly reduced SSRTs compared to 
their WT littermate controls, again indicative of enhanced response inhibition/reduced 
impulsivity. Despite this apparent reduction in impulsivity, C59X homozygous ENU-mutants 
also demonstrated significantly quicker initiation latencies and go reaction times (there 
were no differences in the number of correct go trials made) than WT littermate controls, 
both during baseline sessions and during manipulation of the stop-signal position, indicating 
both improved going and stopping processes in these mutants. 
 The enhanced response control, or decreased impulsivity, shown by the C59X 
homozygous ENU-mutant mice is contrary to what might be expected from a mouse model 
for schizophrenia, where slower SSRTs, indicative of increased impulsivity, have been 
observed in patients (Enticott, 2008; Huddy et al., 2009). However, these findings are 
equivocal (Rubia et al., 2001; Bellgrove et al., 2005), nevertheless there are no studies (to 
our knowledge) that have reported decreases in impulsivity as measured with the SSRTT, as 
was found here. Although there are minimal studies investigating SSRTT performance in 
bipolar disorder, in general these patients similarly show reduced response inhibition 
(Strakowski et al., 2010). To our knowledge, there are no other mouse models for 
schizophrenia (or bipolar disorder) that have utilised response inhibition tasks, and certainly 
none with the SSRTT. Other rodent models using the SSRTT have commonly found poorer 
stopping behaviour following pre-frontal cortex, orbitofrontal cortex and subthalamic 
nucleus lesions (Humby et al., 2013; Eagle et al., 2008), with improvements in this function 
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after administration of methylphenidate, atomoxetine and the 5HT2C receptor antagonist 
SB242084 (Humby et al., 2013; Eagle & Robbins, 2003a,b; Eagle et al., 2007). Thus, SSRTT 
performance appears dependent on frontostriatal brain systems, which are also involved in 
the pathophysiology of schizophrenia (Rubia, 2002; Rubia et al., 2001; Rubia et al., 2003), 
with the involvement of forebrain dopaminergic, noradrenergic and serotonergic systems. It 
would also be interesting to manipulate the stop-signal itself, for example via degradation of 
the stop-signal and/or increased/decreased stop-signal length. This would tax the 
attentional function of the mice and potentially draw out further differences between the 
C59X homozygous ENU-mutants and their WT littermate controls. 
 Reconciling the present results in terms of schizophrenia or bipolar disorder is 
somewhat difficult, however, the data do indicate that manipulation of Zfp804a does alter a 
disease-related phenotype and therefore suggests that forebrain neurotransmitter systems 
or frontostriatal brain systems have been affected in C59X homozygous ENU-mutant mice. It 
also difficult to reach a general conclusion in how overall mechanisms of impulse control 
may be affected in C59X and C417Y ENU-mutant mice, as the SSRTT primarily assesses only 
one facet of impulsivity: impulsive action (Winstanley et al., 2006). Therefore, investigating 
mechanisms of impulsive choice, which have dissociable neurobiological systems (Evenden, 
1999b; Winstanley et al., 2006) may yield different patterns of effects in the two mutant 
lines of mice. 
 
7.4.1. Summary of key results from Chapter VII 
 All mice from the C59X and C417Y lines were capable of learning a complex operant 
task, and were quick to acquire the various stages of the SSRTT. 
 Moving the stop-signal position within the individualised go responses of each 
subject led to a systematic decrease in the ability of the mice to cancel the go 
response. 
 The C59X homozygous ENU-mutants demonstrated enhanced response inhibition 
(quicker SSRTs) as compared to their WT littermate controls when stopping 
behaviour was normalised to 50% correct stopping. 
 There were no significant differences in inhibitory, or other task-related behaviour 
between C417Y homozygous ENU-mutants and their WT littermate controls. 
 
177 
 
Chapter VIII; General discussion 
In a recent GWAS, a single nucleotide polymorphism within ZNF804A was found to be 
associated with risk for developing schizophrenia (O’Donovan et al., 20008), with this 
association strengthened when bipolar cases were added to the affected sample. 
Furthermore, the genetic association between the ZNF804A risk allele and schizophrenia has 
since been thoroughly replicated (Riley et al., 2009; Steinberg et al., 2011; Williams et al., 
2011). The aims of the present thesis were to further characterise the function(s) of 
Zfp804a, the mouse orthologue of ZNF804A, with the goal of understanding more about 
how variance in this gene may increase the risk of developing schizophrenia/bipolar 
disorder. This was achieved by testing mouse models bearing ENU-mutations in Zfp804a on 
a wide range of behavioural tasks.  
 
8.1 Utility of the models: limitations and advantages 
 A potential limitation of testing mutants derived from ENU mutagenesis is that this 
technique causes multiple mutations in the genome, meaning that many other residual 
ENU-induced mutations may be inherited along with the mutation of interest (this has been 
estimated to be approximately 31 in founder mice, see Keays et al., 2006), leading to 
possible confounds in interpreting genotype-phenotype relationships. However, after 
backcrossing the Zfp804a lines onto the C57BL/6JOlaHsd strain (C57BL/6J) they were 
estimated to be 98.5% genetically identical. It was therefore calculated that our G7i/ii 
Zfp804a mice should be carrying on average less than 0.49 other residual mutations (as 
calculated from Keays et al., 2006). Furthermore, the chances of this very low level of ‘off 
target’ mutations being distributed systematically, as opposed to randomly, were extremely 
slim in any case. 
There is also the potential for other ‘hitchhiking genes’ derived from the original ENU 
treated mouse strain that flank Zfp804a to co-occur with the selected mutation despite the 
backcrossing protocol if they are in linkage disequilibrium, leading to the possibility that 
phenotypic differences between the mutants and wild type controls may be influenced by 
polymorphisms in these flanking genes occurring between the ENU strain (BALB/c x 
C3H/HeJ) and C57Bl/6J. This can be a general problem in the interpretation of data using 
many genetically modified animal models (both ENU and knockouts made using 
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homologous recombination methods) and is only solved, definitely, by specific genetic 
rescue of the phenotype. However, the same ENU strain derived flanking genes and any 
polymorphisms within them should be inherited with both the C59X and C417Y mutation. 
Thus, the general strategy employed throughout the thesis of comparing the effects of the 
two ENU mutations relative to wild type littermate controls, not only revealed the effects of 
variance in two parts of the Zfp804a gene, but also acted as a control; insofar as common 
effects across both the C59X and C417Y ENU-mutant mice, relative to wild type littermate 
controls, could theoretically be due to these ‘hitchhiking’ flanking genes, the many instances 
of clear phenotypic differences between the C59X and C417Y homozygous ENU-mutants 
pointed towards specific effects of ENU-induced changes in Zfp804a function. Additionally, 
the background strain used for this work was the C57BL/6JOlaHsd strain (Harlan, Bicester, 
UK) which carries a deletion spanning the alpha-synuclein (Snca) locus (Specht & Schoepfer, 
2001). This was not thought to pose a problem with the Zfp804a mice tested in this work, as 
they were estimated to have c.98.5% C57BL/6JOlaHsd background; and should therefore all 
have the Snca deletion (Knight, 2013), with a sample of PCRs for the Snca gene showing this 
to be the case. 
 It has been argued that ENU-mutagenesis best mimics the naturally occurring single-
base pair mutations found in the human genome (Jiao, Cai, Kermany et al., 2009), and as 
such, mutants derived from ENU-mutagenesis versus mutants derived from knockout 
technologies may be better placed to investigate the genetics behind certain clinical 
disorders (Acevedo-Arozena, Wells, Potter et al., 2008). The work in this thesis is based, in 
general, upon the GWAS which identified SNPs in ZNF804A as having an association with 
increased risk for a schizophrenia/bipolar disorder diagnosis. Recently, the complexity of the 
genetic architecture of mental disorders has been added to by the discovery of a number of 
rare, highly penetrant copy number variants (CNVs).  It might be argued that rather than 
studying evolutionary conserved, common, low penetrant risk variants such as those found 
in ZNF804A, models based on more highly penetrant (often de-novo) CNVs, would be the 
optimal rationale. However, it should be emphasised that, despite many of the discovered 
variants from GWAS having little effect on overall risk burden, functional studies examining 
their mechanism(s) of action and the pathways they interact with can be highly illuminating 
in terms of pathogenesis and options for treatments (Willer & Mohlke, 2012). 
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 The two mutations in Zfp804a selected for re-derivation, the C59X (nonsense) and 
the C417Y (missense), were chosen due to their perceived functional effects. The C59X 
mutation in exon 2 encodes a premature stop codon, which was predicted to serve as a 
functional null of the gene. Reverse transcription PCR analysis (RT-PCR) conducted in parallel 
to this work, and subsequent RT-PCR presented in Section 8.4.3 below, confirms that the 
C59X mutation has escaped nonsense-mediated decay (NMD), and as such, cannot 
technically be described as a null. An antibody to characterise the C59X mutation at a 
Zfp804a proteomic level is needed to confirm the assumed influence of the mutation on the 
Zfp804a protein, as without this the nature of the C59X mutation remains unclear. The 
C417Y mutation is missense and constitutes a cysteine to tyrosine substitution in exon 4. 
This mutation was predicted to change the structure of the protein, and was deemed 
‘probably damaging’ by PolyPhen, a bioinformatics program which can be used to predict 
the effects of non-synonymous SNPs in mice. It has recently been posited that the C417Y 
mutation may be polymorphic (D. Blake, personal communication). Internet programs such 
as BLAST (Basic Local Alignment Search Tool) have been used to examine the protein 
sequence around the mutation, finding the region to be highly conserved in humans and 
rodents, but not conserved across other species, with one species, the ferret, showing the 
cysteine to tyrosine substitution naturally. It could be argued this makes the C417Y 
polymorphism a good control for the C59X mutation, and as predicted, it was the C59X 
mutation that had a greater effect on phenotype (though not exclusively). 
  The most obvious limitation to the current work is the translatability of mouse 
models to study uniquely human disorders such as schizophrenia and bipolar disorder. 
However, the aim of this thesis was not to study a mouse model of schizophrenia, nor to 
model the human ZNF804A risk variant rs1344706 in mice. The purpose was to understand 
the function of Zfp804a at a behavioural level, using tasks that tap into the symptoms of 
schizophrenia and bipolar disorder. Mouse models are a crucial first step in understanding 
gene function, and contribute greatly to our understanding of genes when used in 
conjunction with molecular, cellular and clinical work. 
 
8.2 Main findings 
 Monitoring of the early development of the Zfp804a mutants did not uncover any 
gross developmental phenotypes. There were no obvious signs of breeding related 
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problems with pups appearing normal at birth and somatic indices of development 
emerging within normal time frames. A Mendelian inheritance pattern for the three 
genotypes of both mutant lines was observed, but fewer males (of any genotype) were born 
to both mutant lines, perhaps indicating that both mutations were influencing the pre-natal 
survivability of males. It would therefore be interesting to examine a number of litters 
prenatally to ascertain the number, genotype and gender of pups in utero to determine if 
more male pups are present prenatally and if Mendelian ratios are intact before birth. 
 The other main developmental finding was that C59X male homozygous ENU-
mutants weighed less than their WT littermate controls between postnatal days 11-20, as 
well as between postnatal days 21-30 (weaning), and in adulthood. The C59X female 
homozygous ENU-mutants also weighed less than their WT littermate controls but only 
between postnatal days 21-30. The reduced weight seen in the C59X male homozygous 
ENU-mutants appears at around the same time that mice are weaned from their mother’s 
milk and switch to solids, coinciding with the point at which the pup’s eyes are open and 
they become more independent around the cage (Silver, 1995), potentially implying a 
delayed weaning in these mutants, with the effects of this continued into adulthood. This 
delayed weaning could be due to increased neophobia to the solid food or perseveration of 
maternal contact, although both are speculation at this point. These reduced adult weights 
were also found in the C59X homozygous ENU-mutants of the Zfp804a G4i cohort 
supporting the idea that the C59X mutation might be having an effect on the growth of 
these mutants.  
 Table 8.1 shows the summary behavioural results of homozygous ENU-mutants from 
both lines, in comparison to their WT littermate controls. Initial sensory-motor testing 
utilising four tests from the SHIRPA battery (Rogers et al., 1997) found that C59X 
homozygous ENU-mutants showed enhanced vestibular and proprioceptive function as 
measured on the negative geotaxis test (Chapter III). This could be a genuine result, but 
might also be due to poorer WT capabilities, where 35% of the C59X WT controls showed 
poor negative geotaxis performance as compared to 0% poor performance in the C417Y 
WTs, so the enhanced abilities of the C59X homozygous ENU-mutants were more likely to 
be significantly different from their WT littermate controls. If it is a genuine result, then it 
corresponds with the Zfp804a G4i C59X male homozygous ENU-mutants displaying 
enhanced sensorimotor abilities on the RotaRod, with mutants staying on the rotating 
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apparatus for significantly longer than their WT littermate controls (Al-Janabi, 2012). These 
improved sensorimotor abilities in the C59X homozygous ENU-mutants have not been 
shown (to our knowledge) in any other mouse model for schizophrenia/bipolar disorder, 
with other mouse models for schizophrenia displaying impaired sensorimotor capabilities, 
for example, in mice overexpressing Nrg1 (Deakin, Law, Oliver et al., 2001) or Sdy mice 
carrying a deletion in Dtnbp1 (Takao, Toyama, Nakanishi et al., 2008). 
 
Table 8.1: Summary of behavioural results for homozygous ENU-mutant mice 
from both lines, in respect to their WT littermate controls. 
Behavioural Task C59X Homozygous C417Y Homozygous 
SHIRPA (sensorimotor) ↑ ↔ 
Locomotor activity ↔ ↔ 
Reactivity to novel food  ↑ ↔ 
Anxiety ↓ ↔ 
Motivation ↔ ↑ 
Hedonia ↓ ↔ 
Acoustic startle ↓ ↔ 
Pre-pulse inhibition ↓ ↔ 
Response control ↑ ↔ 
 
 Locomotor activity did not significantly differ between homozygous ENU-mutants 
and WT littermate controls in either mutant line in the LMA (Chapter III), although the C59X 
homozygous ENU-mutants appeared to be less active than their WT littermate controls, in 
line with previous data from the Zfp804a G4i cohort (Al-Janabi, 2012). Reactivity to a novel 
food substance uncovered neophobia to the novel condensed milk substance on the 1st day 
of testing in the C59X homozygous ENU-mutants, compared to their WT littermate controls. 
This neophobia had disappeared by the 2nd day of testing, and both C59X homozygous ENU-
mutants and their WT counterparts had equivalent preference for the condensed milk (over 
water) by the last day of testing. Neophobia on this task has been shown to be related to 
heightened anxiety on standardised tests such as the elevated plus-maze and open field 
(Mikaelsson et al., 2013). Based on this, one might hypothesise that the C59X homozygous 
ENU-mutants would show anxiogenic responses on various rodent tests of anxiety, but this 
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was not found to be the case (Chapter IV). The apparent neophobia therefore could be due 
to the C59X homozygous ENU-mutants displaying anhedonic tendencies (Chapter V); i.e. the 
C59X homozygous ENU-mutants did not ‘like’ the condensed milk solution as much as their 
WT littermate controls on their first encounter with it. 
 The reduced anxiety phenotype seen with the C59X homozygous ENU-mutants (as 
indexed by increased time in the more anxiety-provoking zone) was significantly different to 
their WT littermate controls on the elevated zero-maze (EZM) and backed up by tendencies 
in the elevated plus-maze (EPM) and the open field (OF), and further corroborated by 
increased amounts of ancillary ethological behaviours such as stretch-attend postures, 
rearing and head dips (Chapter IV). Importantly, the reduced anxiety was not simply a result 
of hyperactivity in the C59X homozygous ENU-mutants, as they were not hyperactive in the 
LMA or in the anxiety tasks as compared to their WT littermate controls.  
 Chapter V revealed the only behavioural phenotype found with the C417Y 
homozygous ENU-mutants; increased motivation. This increased motivation was hinted at 
when the mutant lines were required to work for a 10% CM reward but was further 
substantiated when the reward was devalued (0% CM), with the C417Y homozygous ENU-
mutants achieving significantly higher breakpoints than their WT littermate controls. 
Motivation in the C59X homozygous ENU-mutants was not significantly different to their WT 
littermate controls, however, in the lick cluster analysis, these mutants showed reduced lick 
cluster sizes to the 4% and 10% sucrose solutions in comparison to their WT counterparts, 
indicating a reduced pleasure in these palatable solutions (anhedonia). There was no effect 
of genotype in lick cluster size for the C417Y mutant line, suggesting a dissociation between 
the two mutations in terms of motivation and hedonia, with the C59X homozygous ENU-
mutants equally driven to earn rewards but finding them less pleasurable than their WT 
littermate controls, and the C417Y homozygous ENU-mutant mice more motivated to earn 
rewards but finding them equally as pleasurable as their WT counterparts. 
In terms of sensorimotor gating (Chapter VI), the C59X homozygous ENU-mutants 
showed reduced startle to a loud acoustic stimulus and displayed reduced prepulse 
inhibition (PPI). This failure to attenuate to a startling stimulus when preceded by a weaker 
stimulus is considered an endophenotype of schizophrenia and has been shown in other 
animal models for this disorder (Hikida et al., 2007; Clapcote et al., 2007; Stefansson et al., 
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2002). There were no differences between C417Y homozygous ENU-mutants and their WT 
littermate controls on acoustic startle response or PPI. 
Response control exhibited by the C59X and C417Y lines was tested using the stop-
signal reaction time task (Chapter VII). It was found that all subjects acquired the task to an 
equivalent level but that the C59X homozygous ENU-mutants displayed a pattern of 
enhanced response inhibition, achieving quicker latencies to stop a response which had 
already been initiated than their WT counterparts. Behaviour between the C417Y 
homozygous ENU-mutants and their WT littermate controls was equivalent. 
All but one of the behavioural phenotypes were found with the C59X and not the 
C417Y homozygous ENU-mutants, adding weight to the idea that the C417Y mutation is 
more likely a polymorphism, with the C59X mutation a more damaging genetic insult. The 
observable differences between the C59X and C417Y homozygous ENU-mutants means that 
the phenotypes found with the C59X mutants are most likely due to the C59X mutation 
itself, and not co-segregating genes around the mutation. 
 
8.3 Further interpretation of key findings  
8.3.1 Reduced anxiety in C59X homozygous ENU-mutants 
 Anxiety is not commonly modelled in mouse models for schizophrenia, although 
schizophrenia and bipolar patients often report altered levels of anxiety (Braga et al., 2004; 
Pokos & Castle, 2006; Keller, 2006). The effects observed in the C59X homozygous ENU-
mutants are consistent and relevant to both schizophrenia and bipolar disorder, but it is 
difficult to directly translate the effects found in the Zfp804a mutants to clinical studies. It 
would have been interesting to have tested the corticosteroid release of the C59X 
homozygous ENU-mutants and their WT littermate controls, with the hypothesis being that 
the C59X mutants would have shown a reduced level of the ‘stress hormone’ cortisol in their 
blood immediately after the anxiety assays.  
 The reduced anxiety in the C59X mutants mimics the anxiolysis seen in treatment 
with benzodiazepines which enhance the effect of the GABAA receptor (Treit et al., 2010). 
Mouse models targeting the glutamatergic system have also shown reduced anxiety, with 
GRIN1 (D481N) mutants, which display a 5-fold reduction in NMDA receptor glycine affinity, 
showing anxiolysis on the EPM and OF (Labrie, Clapcote & Roder, 2009), with these effects 
reversed by administration of a direct activator of the NMDA receptor glycine site. Other 
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mouse models manipulating the serotonin (5-HT) system have shown anxiolysis on the EPM 
through over-expression of the 5-HTT transporter gene (Jennings et al., 2006), and 
anxiogenesis observed in mutants with the 5-HTT transporter gene knocked out (Holmes et 
al., 2003). It is unclear what the neurobiological causes are for the reduced anxiety in the 
C59X mutants although the GABAergic, serotonergic and glutamatergic systems may have a 
role. Further investigation into the mechanisms behind the reduced anxiety is required in 
the C59X mutants, perhaps using pharmacological manipulations to further elucidate the 
role of certain neurotransmitters in the anxiolysis phenotype. 
 
8.3.2 Anhedonia in C59X homozygous ENU-mutants 
 The observation of anhedonia in the C59X homozygous ENU-mutants is, to our 
knowledge, the only incidence of anhedonia in a genetic mouse model for schizophrenia. 
Anhedonia is seen in both schizophrenia and bipolar disorder (Horan et al., 2006b; Gard et 
al., 2007; Serretti & Olgiati, 2004) and remains, as a negative symptom, difficult to treat 
(Kirkpatrick et al., 2006). Research has linked hedonic reactions to opiate systems in the 
brain and to hedonic hot spots within the brain such as the nucleus accumbens shell and 
ventral pallidum (Peciña et al., 2006). Hedonic reactions to taste in rats have been measured 
with affective taste reactivity tests that measure orofacial liking reactions, which are similar 
between species to certain flavours i.e. sweet and bitter. Much of the research into hedonic 
reactivity has focused on opiate systems in the brain (Peciña et al., 2006), with micro-
injection of DAMGO (an opiod agonist) into the rostral half of the medial nucleus accumbens 
shell elevating the hedonic reactions to sucrose in rats (Peciña & Berridge, 2005). DAMGO 
administration in other parts of the nucleus accumbens did not increase hedonic reactions 
to sucrose in rats, although it did increase ‘wanting’ of foods as demonstrated by increases 
in consumption (Peciña & Berridge, 2005). μ-Opioid agonists elevate the consumption of 
sucrose and μ-Opioid antagonists suppress the consumption of sucrose in the wider 
accumbens region of a rat (Peciña & Berridge, 2000), hence individuals with increased μ-
opioid activity in the hedonic hot spot of the nucleus accumbens shell may eat because food 
tastes nicer, but individuals with higher μ-opioid activity in the surrounding areas of the 
nucleus accumbens shell may eat more because of motivational reasons, i.e. they want it 
more but don’t necessarily like it more (Pecina et al., 2006).  
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This hypothesis has implications for the anhedonia shown in the C59X homozygous 
ENU-mutants, perhaps suggesting a reduction of opiod activity in the hedonic hot spot of 
the nucleus accumbens shell in the C59X mutants. To test if this is the case, the anhedonia 
in the C59X homozygous ENU-mutant mice might be reversed using micro-injection of μ-
opioid agonists in the hot spot of the nucleus accumbens shell. Although the mouse brain is 
exceptionally small, and the likelihood of hitting the hedonic hot spot is fairly minimal. 
Dopamine antagonists have been shown to produce reduced lick cluster sizes in rats 
(D’Aquila, 2010) suggesting a role for dopamine in the ‘liking’ of rewards as well as the 
‘wanting’, despite Berridge’s argument to the contrary (Berridge, 2004). It would therefore 
be interesting to administer dopamine agonists to the C59X homozygous ENU-mutants to 
see if the anhedonia in these mutants can be reversed. 
 
8.3.3 Increased motivation in C417Y homozygous ENU-mutants 
 The increased breakpoints demonstrated by the C417Y homozygous ENU-mutants 
can be interpreted as an increased motivation to work for a reward. This enhanced 
motivation, however, could also be seen as perseverative responding, manifest as an 
inability to inhibit the nose-poke response and so a reflection of a facet of impulsivity 
(O’Tuathaigh et al., 2010). However, against this idea, there were no differences in the intra-
nose-poke latency during the PRT; but also, in Chapter VII, this same line did not show any 
effects of genotype in the stop-signal reaction time task, a specific test of impulsivity. The 
fact that the C417Y homozygous ENU-mutants were even willing to work harder for a 
reward that was devalued (less sweet), could indicate that these mice were actually more 
thirsty, as opposed to being more motivated to work specifically for the sweet condensed 
milk solution. However, the idea that the consistently increased breakpoints could have 
been due to the C417Y homozygous ENU-mutants simply being thirstier than their WT 
littermate controls is unlikely, as under free drinking conditions (i.e. no requirement to work 
for the reinforcer, See Chapter III, Section 3.3.4.3) consumption was equivalent between the 
ENU-mutants and WT littermate controls. Thus, increased motivation to work for a reward 
remains the most plausible explanation for the increase in breakpoints demonstrated by 
C417Y homozygous ENU-mutant mice, even when the reward is devalued. However, this 
could be further validated by investigations using different reward concentrations or 
different sizes of reward. The concentration used in this study (10%) was the optimum 
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concentration of condensed milk for mice (Humby et al., 2005), potentially causing the 
Zfp804a mice to operate at ceiling performance. Thus, future studies could start with lower 
baseline concentrations and smaller reward sizes to provide a more complete investigation 
of the effects of motivational levels on PRT performance.  
 Putting forward a neurobiological mechanism for the enhanced motivation in the 
C417Y homozygous ENU-mutants is difficult, particularly as schizophrenia and bipolar 
patients show reduced levels of motivation (Barch, 2008). The incentive salience hypothesis 
seems to suggest that dopamine may play a role in the ‘wanting’ of rewards, but not 
necessarily in the ‘liking’ (Berridge, 2004). The mesolimbic and striatal regions are seen as 
crucial areas for dopamine related reward reactivity, with many studies using dopamine 
receptor blockade to demonstrate reduced motivation in rodents (Berridge & Robinson, 
1998). One recent study using mice over-expressing subcortical D2 receptors showed that 
these mutants had lower incentive motivation on a progressive ratio schedule (Drew et al., 
2007). It appears that increased striatal D2 activity was most likely not sufficient by itself to 
reduce motivation as D2 antagonists in schizophrenia patients are not enough to improve 
the motivational deficits seen (Ward, Simpson, Kandel et al., 2011), clearly additional 
neurobiological mechanisms are at work. 
 The fact that the C417Y homozygous ENU-mutants showed increased motivation but 
equivalent hedonic reaction to reward as their WT littermate controls also fits with a 
dopamine related hypothesis, as dopaminergic functioning is not thought to influence the 
hedonic reactions to reward (Berridge, 2004). Research using microdialysis and in vivo 
electrochemistry has shown that dopaminergic systems are activated before animals receive 
a pleasurable incentive, not during as might have been predicted by the anhedonia 
hypothesis (reduction of dopamine induces anhedonia) (Martel & Fantino, 1996). Dopamine 
transporter gene (DAT) knockdown mice show 70% elevated levels of dopamine and 
demonstrated higher levels of incentive motivation on a runway task, but did not show 
increased orofacial ‘liking’ reactions to sucrose in an affective taste reactivity test (Peciña, 
Cagniard, Berridge et al., 2003). It could be argued that altered dopaminergic activity in the 
C417Y homozygous ENU-mutants contributed to their enhanced motivation. If this is the 
case it would be interesting give the C417Y mutant mice amphetamine and then run them 
on the locomotor activity test, if the C417Y homozygous ENU-mutants are 
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hyperdopaminergic they should have an attenuated response to the amphetamine than 
their WT littermate controls. 
 
8.3.4 Reduced acoustic startle response and prepulse inhibition in C59X homozygous ENU-
mutants 
 The reduced prepulse inhibition demonstrated by the C59X homozygous ENU-
mutants is in line with the reduced PPI found in schizophrenia and bipolar patients (Geyer et 
al., 2001; Braff et al., 2001; Giakoumaki et al., 2007; Perry et al., 2001). Work with other 
mouse models for schizophrenia have shown similar effects, particularly with DISC1 
(Clapcote et al., 2007; Hikida et al., 2007) and Nrg1 mutants (Stefansson et al., 2002). PPI is 
thought to be regulated by frontal, striatal and mesolimbic circuitries, and potentially the 
disrupted PPI shown by the C59X homozygous ENU-mutants indicates that Zfp804a may be 
involved in brain regions thought to play a role in sensorimotor gating (Powell et al., 2009). 
To test this hypothesis, and see if the reduced PPI found with the C59X mutants is a true 
result it is necessary to reverse the PPI deficit by administering antipsychotics to the C59X 
mutants.  
 Dopamine transporter gene (DAT) knockout mice demonstrate increased levels of 
dopamine and marked reductions in sensorimotor gating, with these effects reversed by 
administration of D1/D2 receptor antagonists (Ralph, Paulus, Fumagalli et al., 2001). Other 
neurotransmitter systems also produce deficits in PPI in rats, including 5-HT1A receptor 
agonists (Rigdon & Weatherspoon, 1992), NMDA receptor antagonists (PCP) (Mansbach & 
Geyer, 1989) and GABA antagonists (Swerdlow, Braff & Geyer, 1990). Further investigation 
into the mechanisms behind the reduced PPI seen in the C59X mutants is required, perhaps 
using pharmacological manipulations to further elucidate the role of key neurotransmitters 
in the sensorimotor phenotype.  
 
8.3.5 Enhanced response inhibition in C59X homozygous ENU-mutants 
 The enhanced response inhibition shown by the C59X homozygous ENU-mutants is 
difficult to reconcile in terms of schizophrenia and bipolar disorder as these illnesses are 
characterised by deficits in response control (Newman et al, 1985; Heerey et al., 2007; 
Swann, 2010). It is also difficult to interpret how neurobiological mechanisms in the C59X 
mutants may be contributing to the enhanced response inhibition seen, although research 
188 
 
has indicated that frontostriatal brain systems are involved in impulsivity and response 
inhibition (Rubia, 2001; 2002; 2003; Townsend et al., 2012) and that pharmacological 
manipulations via the dopaminergic, noradrenergic and serotonergic systems have impacts 
on SSRTT performance (Humby et al., 2013; Eagle & Robbins, 2003a,b; Eagle et al., 2007). 
Further work investigating other aspects of impulsivity would be interesting, as other facets 
(i.e. impulsive choice) are thought to have dissociable neurobiological systems (Evenden, 
1999b; Winstanley et al., 2006); therefore additional tests could help to clarify the 
mechanism by which the C59X mutation is affecting response inhibition, and may yield 
possible effects in the C417Y mutant line. 
 
8.4 Recent work 
 The work on Zfp804a extends beyond the behavioural analyses conducted in this 
thesis. Colleagues at the MRC centre of Neuropsychiatric Genetics and Genomics have been 
investigating the expression and splicing patterns of Zfp804a in the C59X mutant mouse line 
(Dr Knight) as well looking into the function of the human orthologue ZNF804A (Dr 
Chapman). I have also conducted further initial molecular work to ascertain the nature of 
Zfp804a expression in the C59X mutant line. The following section focuses on some of the 
interesting findings on Zfp804a/ZNF804A. 
 
8.4.1 Zfp804a expression in WT C57BL/6J mice 
 Previous RT-PCRs performed by a colleague Dr Tinsley found that Zfp804a mRNA 
transcript was expressed in the brains of WT male mice, but not in other organs such as the 
heart, liver, lungs, spleen, kidney, muscles or testes (See Appendix 7.1A). This led to a 
further RT-PCR examining Zfp804a expression in differing brain regions of a male WT mouse 
with findings indicating that Zfp804a mRNA was present in each of the regions investigated 
(See Appendix 7.1C), with highest expression in the hippocampus (HPC), ventral striatum 
(VS) and prefrontal cortex (PFC), regions thought to be important neural correlates of 
schizophrenia and bipolar disorder (for reviews see Goghari, Sponheim & MacDonald, 2010; 
Strakowski, DelBollo & Adler, 2005).  
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8.4.2 Alternative transcripts in Zfp804a  
At the outset of this work the predicted effects of the two ENU mutations was based on the 
presence of a single protein coding Zfp804a transcript. However, recently an additional 
alternate full length non-protein coding transcript has been reported in Ensemble 
(http://genome-euro.ucsc.edu/cgi-bin/hgTracks). Very recently, a third alternate non-coding 
transcript has been discovered by colleagues in the lab. This third alternative isoform is 
thought to contain a novel exon upstream to the Reference sequence exon 1 appearing to 
skip the constitutive exon 1 and splice to exon 2 of Zfp804a. RT-PCR and sequencing 
validated this transcript in both C59X homozygous ENU-mutants and their WT counterparts 
and confirmed that the C59X mutation was also present in exon 2 of both of the C59X 
mutants used in the analysis (Knight, 2013). This discovery informed later RT-PCR work 
comparing Zfp804a expression in C59X homozygous ENU-mutants versus WT littermate 
controls. 
 
8.4.3 Analysis of Zfp804a isoform gene expression in WT and C59X homozygous ENU-
mutant mice 
 The C59X mutation encodes a premature stop codon and it was thought initially that 
the mutant mRNA transcript will not be fully translated due to nonsense mediated decay 
(NMD), which selectively degrades mRNAs harbouring premature stop codons (Chang et al., 
2007). Previous work from RT-PCR studies of C59X homozygous and heterozygous ENU-
mutants and WT control brain tissue revealed Zfp804a mRNA transcript in C59X 
homozygous ENU-mutants, suggesting that the C59X stop codon mutation has escaped 
NMD (C. Tinsley, personal communication, see Appendix 7.2).  
 The discovery of an alternative Zfp804a transcript (Knight, 2013) informed later 
expression analyses conducted in parallel to the work undertaken in this thesis. RT-PCR was 
performed on the C59X ENU-mutant line to assess the expression of Zfp804a in all three 
transcripts in brain regions shown to have high expression in WT C57BL/6J mice (HPC, VS 
and PFC). It was thought that this would confirm the Zfp804a expression in WT mice and 
assess the extent to which Zfp804a expression in all 3 (known) Zfp804a transcripts was 
affected by the C59X mutation. Within the limitations of RT-PCR (semi-quantitative) it 
appeared that all three transcripts were expressed in both the C59X homozygous ENU-
mutant mouse and the WT control (Fig. 8.1).  
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Figure 8.1: RT-PCR showing expression of the three Zfp804a transcripts in different 
brain regions of a C59X homozygous ENU-mutant and a WT littermate control. 
 
                                                                  
RT-PCR, using specific primers specific to each of the 3 Zfp804a transcripts and a Hprt control, was 
performed on samples dissected from different brain regions of a C59X male homozygous ENU-mutant 
and a WT littermate control. Results show that Zfp804a mRNA was present in each of the brain 
regions investigated, although the three transcripts were expressed at differing levels. This semi-
quantitative assay did not suggest that expression levels of any of the Zfp804a transcripts differed 
between C59X genotype. Arrows show bands of interest. RT+ve: reverse transcriptase positive control 
and RT-ve: reverse transcriptase negative control, NTC: no template control, PFC: prefrontal cortex, 
HPC: hippocampus and VS: ventral striatum. 
 
The three Zfp804a transcripts were expressed in all of the brain regions looked at (HPC, VS 
and PFC), although they were expressed at differing levels, with highest expression in the 
protein-coding transcript, lower expression in the processed transcript (identified on 
Ensemble) and even lower expression in the alternative transcript most recently identified 
(Knight, 2013). There did not appear to be any C59X genotype differences in expression of 
the three transcripts but a more in-depth analysis using quantitative PCR (qPCR) would be 
useful. These results further support the hypothesis that the C59X stop-codon mutation has 
escaped NMD, which is not an uncommon finding in these types of mutations (C. Tinsley, 
personal communication) and suggests that the C59X mutation should have a more 
damaging effect at a proteomic rather than transcriptional level. 
  There are currently no viable Zfp804a antibodies available to verify the 
presence/absence of the Zfp804a protein in tissue from C59X homozygous ENU-mutant 
mice; however, even if the mutation has escaped NMD, substituting the lost cysteine 
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residue with anything but another cysteine or histidine residue should result in loss of 
function (Wolfe, Nekludova & Pabo, 1999). Further confirmation of the effect of C59X 
mutation on the Zfp804a protein is required before a definitive conclusion about the precise 
molecular nature of the C59X mutation can be reached but irrespective of the molecular 
consequences of the C59X mutation the multiple behavioural phenotypes observed in the 
C59X homozygous ENU-mutants support the assumption that the C59X mutation is causing 
behavioural phenotypes of relevance to schizophrenia and bipolar disorder. 
 
8.4.3 ZNF804A  
 Yeast two-hybrid screens have shown that ZNF804A interacts with known 
transcription and splicing factors, supporting the supposed role of ZNF804A in regulating 
transcription (Chapman, 2013). Exon arrays on the effect of ZNF804A knockdown on 
expression showed effects on genes thought to be involved in nervous system development, 
such as synaptic contact and axon guidance (Chapman, 2013). Other work on cell lines over-
expressing ZNF804A has shown that the commercial antibodies currently available for 
ZNF804A either do not work (in cell lines overexpressing ZNF804A), or that the ZNF804A 
protein is only expressed transiently and may be rapidly degraded by the proteosome 
(Professor Derek Blake, personal communication). Their work supports the latter 
assumption as when the proteosome was inhibited; the ZNF804A protein was visible in cell 
lines overexpressing ZNF804A (Chapman, 2013).  
 
8.4.4 Recent behavioural work 
 Recent work with the Zfp804a mutant lines has included marble burying for 
anxiety/compulsivity, biconditional learning and the tube test for social dominance. The 
C417Y homozygous ENU-mutants were no different to WTs in terms of the amount of 
marbles buried or movement around the arena. However, the C59X homozygous ENU-
mutants buried and touched more marbles and moved more around the cage, as compared 
to their WT littermate controls. There are two interpretations for this behaviour, one being 
a sign of anxiety, and the other a compulsive phenotype (Thomas, Burant, Bui et al., 2009). 
It could be argued that this behaviour is more likely due to compulsivity in the C59X mutants 
rather than increased anxiety, as these mice were significantly less anxious than their WT 
littermate controls on assays of anxiety and also show reduced startle to a loud stimulus. 
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This compulsivity phenotype is interesting as obsessive compulsive disorder has been shown 
to be co-morbid with bipolar disorder (Cosoff & Hafner, 1998), and is seen as on a spectrum 
with impulsivity (Hollander & Wong, 1995), known to be a problem in schizophrenia 
(Newman et al., 1985; Heerey et al., 2007).   
 The behavioural work in this thesis mainly focuses on tasks thought to tax frontal 
regions of the brain, e.g. the SSRTT, and is relatively lacking on tasks which focus on 
hippocampal functioning (another brain region associated with schizophrenia and bipolar 
disorder). The biconditional learning paradigm is one such task, and is based on certain 
combinations of stimuli being rewarded and other combinations not. The discrimination 
cannot be solved by selecting individual elements, as these can be equally reinforced and 
not reinforced, and as such, only the combinations of stimuli are relevant to solving the 
discrimination, with this type of learning thought to be heavily reliant on hippocampal 
functioning (Sanderson, Pearce, Kyd et al., 2006). This task is being run in the Zfp804a mice 
with results expected soon, although initial observations suggest that the C417Y 
homozygous ENU-mutant mice are unable to learn the biconditional discriminations (J. 
Haddon, personal communication). 
 Reduced social functioning is often seen in schizophrenia patients (Couture, Penn & 
Roberts, 2006). Social cognition is a term used to describe how people think about 
themselves and the social world (Penn, Sanna & Roberts, 2008), and includes concepts such 
as theory of mind, emotional processing and social perception, with deficits in these areas 
associated with reduced social functioning in schizophrenia (Couture et al., 2006). The 
Zfp804a mutants were run on the tube test, a task designed to assess the social dominance 
of mice (Lindzey, Winston & Manosevitz, 1961). Here two mice are placed at opposite ends 
of a clear plastic tube and are forced into an interaction where one mouse (the dominant) 
forces the other mouse to back out of the tube (subordinate). After several ‘battles’, one 
can ascertain the social hierarchy within a cage. Initial results indicate that both the C59X 
and C417Y homozygous ENU-mutant mice are no different to their WT littermate controls in 
terms of social dominance. 
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8.5 Future directions 
8.5.1 Molecular work 
 The future direction of the molecular work remains heavily reliant on the availability 
of viable Zfp804a and ZNF804A antibodies. Until then it would be sensible to repeat the RT-
PCR done on the C59X line with more C59X homozygous ENU-mutants and WTs, and 
extending the work using quantitative PCR (qPCR) methods to be absolutely sure that there 
are no subtle effects of the C59X mutation on the expression of Zfp804a transcripts. It 
would also be interesting to look at expression in the C417Y line, as although the C417Y line 
was not predicted to have any gross effects on transcript expression it would make an ideal 
comparison to the C59X mutation. It would also be logical to follow up a developmental 
angle and analyse the foetal profile of Zfp804a transcript expression in the C59X mutant line 
(using RT-PCR and qPCR methods), not only because of the neurodevelopmental hypothesis 
of schizophrenia, but also as the ZNF804A risk allele (rs1355706) in human foetal brain 
tissue was associated with a relative decrease in expression of ZNF804A during the second 
trimester of development (Hill & Bray, 2012). 
 Once a Zfp804a antibody is available there are plans to culture primary cell lines of 
embryonic mouse tissue. Recent research suggests that ZNF804A may be degraded rapidly 
by the protesome (Chapman, 2013), and as such, Zfp804a may also be degraded rapidly, 
therefore the proteosome in Zfp804a would have to be inhibited to enable visualisation of 
Zfp804a in primary cell lines. Hippocampal and cortical neurons could be cultured from both 
C59X homozygous ENU-mutant mice and their WT littermates with the aim of uncovering 
whether the C59X stop codon mutation does or does not produce a protein. If a protein is 
produced, various Zfp804a antibodies could be used to characterise the size of the 
translated protein in the C59X homozygous ENU-mutants, as a truncated protein could also 
have a damaging effect on Zfp804a functioning. 
 
8.5.2 Further behavioural work 
 Several suggestions on future behavioural experiments were put forward in Section 
8.3 as potential ways of elucidating the neurobiological mechanisms behind the phenotypes 
uncovered with the Zfp804a mutants. As an extension of this and a concept not looked at in 
the mutants before, it would be interesting to manipulate the early life environment of the 
Zfp804a mutants, for example using maternal separation or isolation rearing as an 
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environmental stressor, to look at the interaction between genetic and environmental 
manipulations. Perhaps the lack of behavioural phenotypes found in the C417Y homozygous 
ENU-mutant mice are due to the need for an early life environmental factor to bring the 
genetic manipulation out. For example, whole C417Y litters could undergo isolation rearing 
and then be tested on acoustic startle and PPI, as well as an anxiety assay. If PPI deficits or 
anxiety phenotypes were then observed it would be the result of an interaction between 
the genetic and environmental manipulations. Similarly, the effects seen in the C59X 
mutants may be moderated, either exacerbated or attenuated, by environmental stimuli. 
 Circadian effects in the Zfp804a mutants have not been considered previously. Sleep 
disturbances (Chouinard, Poulin, Stip & Godbout, 2004) and circadian rhythm disruption 
(Wulff, Dijk, Middleton et al, 2012) are often observed in patients with schizophrenia. It is 
hypothesised that these sleep disturbances may contribute to the cognitive deficits shown 
(Phillips et al., 2012). Reduced anxiety and depressive-like behaviour have been shown in 
Afh (after hours) ENU-mutants who show a mutation in a circadian clock gene Fbxl3, causing 
them to have extended circadian rhythms of 27 hours (Keers, Pedroso, Breen et al., 2012). 
Perhaps the reduced anxiety shown in the C59X homozygous ENU-mutants is due to an 
altered circadian rhythm in these mice. It would therefore be interesting to observe the 
sleeping patterns of the Zfp804a mutants to ascertain whether the sleeping cycles of the 
C59X and C417Y homozygous ENU-mutants are any different to their WT littermate 
controls. 
 The most sophisticated way of observing the effect a gene may have on behavioural 
and molecular phenotypes is to knock it out, but also to be able to knock it back in. Termed 
a conditional knockout, this method would be an ideal way to study the effect of Zfp804a in 
an in vivo system, as the gene could be manipulated both spatially and temporally, i.e. in 
certain brain regions at certain developmental time points. This would most certainly 
further our understanding of the behavioural phenotypes observed with the Zfp804a 
mutants, and potentially help in understanding more about how variance in Zfp804a may 
increase the risk of developing schizophrenia/bipolar disorder.  
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Appendices 
Appendix 1: Chapter II 
Appendix 1.1: Sequencing traces for all genotypes from the C59X and C417Y lines. 
          
          
 
         
 
  
 
 
 
 
 
 
 
A. 
B. 
C. 
D. 
E. 
F. 
A reverse primer sequencing trace depicting 
a C59X WT mouse. ACA = WT. 
A reverse primer sequencing trace depicting 
a C59X heterozygous ENU-mutant mouse. 
The double peaks indicate a mouse 
heterozygous for the double C59X mutation. 
A reverse primer sequencing trace depicting 
a C59X homozygous ENU-mutant mouse. 
TTA = Homozygote. 
A forward primer sequencing trace depicting 
a C417Y WT mouse. TGT = WT. 
A forward primer sequencing trace depicting 
a C417Y heterozygous ENU-mutant mouse. 
The double peak indicates a mouse 
heterozygous for the C417Y mutation. 
A forward primer sequencing trace depicting a 
C417Y homozygous ENU-mutant mouse. TAT = 
Homozygote. 
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Appendix 2: Chapter III 
Appendix 2.1: Scoring sheet for the SHIRPA phenotype assessment 
         Visual Placing (Extension of the forelimbs) 
         0 = None 
         1 = Upon nose contact 
         2 = Upon vibrasse contact 
         3 = Before vibrasse contact (18mm) 
         4 = Early vigorous extension (25mm)          
         Grip Strength  
         0 = None 
         1 = Slight grip, semi-effective 
         2 = Moderate grip, effective 
         3 = Active grip, effective 
         4 = Unusually effective 
         Wire Manoeuvre  
         0 = Active grip with hind legs 
         1 = Difficulty to grasp with hind legs 
         2 = Unable to grasp with hind legs 
         3 = Unable to lift hind legs, falls within seconds 
         4 = Falls immediately 
         Negative Geotaxis  
         0 = Turns and climbs the grid 
         1 = Turns but then freezes        
         2 = Moves, but fails to turn 
         3 = Does not move within 30 seconds  
         4 = Falls off 
 
Appendix 2.2: The post hoc results from a repeated measures analysis of early 
postnatal body weight (Days 21-30) for the males of the C59X line. 
Postnatal day 21 
C59X male homozygous ENU-mutant mice weighed significantly less than 
their WT (p=0.05) and heterozygous ENU-mutant (p=0.001) littermates. 
Postnatal day 24 
C59X male homozygous ENU-mutant mice weighed significantly less than 
their WT (p= 0.05) and heterozygous ENU-mutant (p= 0.001) littermates. 
Postnatal day 25 
C59X male homozygous ENU-mutant mice weighed significantly less than 
their WT (p=0.04) and heterozygous ENU-mutant (p=0.001) littermates. 
Postnatal day 26 
C59X male homozygous ENU-mutant mice weighed significantly less than 
their WT (p=0.03) and heterozygous ENU-mutant (p=0.00) littermates. 
Postnatal day 27 
C59X male homozygous ENU-mutant mice weighed significantly less than 
their WT (p=0.03) and heterozygous ENU-mutant (p=0.00) littermates. 
Postnatal day 28 
C59X male homozygous ENU-mutant mice weighed significantly less than 
their WT (p=0.05) and heterozygous ENU-mutant (p=0.00) littermates. 
Postnatal day 29 
C59X male homozygous ENU-mutant mice weighed significantly less than 
their WT (p=0.04) and heterozygous ENU-mutant (p=0.00) littermates. 
Postnatal day 30 
C59X male homozygous ENU-mutant mice weighed significantly less than 
their WT (p=0.03) and heterozygous ENU-mutant (p=0.00) littermates. 
 
A. 
B.
C. 
D. 
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Appendix 2.3: The ANOVA result for overall genotype effects in the emergence of 
somatic indices. 
C59X females F8,112=1.25, p=0.28 
C59X males F8,96=1.01, p=0.44 
C417Y females F8,102=1.05, p=0.40 
C417Y males F8,68=0.77, p=0.63 
 
Appendix 2.4: Percentage of body weight increase over the first 30 days of postnatal 
life for both the C59X and C417Y line, cohort G7ii. 
   
  
 
There were no significant differences in percentage of body weight change over the first 30 days 
of postnatal life for the C59X females (A), the C59X males (B), the C417Y females (C) or the 
C417Y males (D). However, when only days 5-10 were looked at, the C59X homozygous ENU-
mutant males showed significantly reduced % growth than their male WT littermate controls 
(F2,50=3.5, p<0.05). Data shows the mean values ±SEM, *p<0.05 for pairwise differences related 
to genotype. For subject N see Table 3.1. 
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Appendix 3: Chapter IV 
Appendix 3.1: Correlational analyses between behaviour on the EPM, OF and EZM. 
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Scatter plots showing the strong positive correlation between entries into the open zone of the EPM and 
entries into the central zone of the OF (A), and between entries into the open zone of the EZM and EPM (B). 
There was no correlation between entries into the open zone of the EZM and entries into the central zone of 
the OF (C). Scatter plots also show the moderately strong positive correlation between the duration of time 
spent in the open zone of the EPM and time spent in the central zone of the OF (D), and between time spent 
in the open zone of the EPM and EZM (E). There was no correlation between time spent in the open zone of 
the EZM and time spent in the central zone of the OF (F). 
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Appendix 4: Chapter V 
Appendix 4.1: The results from a repeated measures ANOVA to test for 
differences between the 3 PR sessions in the progressive ratio task for the C59X 
line. 
Behavioural 
Parameter 
WT Homozygous 
Repeated measures 
ANOVA 
Rewards 20.4 ± 2.3 18.9 ± 2.2 F (1, 25) = 0.2, p=0.64 
Breakpoint 20 ± 2.3 18.6 ± 2.2 F (1, 25) =0.2, p=0.69 
Data shows mean ± SEM 
 
Appendix 4.2: The results from a repeated measures ANOVA to test for 
differences between the 3 PR sessions in the progressive ratio task for the C417Y 
line. 
Behavioural 
Parameter 
WT Homozygous 
Repeated measures 
ANOVA 
Rewards 19.4 ± 3.1 26.5 ± 2.7 F (1, 25) = 3.0, p=0.1 
Breakpoint 18.9 ± 3.0 26.1 ± 2.7 F (1, 25) = 3.1, p=0.1 
Data shows mean ± SEM 
 
Appendix 4.3: The results from a repeated measures ANOVA to test for 
differences between the 3 PR sessions in the progressive ratio task.  
Parameters 
over the 3 
sessions 
Repeated measures ANOVA 
C59X line C417Y line 
Rewards 
earned 
F (2, 50) = 7.18, p=0.002, post hocs 
showed significantly greater 
rewards earned during PR1 than 
PR2 (p=0.01) and PR3 (p=0.05) 
 
F (1.629, 40.715) = 0.25, p=0.7 
Breakpoint 
 
F (2, 50) = 6.33, p=0.004, post hocs 
showed PR1 significantly higher 
breakpoint than PR2 (p=0.02) 
F (2, 50) = 0.15, p=0.9 
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Appendix 4.4: The results from a repeated measures ANOVA for the CRF, PR and 
CRF2 sessions in the progressive ratio task for the C59X line. 
Behavioural 
Parameter 
WT Homozygous 
Repeated measures 
ANOVA 
Total Nose Pokes 146.5 ± 20.1 138.8 ± 19.4 F (1, 25) = 0.08, p=0.78 
Total Panel Pushes 106.4 ± 19.8 117.8 ± 19.1 F (1, 25) =0.17, p=0.68 
Total Beam Breaks 536.8 ± 108.4 758.7 ± 104.5 F (1, 25) =2.17, p=0.15 
Session Duration 23.6 ± 1.1 22.4 ± 1.1 F (1, 25) =0.57, p=0.50 
Volume Consumed 1.3 ± 0.09 1.5 ± 0.08 F (1, 25) =3.94, p=0.06 
Data shows mean ± SEM 
 
Appendix 4.5: The results from a repeated measures ANOVA for the CRF, PR and 
CRF2 sessions in the progressive ratio task for the C417Y line. 
Behavioural 
Parameter 
WT Homozygous 
Repeated measures 
ANOVA 
Total Nose Pokes 140.7 ± 29.3 213.1 ± 26.2 F (1, 25) =3.40, p=0.08 
Total Panel Pushes 82.7± 9.5 106.3 ± 8.4 F (1, 25) =3.45, p=0.07 
Total Beam Breaks 665 ± 101 613.4 ± 90.3 F (1, 25) =0.15, p=0.71 
Session Duration 22.2 ± 1.1 22.3 ± 0.98 F (1, 25) =0.01, p=0.94 
Volume Consumed 1.4 ± 0.09 1.5 ± 0.08 F (1, 25) =0.91, p=0.35 
Data shows mean ± SEM 
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Appendix 4.6: The results from a repeated measures ANOVA to test for 
differences between the CRF, PR and CRF2 sessions in the progressive ratio task.  
Parameters 
over the 3 
sessions 
Repeated measures ANOVA 
C59X line C417Y line 
Total Nose 
Pokes 
F (1.017, 25.416) =13.25, p=0.001, post 
hocs showed significantly greater 
nose pokes  during PR than CRF 
(p=0.003) and CRF2 (p=0.004) 
F (1.008, 25.188) =20.02, p=0.00, post 
hocs showed significantly greater 
nose pokes  during PR than CRF 
(p=0.00) and CRF2 (p=0.00) 
Total Panel 
Pushes 
F (1.263, 31.57) =2.5, p=0.12 
 
F (1.349, 33.736) =41.8, p=0.00, post 
hocs showed significantly less 
panel pushes at PR compared to 
CRF (p=0.00) and CRF2 (p=0.00) 
Total Beam 
Breaks 
F (2, 50) =0.42, p=0.66 F (1.505, 37.636) =1.08, p=0.33 
Session 
Duration 
F (1.32, 33.005) =0.89, p=0.38 F (1.388, 34.697) =2.93, p=0.08 
Volume 
Consumed 
F (2, 50) =382.51, p=0.00, post hocs 
showed significantly less volume 
consumed at PR than at CRF (p=0.00) 
and CRF2 (p=0.00) 
F (2, 50) =387.75, p=0.00, post hocs 
showed significantly less volume 
consumed at PR than at CRF 
(p=0.00) and CRF2 (p=0.00) 
 
 
 
 
 
 
 
 
 
 
 
228 
 
Appendix 5: Chapter VI 
 
Appendix 5.1: Table to show the trial presentation in 
the acoustic startle/PPI 
Trial 
Number Trial Type 
Trial 
Number Trial Type 
1 120 dB pulse 29 8 dB prepulse  
2 120 dB pulse 30 120 dB pulse 
3 120 dB pulse 31 8 dB prepulse  
4 120 dB pulse 32 4 dB prepulse  
5 120 dB pulse 33 16 dB prepulse  
6 120 dB pulse 34 120 dB pulse 
7 4 dB prepulse  35 No stimulus 
8 8 dB prepulse  36 No stimulus 
9 16 dB prepulse  37 No stimulus 
10 120 dB pulse 38 No stimulus 
11 8 dB prepulse  39 80 dB pulse 
12 No stimulus 40 90 dB pulse 
13 4 dB prepulse  41 100 dB pulse 
14 120 dB pulse 42 110 dB pulse 
15 16 dB prepulse  43 120 dB pulse 
16 8 dB prepulse  44 120 dB pulse 
17 4 dB prepulse  45 110 dB pulse 
18 120 dB pulse 46 100 dB pulse 
19 No stimulus 47 90 dB pulse 
20 8 dB prepulse  48 80 dB pulse 
21 16 dB prepulse  49 100 dB pulse 
22 120 dB pulse 50 120 dB pulse 
23 4 dB prepulse  51 90 dB pulse 
24 16 dB prepulse  52 80 dB pulse 
25 No stimulus 53 110 dB pulse 
26 120 dB pulse 54 No stimulus 
27 16 dB prepulse  55 No stimulus 
28 4 dB prepulse    
  
 
 
229 
 
Appendix 6: Chapter VII 
Appendix 6.1: Calculation of the SSRT. 
   Calculation of the SSRT 
 
 
 
 
To find SSRT, need to find Nth Go Reaction Time when ranked in order from smallest 
(see graph). The following formula illustrates the calculation: 
 
Nth=(X*Pf) 
 
X=number of correct go trials 
Pf=probability of failing to stop on stop trials 
 
SSRT=(Nth GoRT – SSD) 
 
Example 
In a session with 20 trials 
•  16 go trials (from which GoRT can be measured) 
 4 stop trials (1 correct stop and 3 incorrect stop) => Pf=0.75 
• probability of correctly stopping = 0.25 
•  SSD = 550 ms 
 
To find the nth reaction time: 
•  n = number of Go Reaction Time’s * probability of responding on stop trials 
•  n = (16*0.75) = 12 
•  12th reaction time in Go Reaction Time distribution = 860 ms 
•  Therefore, it is estimated that the stop process finished 860 ms after the onset 
of the go stimulus 
• If we subtract the delay to the stop-signal from this value (860 - 550 = 310), we 
get an estimate of SSRT of 310 ms 
 
Number of events 
Go RT 
1 x 
Nth  
Go RT 
Ranked Go Reaction Times 
1-750 
2-760 
3-770 
4-780 
5-790 
6-800 
7-810 
8-820 
9-830 
10-840 
11-850 
12-860 
13-870 
14-880 
15-890 
16-900 
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Appendix 7: Chapter VIII 
Appendix 7.1: RT-PCRs showing Zfp804a transcript in different organs and discrete 
brain regions of C57BL/6J WT mice. 
   
 
                                                                  
RT-PCR using non-specific Zfp804a primers was performed on samples dissected from 
different organs of a male WT C57BL/6J mouse (A).  Results show that Zfp804a expression 
was limited to the brain only. A separate RT-PCR for calmodulin mRNA was used for 
reference (B). A further RT-PCR was then performed with non-specific Zfp804a primers on 
samples dissected from different regions of the brain of a male WT C57BL/6J mouse (C). 
Results show that Zfp804a mRNA was present in each of the regions investigated, and that 
there appeared to be varying levels of relative expression. From this semi-quantitative study, 
highest Zfp804a expression occurred in the hippocampus (HPC), ventral striatum (VS) and 
prefrontal cortex (PFC), with lower levels in the dorsal striatum (DS) and cerebellum (CER). 
Zfp804a mRNA was also detected in the hind/mid-brain (MB) but at much lower levels of 
expression than the other brain regions. A separate RT-PCR for calmodulin mRNA was again 
used for reference (D). Arrows show bands of interest. RT+ve: reverse transcriptase positive 
control and RT-ve: reverse transcriptase negative control. Figure reproduced with kind 
permission of Tinsley, Humby and Wilkinson. 
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Appendix 7.2: RT-PCR showing the presence of Zfp804a transcript in whole brain 
tissue of C59X mice. 
 
 
 
 
RT-PCR with non-specific primers for Zfp804a was performed on whole brain samples from male 
C59X homozygous, heterozygous and WT mice (A). Results from this semi-quantitative assay show 
that, overall, Zfp804a expression was relatively equivalent in each genotype. Arrow shows band of 
interest, RT-ve: reverse transcriptase negative control and RT+ve: reverse transcriptase positive 
control. Image reproduced with kind permission from Professor Blake & Dr Tinsley. 
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